Monocyclic β-lactam compounds and uses thereof

Through the action of the novel monocyclic-β-lactam compound with the cell membrane binding protein PBP of Gram-negative bacteria, the problem of existing antibiotics being ineffective against metal β-lactamase-resistant bacteria is achieved, and effective inhibition of drug-resistant bacteria is achieved.

CN114746418BActive Publication Date: 2024-11-12SHANGHAI SINOV BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080083843.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-13
Filing Date
2020-12-11
Publication Date
2024-11-12
Estimated Expiration
2040-12-11

AI Technical Summary

Technical Problem

Existing antibiotics are ineffective against metal β-lactamase-resistant bacteria, especially drug-resistant strains in Gram-negative bacteria. They are resistant to a variety of antibiotics and lack effective inhibitors.

Method used

A novel monocyclic-β-lactam compound and its pharmaceutical composition are provided for the action of PBP, a cell membrane-bound protein of Gram-negative bacteria, inhibit bacterial cell wall synthesis, and have an antibacterial effect on metal β-lactamase.

Benefits of technology

Effectively against drug-resistant bacteria produced by metal β-lactamase, especially with significant inhibitory effects on a variety of drug-resistant bacteria such as Acinetobacter baumannii and Klebsiella pneumoniae, providing a new antibacterial treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114746418B_ABST
    Figure CN114746418B_ABST
Patent Text Reader

Abstract

The present invention discloses a monocyclic β-lactam compound or its ester, a stereoisomer thereof and a pharmaceutically acceptable salt thereof represented by the general formula (I). The present invention also discloses a pharmaceutical composition comprising the monocyclic β-lactam compound or its ester, a stereoisomer thereof and a pharmaceutically acceptable salt thereof represented by the general formula (I) and its use for treating bacterial infection. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicinal chemistry and relates to a novel monocyclic-β-lactam compound and use thereof in treating bacterial infection. Background Art

[0002] Since penicillin was widely used to treat bacterial infections in 1943, β-lactam antibiotics have formed a complete production system after more than 70 years of development, becoming an important part of the world's pharmaceutical industry and occupying the largest share of the global antibiotic market of US$42 billion. However, with the continuous launch of new antibiotics, abuse is becoming more and more serious. Bacterial resistance is a natural evolution. Abuse is equivalent to exerting strong selectivity on bacterial resistance, accelerating the generation of resistant strains, and causing some bacteria to mutate and produce highly resistant super bacteria, which are resistant to multiple antibiotics. At present, 70% of the strains isolated clinically are Gram-negative bacteria. Among these bacteria, resistant strains such as Acinetobacter baumannii, Enterobacter, and Klebsiella pneumoniae pose the greatest threat to humans. The development of drugs with good antibacterial activity against these resistant bacteria is an urgent problem to be solved.

[0003] β-lactamase is the main mechanism of Gram-negative bacteria's resistance to lactam antibiotics. It is an inactivating enzyme or passivating enzyme (β-lactam hydrolase) produced by bacteria. After the antibiotic passes through the outer membrane of Gram-negative bacteria through porins, it is hydrolyzed and inactivated by the β-lactamase secreted by the resistant bacteria and cannot interact with the target penicillin-binding protein PBP. The β-lactamase produced by bacteria is divided into two major categories, one is the enzyme with serine residues in the active site, and the other is the enzyme with metal ions in the active site, called metallo-β-lactamase (MBL), referred to as metalloenzyme.

[0004] The biggest feature of this group of enzymes is that they can hydrolyze antibiotics such as carbapenems, while having little effect on monobactam antibiotics such as aztreonam. The active center of the enzyme requires the participation of metal zinc ions to exert catalytic activity, so it is called metallo-β-lactamase. The substrate is a large class of β-lactam antibiotics including carbapenems, and its activity is not inhibited by common β-lactamase inhibitors such as clavulanic acid. Metallo-β-lactamases can be mediated by chromosomes and plasmids. They can be detected in bacteria such as Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Serratia marcescens, Enterobacter, Klebsiella pneumoniae, Aeromonas hydrophila, Acinetobacter, Bacteroides fragilis, and Acinetobacter baumannii. They are widely distributed in bacterial genera and regions, and are a hot topic of clinical concern. There are five genotypes of acquired metalloenzymes found in bacteria so far: IMP, VIM, SPM, GIM, and SIM. The most important IMP and VIM are divided into many subtypes according to the different genes and translated amino acid sequences, and have now developed into IMP-22 and VIM-12. Metallo-β-lactamases are increasingly expressed in drug-resistant strains, and no metalloenzyme inhibitors are currently on the market or in mid- to late-stage clinical research.

[0005] Monobactam is a monocyclic β-lactam antibiotic that inhibits the synthesis of bacterial cell walls by highly binding to penicillin-binding proteins (PBPs) on the cell membrane of Gram-negative bacteria, thereby killing bacteria. Monobactam is stable to metallolactamase (class B enzyme) in β-lactamase, but the known drug aztreonam has no significant inhibitory effect on multiple drug-resistant bacteria. Therefore, new antibacterial drugs are needed, especially antibacterial compounds that can effectively fight Gram-negative drug-resistant bacteria. The present invention provides such compounds. Summary of the invention

[0006] On the one hand, in one embodiment of the present invention, a monocyclic β-lactam compound represented by the general formula (I) is provided:

[0007]

[0008] or an ester thereof, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, L1, L2, L3, X, Y, A, and Z are as defined herein.

[0009] In a further embodiment of the present invention, a pharmaceutical composition is provided, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0010] In a further embodiment of the present invention, a method for treating bacterial infection is provided, which comprises administering to an individual in need thereof a therapeutically effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0011] definition

[0012] As used in the description of the present invention, the following words and phrases are generally deemed to have the meanings set forth below, unless otherwise indicated in the context in which the words or phrases are used.

[0013] As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon having the indicated number of carbon atoms. 1-6 Alkyl means including, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl and neohexyl. The alkyl group may be unsubstituted or optionally substituted with one or more substituents described herein.

[0014] The term "alkylene" refers to a divalent branched or unbranched alkane chain. 1-4 Alkylene-means include, for example, methylene (-CH2-), ethylene (-CH2CH2-), propylene isomers (e.g., -CH2CH2CH2- and -CH(CH3)CH2-), butylene (e.g., -CH2CH2CH2CH2-, -CH2CH(CH3)CH2-, -CH(CH3)CH2CH2- and -C(CH3)2CH2-). Alkylene groups can be unsubstituted or optionally substituted with one or more substituents described herein.

[0015] The term "hydroxy" refers to the group -OH.

[0016] The term "alkoxy" refers to the group RO-, wherein R is an alkyl group as defined herein. In some embodiments, alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentyloxy, n-hexyloxy, 1,2-dimethylbutoxy, and the like.

[0017] The term "cycloalkyl" refers to a cycloalkyl group having 3-20, preferably 3-12, more preferably 4-8, and most preferably 3-6 carbon atoms, having a single ring or multiple condensed rings. Such cycloalkyl groups include, for example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, etc., or polycyclic structures such as adamantyl and bicyclo[2.2.1]heptane, or cycloalkyl groups fused to aryl groups, such as indan, etc., if the point of attachment is through the cycloalkyl group.

[0018] The term "aryl" includes substituted or unsubstituted aromatic groups, wherein each ring atom is carbon. Preferably, the ring is a 6-14-membered ring, more preferably a 6-membered ring. Aryl includes, but is not limited to, phenyl. The term "aryl" also includes "polycyclic radicals" and "polycyclic" systems having two or more rings in which two or more atoms are common to two adjacent rings (e.g., the ring is a "condensed ring"), wherein at least one of the rings is aromatic, for example, other rings may be cycloalkyl, cycloalkenyl, cycloalkynyl or aromatic rings. In some preferred embodiments, polycyclic rings have 2-3 rings. In certain preferred embodiments, polycyclic ring systems have two rings in which two rings are aromatic. Each ring in the polycyclic ring may be substituted or unsubstituted. In certain embodiments, each ring in the polycyclic ring contains 3 to 10 carbon atoms, preferably 5 to 7 carbon atoms, in the ring. For example, aryl includes, but is not limited to, phenyl (benzene), tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, and benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl, etc. In some embodiments, aryl is a monocyclic aromatic group. In some embodiments, aryl is a bicyclic aromatic group. In some embodiments, aryl is a tricyclic aromatic group.

[0019] As used herein, the term "heterocycloalkyl" refers to a saturated or partially saturated non-aromatic ring structure substituted or unsubstituted with 3 to 18 rings, preferably 3 to 10 rings, more preferably 3 to 6 rings, and its ring structure includes at least one heteroatom, preferably one to three heteroatoms, more preferably one or two heteroatoms. In certain embodiments, the ring structure may have two rings. In some embodiments, two rings may have two or more atoms in common, for example, the ring is a "condensed ring". Heterocycloalkyl includes, for example, piperidine, piperazine, pyrrolidine, morpholine, lactone, lactam, etc. Heterocycles are described in Paquette, Leo A.; "Principles of Modern Heterocycle Chemistry" (WA Benjamin, New York, 1968), especially Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, Aseries of Monographs" (published by John Wiley & Sons, New York, 1950), especially Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566. Examples of heterocycloalkyl include, but are not limited to, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, tetrahydropyran, dihydropyran, tetrahydrothiopyran, thiomorpholine, thioxane, homopiperazine, azetidine, oxetane, thietane, homopiperidine, piperidine, piperazine, pyrrolidine, morpholine, oxepane, thiepane, nitroxide , dinitrogen , sulfur and nitrogen , 2-pyrroline, 3-pyrroline, indoline, 2H-pyran, 4H-pyran, dioxane, 1,3-dioxolane, pyrazoline, dithiane, dithiolane, dihydropyran, dihydrothiophene, dihydrofuran, pyrazolidinyl imidazoline, imidazolidine, 3-azabicyclo [3.1.0] hexane, 3-azabicyclo [4.1.0] heptane and azabicyclo [2.2.2] hexane. Spirocyclic moieties are also included within the scope of this definition. Examples of heterocyclic groups whose ring atoms are substituted with oxo (=O) moieties are pyrimidone and 1,1-dioxo-thiomorpholine.

[0020] As used herein, the term "heteroaryl" refers to a substituted or unsubstituted aromatic monocyclic structure including at least one heteroatom (e.g., O, N or S), preferably one to three, more preferably one or two heteroatoms in the ring structure, preferably a 5- to 7-membered ring, more preferably a 5- to 6-membered ring. When two or more heteroatoms are present in a heteroaromatic ring, they may be the same or different. The term "heteroaryl" also includes "polycyclic radicals" and "polycyclic" systems having two or more ring atoms shared by two adjacent rings (e.g., the ring is a "condensed ring"), wherein at least one of the rings is heteroaromatic, for example, the other rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaromatic and / or heterocyclic. In some preferred embodiments, polycyclic heteroaryl has 2-3 rings. In certain embodiments, it is preferred that polycyclic heteroaryl has two rings in which two rings are aromatic. In certain embodiments, each ring in the polycyclic contains 3 to 10 atoms in the ring, preferably 5 to 6 atoms in the ring. For example, heteroaryl includes, but is not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, quinoline, pyrimidine, indolizine, indole, indazole, benzimidazole, benzothiazole, benzofuran, benzothiophene, cinnoline, phthalazine, quinazoline, carbazole, phenoxazine, quinoline, purine, etc. In some embodiments, heteroaryl is a monocyclic aromatic group. In some embodiments, heteroaryl is a bicyclic aromatic group.

[0021] The term "amino" refers to the group -NH2.

[0022] The term "halogen" refers to fluorine, chlorine, bromine and iodine.

[0023] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention. Exemplary salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, bisulfates, phosphates, acid phosphates, isonicotinates, lactates, salicylates, acid citrates, tartrates, oleates, tannates, pantothenates, bitartrates, ascorbates, succinates, maleates, gentisates, fumarates, arginates, gluconates, glucuronates, sugarates, formates, benzoates, glutamates, methanesulfonates (mesylate), ethanesulfonates, benzenesulfonates, p-toluenesulfonates, and pamoates; or ammonium salts (e.g., primary amine salts, secondary amine salts, tertiary amine salts, quaternary ammonium salts), metal salts (e.g., sodium salts, potassium salts, calcium salts, magnesium salts, manganese salts, iron salts, zinc salts, copper salts, lithium salts, aluminum salts).

[0024] As used herein, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammals to be treated therewith.

[0025] As used herein, the term "treatment" refers to both therapeutic treatment and prophylactic or preventive or preventive measures, wherein the purpose is to prevent or slow down (mitigate) an undesirable pathological change or condition. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in disease severity, delay or slowing of disease progression, improvement or alleviation of the disease state, and remission (whether partial or complete), whether detectable or undetectable.

[0026] As used herein, the term "therapeutically effective amount" refers to an amount of a compound of the invention that can: (i) treat or prevent a disease or condition described herein, (ii) ameliorate or eliminate one or more diseases or conditions described herein, or (iii) prevent or delay the onset of one or more symptoms of a disease or condition described herein. DETAILED DESCRIPTION

[0027] In one embodiment, the present invention provides a compound represented by formula (I):

[0028] Compound represented by formula (I):

[0029]

[0030] Wherein, R1 and R2 are each independently selected from H, C1-C6 alkyl, C1-C6 haloalkyl; or R1 and R2 together with the carbon atom to which they are connected form a C3-C6 cycloalkyl, or R1 and R2 together with the carbon atom to which they are connected form a C3-C6 heterocycloalkyl; wherein the C3-C6 cycloalkyl, C3-C6 heterocycloalkyl is optionally substituted by C1-C6 alkyl, C1-C6 haloalkyl, halogen, hydroxyl;

[0031] R3 is selected from H, C1-C6 alkyl, halogen, wherein the C1-C6 alkyl is optionally substituted with halogen or hydroxyl;

[0032] L1 is absent or selected from -OT-, -OC(=O)-T-, -OS(=O) r -T-, -S(=O)rT-, -S-CH2-C(O)-T-, -NH-C(=O)-T-, -NH-S(O) r -T-, -NH-C(=N-CN)-T, -NH-C(=NH)-T-, -NH-T-, -(CH2) p -S(O) r -T-, -(CH2) p -C(O)-T-, -(CH2) p -ST-, -(CH2) p -C(=NH)-T-, wherein T is absent or selected from -(CH2) p -、-(CH2)p -NH-(CH2) q -、-(CH2) p -O-(CH2) q -、-(CH2) p -C(=O)-NH-(CH2) q -、-(CH2) p -NH-C(=O)-(CH2) q -、-CH(CH3)-NH-C(=O)-(CH2) q -、-(CH2) p -NH-C(=O)-NH-(CH2) q -, -CH(CH3)-NH-C(=O)-NH-(CH2) q -, -CH(CH3)-NH-C(=O)-NH-(CH2) q -、-(CH2) p -C(=O)-(CH2) q -

[0033] wherein r is 1 or 2; wherein p and q are 0, 1 or 2;

[0034] X is selected from 5-6 membered heteroaryl, 6-10 membered aryl, 4-8 membered cycloalkyl or 4-8 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl or 4-8 membered heterocycloalkyl contains 1, 2 or 3 heteroatoms selected from N, O, S as ring atoms, and wherein the 5-6 membered heteroaryl, 6-10 membered aryl, 4-8 membered cycloalkyl or 4-8 membered heterocycloalkyl is optionally substituted by P, P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substitution;

[0035] Y is absent or selected from 5-6 membered heteroaryl, 6-10 membered aryl, 4-8 membered cycloalkyl or 4-8 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl or 4-8 membered heterocycloalkyl contains 1, 2 or 3 heteroatoms selected from N, O, S as ring atoms, and the 5-6 membered heteroaryl, 6-10 membered aryl, 4-8 membered cycloalkyl or 4-8 membered heterocycloalkyl is optionally substituted by Q, Q is selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, -C 1-4 Alkylene-N(R5)2, -C 1-4Alkylene-NR5-C(=NR5)-N(R5)2, -C 1-4 Alkylene-NR5-CR5(=NR5), -C 1-4 Alkylene (C 1-4 Alkylene-N(R5))2,-C 1-4 Alkylene-N + (R7)3, wherein said C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substituted; the C 1-4 The alkylene group is optionally substituted with NR4R4', hydroxy or halogen;

[0036] R4 and R4' are each independently selected from H or C 1-4 alkyl;

[0037] R5 is selected from H or C optionally substituted by -OR6, -NR6R6' 1-4 Alkyl; or two R5 on the same N can be cyclized to form optionally C 1-4 Alkyl, C 1-4 4-6 membered heterocycloalkyl substituted with alkoxy, hydroxy, amino or oxo;

[0038] R6 and R6' are each independently selected from H or optionally substituted by hydroxyl, C 1-4 Alkoxy, NR4R4' substituted C 1-4 alkyl;

[0039] R7 is selected from H, C 1-4 Alkyl, -CH(-C 1-4 Alkylene-N(R5)2)2;

[0040] L2 is absent or selected from -(NR4) m -C 1-4 Alkylene-(NR4) n -、-(NR4) m -C 1-4 Alkylene-NR4-C(=NR4)-NR4-, -C 1-4 Alkylene-NR4-C 1-4 Alkylene-; wherein m is 0 or 1, n is 1 or 2; C 1-4 The alkylene group is optionally replaced by C 1-4 Alkyl, NH2, -C 1-4 Alkylene-NH2 substitution;

[0041] A is selected from H, M or -(CO)-M, wherein M is selected from Wherein R8 is selected from H, C1-C6 alkyl, hydroxyl, C 1-4 Alkoxy; R9, R 10 , or R11 are each independently selected from H, halogen, CN or OR 12 , R 12 is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylcarbonyl or -C(O)-NH2; R 14 and R 15 Each independently selected from: H, C 1-6 Alkyl, halogen, cyano, OR 16 ; where R 16 Selected from H, C1-C6 alkyl;

[0042] L3 does not exist or is -O-;

[0043] Z is selected from N, CR 13 , where R 13 Selected from H, or halogen;

[0044] or its esters, stereoisomers and pharmaceutically acceptable salts.

[0045] In a specific embodiment, the present invention provides a compound as shown below:

[0046]

[0047] or its esters, stereoisomers and pharmaceutically acceptable salts.

[0048] In a preferred embodiment, R3 is selected from H, C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with halogen;

[0049] X is selected from 5-6 membered heteroaryl, 6-10 membered aryl, 4-8 membered cycloalkyl or 4-8 membered heterocycloalkyl; wherein at least one of the heteroatoms of the 5-6 membered heteroaryl or 4-8 membered heterocycloalkyl is an N atom, and wherein the 5-6 membered heteroaryl, 6-10 membered aryl, 4-8 membered cycloalkyl or 4-8 membered heterocycloalkyl is optionally substituted by P, and P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4'substituted; R4 and R4' are each independently selected from H or C 1-4 alkyl.

[0050] In a preferred embodiment, R3 is selected from H, C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with halogen;

[0051] X is selected from a 5-membered heteroaryl or a phenyl group; wherein at least one of the heteroatoms of the 5-membered heteroaryl group is an N atom, and wherein the 5-membered heteroaryl or the phenyl group is optionally substituted by P, and P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4'substituted; R4 and R4' are each independently selected from H or C 1-4 alkyl.

[0052] In a preferred embodiment, R3 is selected from H, methyl, halomethyl;

[0053] X is selected from oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, phenyl; these groups are optionally substituted by P, P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4'substituted; R4 and R4' are each independently selected from H or C 1-4 alkyl.

[0054] In a preferred embodiment, R1 and R2 are each independently selected from H, methyl, halomethyl, or R1 and R2 together with the carbon atom to which they are attached form cyclopropane, cyclobutane or cyclopentane; wherein the cyclopropane, cyclobutane or cyclopentane is optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl, halogen, hydroxyl;

[0055] In a preferred embodiment, R1 and R2 are methyl or R1 and R2 together with the carbon atom to which they are attached form cyclopropane, cyclobutane or cyclopentane; wherein the cyclopropane, cyclobutane or cyclopentane is optionally substituted by C1-C6 alkyl, C1-C6 haloalkyl, halogen, hydroxyl;

[0056] R3 is selected from H, methyl, CH2F;

[0057] X is selected from oxazolyl, isoxazolyl, thiazolyl, phenyl, which are optionally substituted by P, which is selected from C 1-4 Alkyl or NR4R4'; R4 and R4' are each independently selected from H or C 1-4 alkyl;

[0058] Y is absent or selected from 5-6 membered heteroaryl, phenyl or 4-6 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl or 4-6 membered heterocycloalkyl contains 1 or 2 N atoms as ring atoms, and the 5-6 membered heteroaryl, phenyl or 4-6 membered heterocycloalkyl is optionally substituted by Q, Q is selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, -C 1-4 Alkylene-N(R5)2, -C 1-4 Alkylene-NR5-C(=NR5)-N(R5)2, -C 1-4 Alkylene-NR5-CR5(=NR5), -C 1-4 Alkylene (C 1-4 Alkylene-N(R5))2,-C 1-4 Alkylene-N + (R7)3, wherein said C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substituted; the C 1-4 The alkylene group is optionally substituted with NR4R4', hydroxy or halogen;

[0059] R4 and R4' are each independently selected from H or C 1-4 alkyl;

[0060] R5 is selected from H or C optionally substituted by -OR6, -NR6R6' 1-4 Alkyl; or two R5 on the same N can be cyclized to form optionally C 1-4 Alkyl, C 1-4 4-6 membered heterocycloalkyl substituted with alkoxy, hydroxy, amino or oxo;

[0061] R6 and R6' are each independently selected from H or optionally substituted by hydroxyl, C 1-4 Alkoxy, NR4R4' substituted C 1-4 alkyl;

[0062] R7 is selected from H, C 1-4 Alkyl, -CH(-C 1-4 Alkylene-N(R5)2)2.

[0063] In a preferred embodiment, X is selected from oxazolyl, isoxazolyl, thiazolyl, phenyl, which are optionally substituted by P, P is methyl;

[0064] Y is absent or selected from pyrazolyl, pyridyl, pyrrolyl, azetidinyl, pyrimidinyl, phenyl, said group being optionally substituted by Q, Q being selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C1-4 Haloalkyl, C 1-4 Alkoxy, -C 1-4 Alkylene-N(R5)2, -C 1-4 Alkylene-NR5-C(=NR5)-N(R5)2, -C 1-4 Alkylene-NR5-CR5(=NR5), -C 1-4 Alkylene (C 1-4 Alkylene-N(R5))2,-C 1-4 Alkylene-N + (R7)3, wherein said C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substituted; the C 1-4 The alkylene group is optionally substituted with NR4R4', hydroxy or halogen;

[0065] R4 and R4' are each independently selected from H or C 1-4 alkyl;

[0066] R5 is selected from H or C optionally substituted by -OR6, -NR6R6' 1-4 Alkyl; or two R5 on the same N can be cyclized to form optionally C 1-4 Alkyl, C 1-4 4-6 membered heterocycloalkyl substituted with alkoxy, hydroxy, amino or oxo;

[0067] R6 and R6' are each independently selected from H or optionally substituted by hydroxyl, C 1-4 Alkoxy, NR4R4' substituted C 1-4 alkyl;

[0068] R7 is selected from H, C 1-4 Alkyl, -CH(-C 1-4 Alkylene-N(R5)2)2;

[0069] A is selected from H, M or -(CO)-M, wherein M is selected from Wherein R8 is hydroxyl; R9, R 10 , or R 11 Each is independently selected from H, halogen; R 14 and R 15 Each independently selected from: H, C 1-3 Alkyl, halogen, cyano, OR 16 ; where R 16 Selected from H, C1-C3 alkyl.

[0070] In a preferred embodiment, R1 and R2 are methyl groups or R1 and R2 together with the carbon atoms to which they are attached form cyclopropane, cyclobutane or cyclopentane;

[0071] R3 is selected from H, methyl, CH2F;

[0072] L1 is -NH-C(O)-;

[0073] Y is absent or selected from Phenyl;

[0074] L2 is absent or selected from -(NR4) m -C 1-4 Alkylene-(NR4) n -、-(NR4) m -C 1-4 Alkylene-NR4-C(=NR4)-NR4-, -C 1-4 Alkylene-NR4-C 1-4 Alkylene-; wherein m is 0 or 1, n is 1 or 2; C 1-4 The alkylene group is optionally replaced by C 1-4 Alkyl, NH2, -C 1-4 Alkylene-NH2 substitution;

[0075] A is selected from H, M or -(CO)-M, wherein M is selected from Wherein R8 is hydroxyl; R9, R 10 , or R 11 Each is independently selected from H, halogen; R 14 and R 15 Each independently selected from H, C 1-3 alkyl;

[0076] L3 does not exist;

[0077] Z is CH, N, or CCl.

[0078] In a preferred embodiment, R1 and R2 are methyl groups or R1 and R2 together with the carbon atoms to which they are attached form cyclopropane, cyclobutane or cyclopentane;

[0079] R3 is selected from H, methyl, CH2F;

[0080] L1 is -NH-C(O)-;

[0081] X is selected from

[0082] Y is absent or selected from pyrazolyl, pyridinyl, pyrrolyl, azetidinyl, pyrimidinyl, phenyl, said group being optionally substituted by Q, Q being selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, -C 1-4 Alkylene-N(R5)2, -C1-4 Alkylene-NR5-C(=NR5)-N(R5)2, -C 1-4 Alkylene-NR5-CR5(=NR5), -C 1-4 Alkylene (C 1-4 Alkylene-N(R5))2,-C 1-4 Alkylene-N + (R7)3, wherein said C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substituted; the C 1-4 The alkylene group is optionally substituted with NR4R4', hydroxy or halogen;

[0083] R4 and R4' are each independently selected from H or C 1-4 alkyl;

[0084] R5 is selected from H or C optionally substituted by -OR6, -NR6R6' 1-4 Alkyl; or two R5 on the same N can be cyclized to form optionally C 1-4 Alkyl, C 1-4 4-6 membered heterocycloalkyl substituted with alkoxy, hydroxy, amino or oxo;

[0085] R6 and R6' are each independently selected from H or optionally substituted by hydroxyl, C 1-4 Alkoxy, NR4R4' substituted C 1-4 alkyl;

[0086] R7 is selected from H, C 1-4 Alkyl, -CH(-C 1-4 Alkylene-N(R5)2)2;

[0087] L2 is absent or selected from -(NH) m -C 1-4 Alkylene-(NH) n -、-(NH) m -C 1-4 Alkylene-NH-C(=NH)-NH-, -C 1-4 Alkylene-NH-C 1-4 Alkylene-; wherein m is 0 or 1, n is 1 or 2; C 1-4 The alkylene group is optionally replaced by C 1-4 Alkyl, NH2, -C 1-4 Alkylene-NH2 substitution;

[0088] A is selected from H, M or -(CO)-M, wherein M is selected from

[0089] L3 does not exist;

[0090] Z is CH, N, or CCl.

[0091] In a preferred embodiment, wherein: R1 and R2 are methyl groups, or R1 and R2 together with the carbon atoms to which they are attached form cyclopropane, cyclobutane, or cyclopentane;

[0092] R3 is selected from H, methyl, CH2F;

[0093] L1 is -NH-C(O)-;

[0094] X is selected from

[0095] Y is absent or selected from the following groups:

[0096] Phenyl;

[0097] L2 is absent or selected from -C 1-4 Alkylene-NH-, -C 1-4 Alkylene -(NH)2-, -NH-C 1-4 Alkylene-NH-, -C 1-4 Alkylene-NH-C(=NH)-NH-, -C 1-4 Alkylene, NH-C 1-4 Alkylene-; wherein C 1-4 The alkylene group is optionally substituted with NH2, -CH2-NH2;

[0098] A is selected from H, M or -(CO)-M, wherein M is selected from

[0099] L3 does not exist;

[0100] Z is CH, N, or CCl.

[0101] In a preferred embodiment, the compound of the present invention is selected from:

[0102]

[0103]

[0104]

[0105]

[0106]

[0107] or its esters, stereoisomers and pharmaceutically acceptable salts.

[0108] On the other hand, the present invention provides a pharmaceutical composition comprising a compound or an ester thereof, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier according to formula (I) of the present invention. A pharmaceutically acceptable carrier may be solid or liquid. Among them, a solid carrier may be one or more substances used as an excipient, a diluent, a sweetener, a solubilizer, a lubricant, an adhesive, a tablet disintegrating agent, a stabilizer, a preservative, or an encapsulating material. A liquid carrier may be a solvent or a liquid dispersion medium. Suitable solid carriers include, but are not limited to, for example, cellulose, glucose, lactose, mannitol, magnesium stearate, magnesium carbonate, sodium carbonate, saccharin sodium, sucrose, dextrin, talc, starch, pectin, gelatin, tragacanth gum, gum arabic, sodium alginate, parabens, methylcellulose, sodium carboxymethylcellulose, low melting point wax, cocoa butter, etc. Suitable liquid carriers include, but are not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, and the like), vegetable oils (e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil), glycerides, agar, pyrogen-free water, isotonic saline, Ringer's solution, and mixtures thereof.

[0109] The pharmaceutical composition of the present invention may also additionally include one or more β-lactam antibiotics and β-lactamase inhibitors. In this article, β-lactam antibiotics may include penicillin antibiotics, cephalosporin antibiotics, monolactam antibiotics, carbapenem antibiotics, penicillin enzyme inhibitors. Specifically, β-lactam antibiotics may include penicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, ampicillin, pivampicillin, amoxicillin, carbenicillin, furicellin, sulbenicillin, ticarcillin, piperacillin, mecillin, cephalothin, cephalothin, ceftriaxone, cefuroxime, cefaclor, cefotaxime, ceftriaxone, ceftazidime, cefoperazone, cefoxitin, imipenem, aztreonam, etc. The β-lactamase inhibitor may include various β-lactamase inhibitors that have been reported or used clinically, such as clavulanic acid, tazobactam, avibactam, and diazaspiro[bicyclo[3.2.1]octane compounds.

[0110] The pharmaceutical composition of the present invention can be applied to patients or subjects in need of treatment by any suitable mode of administration, including oral administration, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration, administration by inhalation spray, topical administration, rectal administration, nasal administration, buccal administration, vaginal administration or administration via implanted reservoir. In some embodiments, the pharmaceutical composition provided is intravenous and / or intraperitoneal administration.

[0111] In another aspect, the present invention provides use of the compound represented by formula (I) of the present invention or its ester, stereoisomer and pharmaceutically acceptable salt in the preparation of a medicament for treating and preventing bacterial infection.

[0112] In addition, the present invention also provides a method for inhibiting bacteria or treating and / or preventing diseases caused by bacterial infection, comprising administering a therapeutically and / or preventively effective amount of a compound represented by formula (I) of the present invention or its ester, stereoisomer or pharmaceutically acceptable salt thereof to a patient or subject in need.

[0113] In a preferred embodiment, the bacterium is a Gram-negative bacterium, which is selected from: Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae, Citrobacter acidophilus, Citrobacter freundii, Proteus (including Proteus mirabilis), Shigella, Serratia marcescens, Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis, Campylobacter, Helicobacter pylori, Vibrio cholerae, Haemophilus influenzae, Mycobacterium, Bacteroides fragilis, Bacillus cereus and Stenotrophomonas maltophilia. One or more.

[0114] In one embodiment, the disease caused by the bacteria is selected from: respiratory tract infection (upper respiratory tract infection such as pharyngitis, lower respiratory tract infection including tracheitis, bronchitis, pneumonia caused by Enterobacter and Serratia marcescens such as community-acquired pneumonia, ventilator-acquired pneumonia, hospital-acquired pneumonia, bronchiectasis), pulmonary tuberculosis and lung infection complicated by pulmonary fibrosis, urinary tract infection (including simple and complicated pyelonephritis, recurrent cystitis, complicated urinary tract infection, simple urinary tract infection), central nervous system infection (encephalitis, meningitis, brain abscess), ear infection (otitis externa, otitis media), abdominal infection including peritonitis, cardiovascular infection (blood infection such as sepsis or bacteremia, endocarditis, myocarditis, pericarditis), skin or soft tissue infection, bone and joint infection (arthritis, osteomyelitis), genital infection (genital ulcer, vaginitis, cervicitis), eye infection (conjunctivitis, keratitis, endophthalmitis), oral infection (including gingivitis, periodontitis, pulpitis), etc. It is particularly useful for the treatment of infections caused by aztreonam-resistant bacteria.

[0115] When desired, the compound or pharmaceutical composition of the present invention can be provided in a package or dispensing device containing one or more unit dosage forms. For example, the package may comprise metal or plastic foil or glass and a rubber stopper (e.g., in a vial). The package or dispensing device may be accompanied by instructions for use of the drug.

[0116] The dosage depends on various factors, including the patient's age, weight and state and the route of administration. The exact dosage used is determined based on the judgment of the treating physician. The actual dosage level and time course of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain the following amount of active ingredient, which can effectively achieve the desired therapeutic response for a specific patient, composition and mode of administration without toxicity to the patient. Typically, the medicament or pharmaceutical composition of the present invention is administered in an amount sufficient to reduce or eliminate the symptoms associated with bacterial infection.

[0117] The present invention is further described below by way of specific embodiments, but this is not intended to limit the present invention. Those skilled in the art may make various modifications or adjustments based on the teachings of the present invention without departing from the spirit and scope of the present invention.

[0118] Preparation Example

[0119] Example 1 Synthesis of Compound I-1

[0120]

[0121] Synthesis of compound 3

[0122]

[0123] 1H-pyrazole-4-carboxaldehyde (20 g, 208.3 mmol), N-Boc-3-aminopropyl bromide (49.56 g, 208.16 mmol), and cesium carbonate (68 g, 208.16 mmol) were added to 160 ml of N, N-dimethylformamide. The reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was diluted with 800 ml of ethyl acetate, washed twice with 500 ml of sodium chloride, and the organic phase was dried over anhydrous sodium sulfate. The organic phase was spin-dried to obtain 50 g of a colorless oil, which was directly used in the next step. m / z (ES + ), [M+H] + =254.

[0124] Synthesis of compound 4

[0125]

[0126] Compound 3 (crude 50 g, 208 mmol), hydroxylamine hydrochloride (20.84 g, 300 mmol) and pyridine (47.44 g, 600 mmol) were added to 400 ml of ethanol, and the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was spin-dried and directly passed through a silica gel column (PE: EA = 0-50%) to obtain a white solid compound 4 (40 g, 71.6%). m / z (ES + ), [M+H] + =269.

[0127] Synthesis of compound 6

[0128]

[0129] Compound 4 (20 g, 74.62 mmol) and tert-butyl propiolate (25.2 g, 200 mmol) were added to 160 ml of tert-butyl alcohol and 80 ml of water, and then [bis(trifluoroacetyloxy)iodobenzene (56 g, 133.32 mmol) was added in batches. The reaction mixture was stirred at room temperature overnight. 800 ml of ethyl acetate was added to the reaction mixture, washed with 800 ml of water, the organic phase was washed with 600 ml of saturated sodium chloride aqueous solution, the organic phase was dried over anhydrous sodium sulfate, the organic phase was spin-dried and passed through a silica gel column (PE: EA = 0-50%) to obtain a light-colored oily compound 6 (3 g, 10.3%). m / z (ES + ), [M+H] + =393.

[0130] Synthesis of compound 7

[0131]

[0132] Compound 6 was added to 12 ml of N,N-dimethylformamide and 6 ml of iodomethane. The reaction mixture was reacted at 80 degrees in a microwave for 5 hours. After the reaction was completed and the temperature was lowered, a solid precipitated. The solid was filtered to obtain a yellow compound 7 (2.5 g, 80.6%). m / z (ES + ), [M+H-56] + =351.

[0133] Synthesis of compound 8

[0134]

[0135] Trifluoroacetic acid (3 mL) was added dropwise to compound 7 (2.5 g, 6.1 mmol) in dichloromethane (6 ml), and stirred at room temperature overnight. Solid precipitated, and the yellow solid was filtered and used directly in the next step. m / z (ES + ), [M+H-56] + =251.

[0136] Synthesis of compound 9

[0137]

[0138] Compound 8 (about 6.1 mmol) was added to a mixed solution of water (40 mL) and tetrahydrofuran (20 mL), and then the pH was adjusted to 8 with sodium bicarbonate. Boc anhydride (2.5 g) was then added, and the reaction mixture was stirred at room temperature for 4 hours. The solution was spin-dried and the obtained solid was purified by reverse phase to obtain white compound 9 (1 g, 46.5% for 2 steps). m / z (ES + ), [M+H] + =352.

[0139] Synthesis of compound 11

[0140]

[0141] Compound 10 (315 mg, 0.6 mmol) and compound 9 (252 mg, 0.72 mmol) were added to tetrahydrofuran (6 mL) and N,N-dimethylformamide (4 mL), and DMTMM (200 mg, 0.96 mmol) was added to the reaction solution. The reaction mixture was stirred at room temperature under nitrogen for 1.5 hours. Reverse phase purification was performed to obtain white solid compound 11 (196 mg, 38%). M / z (ES+), [M+H]+=860; acid, HPLC tR=0.935 min.

[0142] Synthesis of compound 12

[0143]

[0144] Sulfur trioxide pyridine complex (200 mg, 1.14 mmol, 5 eq) was added to a solution of compound 11 (196 mg, 0.228 mmol, 1.00 eq) in N,N-dimethylformamide (3 mL). The reaction mixture was stirred overnight under nitrogen at room temperature. The reaction mixture was purified by reverse phase to give white solid compound 12 (66 mg, 30.8%). M / z (ES+), [M]+=939; acid, HPLCtR=2.170 min.

[0145] Synthesis of Compound I-1

[0146]

[0147] Trifluoroacetic acid (1 ml) was added dropwise to a solution of compound 12 (60 mg, 0.06 mmol, 1.00 eq) in dichloromethane (4 mL) at zero degrees. The reaction mixture was stirred at zero degrees for 6 hours, dried with nitrogen, and washed four times by centrifugation with ether. The obtained solid was prepared (column: Xselect CSH OBD column 30*150 mm 5 um, n; mobile phase A:, mobile phase B: ACN; flow rate: 60 mL / min; gradient: 1B to 15B in 7 minutes; 254 / 220 nm;) to give an off-white solid (26.9 mg, 61.6%). M / z (ES+), [M+H]+=683; acid, HPLC tR=0.833 min.1H NMR (D2O, 400MHz): δ (ppm) 1.39 (s, 6H), 2.31 (p, J=7.7Hz, 2H), 2.96-3.17 (m, 2H), 3.77 (d, J=6.4Hz, 2 H), 4.15(s, 3H), 4.53-4.60(m, 3H), 5.31(t, 1H), 7.06(s, 1H), 7.23(s, 1H), 8.73(s, 1H), 8.80(s, 1H).

[0148] Example 2 Synthesis of Compound I-2

[0149]

[0150] Synthesis of compound 2

[0151]

[0152] Add dioxane (50 ml) and water (2.5 ml) Methyl 2-bromothiazole-5-carboxylate (8 g, 36 mmol, 1 eq), 4-Pyrazoleboronic acid pinacol ester (8.389 g, 43 mmol, 1.2 eq), tetrakistriphenylphosphine palladium (0.416 g, 0.36 mmol, 0.01 eq) and potassium carbonate (9.9 g, 72 mmol, 2 eq). The reaction mixture was refluxed for 2 hours under nitrogen. Water was added to the reaction mixture, extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, and dried over a silica gel column to obtain compound 2 (3 g, crude). M / z (ES+), [M+H]+=210; acid, HPLC t R=0.871 min.

[0153] Synthesis of compound 3

[0154]

[0155] Compound 2 (3 g, crude), N-Boc-3-aminopropyl bromide (3.4 g, 0.014 mmol, 1 eq) and cesium carbonate (4.66 g, 0.014 mmol, 1 eq) were added to N,N-dimethylformamide (30 mL), and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, spin-dried, and passed through a column with petroleum ether / ethyl acetate to obtain compound 3 (1.5 g, 11% in two steps). M / z (ES+), [M]+ = 366.9; alkali, HPLC t R = 0.227 min.

[0156] Synthesis of compound 4

[0157]

[0158] Compound 3 (0.5 g, 1.36 mmol) was added to iodomethane (1 mL) and N,N-dimethylformamide (2.5 mL). The reaction mixture was reacted at 80 degrees in a microwave for 3 hours. The solution was spin-dried and the crude product was reversed to obtain compound 4 (0.2 g, 38.6%). M / z (ES+), [M]+=381; acid, HPLC tR=0.737 min.

[0159] Synthesis of compound 5

[0160]

[0161] Sodium hydroxide aqueous solution (0.7 mL, 2M) was added to a methanol (1 mL) solution of compound 4 (0.2 g, 1.36 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was adjusted to pH 7 with citric acid. Solid precipitated and the solid was purified by reverse phase to obtain yellow solid compound 5 (0.15 g, 81%). M / z (ES+), [M]+=367; acid, HPLC tR=0.967 min.

[0162] Synthesis of compound 6

[0163]

[0164] Amine (400 mg, 0.76 mmol) and compound 5 (545 mg, 1.48 mmol) were added to tetrahydrofuran (8 mL) and N,N-dimethylformamide (5 mL), and DMTMM (545 mg, 1.97 mmol) was added under nitrogen. The reaction mixture was stirred at room temperature under nitrogen for 2 hours and purified by reverse phase to obtain white solid compound 6T (20 mg, 3%). m / z (ES+), [M]+=876; acid HPLCtR=1.383 min.

[0165] Synthesis of compound 7

[0166]

[0167] Sulfur trioxide pyridine complex (72 mg, 0.45 mmol, 20 equiv) was added to compound 6 (20 mg, 0.022 mmol, 1.00 equiv) in N, N-dimethylformamide (3 mL), and the reaction mixture was stirred overnight under nitrogen at room temperature. Reverse phase purification gave white solid compound 7 (10 mg, 50%)

[0168] m / z (ES+), [M]+ = 956; acid, HPLC tR = 2.487 min.

[0169] Synthesis of Compound I-2

[0170]

[0171] Trifluoroacetic acid (2 mL) was added dropwise to a solution of compound 7 (10 mg, 0.047 mmol) in dichloromethane (2 mL) at 0°C under nitrogen. The reaction mixture was stirred at 0°C for 5 hours and purified by high pressure preparation (column: Sun Fire C18 OBD preparation column, 5μm, 19mm X 250mm; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60mL / min; gradient: from 1B to 26B in 7 minutes; 254 / 220nm; RT1: 2.42, 6.30; RT2:) to obtain a white compound (1.4mg, 19.1%). 1HNMR (D2O, 400MHz): δ (ppm) 1.43 (d, J = 2.6Hz, 6H), 1.51 (d, J = 4.1Hz, 1H), 2 .40(p, J=7.4Hz, 2H), 3.11-3.24(m, 2H), 3.64-3.86(m, 1H), 4.23(s, 2H), 4.57(q, J=6.3Hz, 1H), 4.65( t, J=7.5Hz, 2H), 5.35 (d, J=5.7Hz, 1H), 6.91 (s, 1H), 8.22 (s, 1H), 8.43 (s, 1H), 8.87 (d, J=29.0Hz, 2H).

[0172] Example 3 Synthesis of Compound I-3

[0173]

[0174] Synthesis of compound 2

[0175]

[0176] Pyridine (23.7 g, 0.3 mol) was added to a solution of 4-pyridinecarboxaldehyde (10.7 g, 0.1 mol) and hydroxylamine hydrochloride (10.3 g, 0.15 mol) in ethanol (70 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and the solid was washed with ethyl acetate. The white solid was dried to give compound 2 (12 g, 98.0 mmol), which was used directly in the next step without purification. m / z (ES+), [M+H]+=123; acid, HPLC tR=0.182 min.

[0177] Synthesis of compound 4

[0178]

[0179] Compound 2 (4.8 g, 39.3 mmol) and tert-butyl propiolate (7.56 g, 60 mmol) were added to a mixture of tetrahydrofuran (80 mL) and water (40 mL), and an aqueous NaOCl solution (61 mL) was added dropwise to the mixture (dropwise for 1 hour). The reaction mixture was stirred at room temperature overnight. Water (60 mL) was added to the mixture and extracted with ethyl acetate (200 mL x 3). The organic phase was washed with saturated brine (100 mL x 3), dried over anhydrous sodium sulfate, and dried by spin drying. The organic phase was passed through a column (EA / PE = 1 / 4 to 1 / 1) to obtain a white solid compound 4 (2 g, 21%) (ES+), [M+H]+ = 247; acid, HPLC tR = 0.804 min.

[0180] Synthesis of compound 6

[0181]

[0182] 2-Bromoethylamine hydrobromide was added to compound 4 (1.8 g, 7.3 mmol) in N,N-dimethylformamide (6 mL) (nitrogen atmosphere). The reaction mixture was stirred at 80 degrees for 22 hours. The reaction mixture was cooled to room temperature, and dichloromethane (20 mL) and methyl tert-butyl ether (30 mL) were added. Solid precipitated, and the solid was filtered and washed with methyl tert-butyl ether (40 mL). A light brown crude product 6 was obtained. m / z (ES+), [M]+=290; acid, HPLC tR=1.326 min.

[0183] Synthesis of compound 7

[0184]

[0185] Trifluoroacetic acid (6 mL) was added to compound 6 (crude 3.8 g, 7.3 mmol) in dichloromethane (15 mL), and the reaction mixture was reacted at room temperature overnight. Methyl tert-butyl ether (70 mL) was added to the reaction solution, and solid precipitated. The solid was filtered to obtain brown compound 7 (3.0 g). m / z (ES+), [M]+=234; acid, HPLC tR=0.366 min.

[0186] Synthesis of compound 8

[0187]

[0188] Compound 7 (crude 1.5 g, 3.65 mmol) was dissolved in N,N-dimethylformamide (36 mL), and triethylamine (5.06 g, 50 mmol) and N,N-di-BOC-1H-1-guanidinopyrazole (2.03 g, 6.57 mmol) were added to the reaction solution under nitrogen at 0 degrees. The reaction mixture was reacted at room temperature for 40 hours. A cold NaH2PO4 / NaCl (1:1, 50 mL) solution was added to the reaction mixture, and a solid precipitated. The solid was filtered and washed with MTBE / PE (1:1100 mL) to give a yellow compound 8 (1.39 g, 80%). m / z (ES+), [M]+=476; acid, HPLC tR=0.827 min. 1H NMR (methanol-d4, 300 MHz): δ (ppm) 1.28 (s, 9H), 1.54 (s, 9H), 3.36 (s, 2H), 4.03 (t, J=5.3 Hz, 2H), 7.46 (s, 1H), 8.57 (d, J=6.5 Hz, 2H), 9.13 (d, J=6.5 Hz, 2H).

[0189] Synthesis of compound 9

[0190]

[0191] Amine (315 mg, 0.6 mmol) and compound 8 (342 mg, 0.72 mmol) were added to tetrahydrofuran (5 mL) and N,N-dimethylformamide (3 mL). DMTMM (166 mg, 0.6 mmol) was added to the mixture under nitrogen conditions, and the reaction mixture was stirred at room temperature for 1 hour. Ice NaH2PO4 (20 mL) was added to the reaction mixture, extracted with ethyl acetate (20 mL x 2), and the organic phase was washed with water (40 mL). The aqueous phase was extracted with ethyl acetate (20 mL). The combined ethyl acetate phase was washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, and the organic phase was spin-dried and purified by reverse phase to obtain a light yellow solid compound 9 (177 mg, 30%). m / z (ES-), [MH] = 984; acid, HPLC tR = 1.191 min.

[0192] Synthesis of compound 10

[0193]

[0194] Sulfur trioxide pyridine complex (200 mg, 1.14 mmol, 6.3 eq) was added to compound 9 (177 mg, 0.18 mmol, 1.00 eq) in N,N-dimethylformamide (3 mL), and the reaction mixture was stirred overnight under nitrogen at room temperature and purified by reverse phase to obtain white solid compound 10 (60 mg, 31.4%). m / z (ES-), [MH] = 1064; acid, HPLC tR = 1.383 min.

[0195] Synthesis of Compound I-3

[0196]

[0197] Trifluoroacetic acid (1 mL) was added dropwise to a solution of compound 10 (60 mg, 0.056 mmol, 1.00 eq) in dichloromethane (4 mL) at 0 °C under nitrogen. The reaction mixture was stirred at 0 °C for 6 hours, the solvent was dried with nitrogen, ether (10 mL) was added to the mixture, and the mixture was washed by centrifugation 4 times. The obtained solid was subjected to high pressure preparation (column: Xselect CSH OBD column 30*150 mm 5 um, n; mobile phase A:, mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 1B to 15B in 7 minutes; 254 / 220 nm; RT1: 6.63; RT2:; injection volume: ml; number of runs:;) to give a white solid compound (14.3 mg). m / z (ES+), [M]+=708; acid, HPLC tR=0.952 min.1H NMR (D2O, 400MHz): δ (ppm) 1.40 (s, 6H), 3.72-3.91 (m, 4H), 4.56 (t, J = 6.1Hz, 1H), 4.79 (t, J = 5.5Hz, 2H), 5.31 (d, J=5.7Hz, 1H), 6.97 (s, 1H), 7.59 (s, 1H), 8.51 (d, J=6.5Hz, 2H), 8.96 (d, J=6.6Hz, 2H).

[0198] Example 4 Synthesis of Compound I-4

[0199]

[0200] Synthesis of compound 2

[0201]

[0202] Pyridine (23.7 g, 0.30 mol) was added to compound 1 (10.7 g, 0.10 mol) and hydroxylamine hydrochloride (10.3 g, 0.15 mol) in ethanol (70 mL). The reaction mixture was stirred at room temperature for 6 hours, and the obtained solid was filtered, washed with ethyl acetate and dried to obtain white solid compound 2 (10 g, 82% yield) which was directly used in the next step. m / z (ES+), [M+H] + =123; 1 H NMR (300MHz, DMSO-d6) δ12.82 (s, 1H), 8.94-8.86 (m, 2H), 8.43 (s, 1H), 8.20-8.09 (m, 2H).

[0203] Synthesis of compound 3

[0204]

[0205] Bis(trifluoroacetyl)iodobenzene (26.4 g, 82.0 mmol) was added in batches to a solution of compound 2 (5 g, 41.0 mmol) and tert-butyl propiolate (13 g, 102.5 mmol) in methanol (60 mL) and water (30 mL) at 0 degrees. The reaction mixture was stirred at room temperature for 2 hours, the methanol was dried by spin drying, water (30 mL) was added to the solution, and it was extracted with ethyl acetate (100 mL x 3). It was washed with saturated brine (100 mL x 2), dried over anhydrous sodium sulfate, and dried by spin drying through a silica gel column (ethyl acetate / petroleum ether = 1 / 4 to 1 / 1) to obtain a white solid compound 3 (2.3 g, 23%). m / z (ES + ), [M+H] + =247.

[0206] Synthesis of compound 4

[0207]

[0208] Will 2-Bromoethylamine hydrobromide (4.2 g, 20.5 mmol) was added to N,N-dimethylformamide (10 mL) of compound 3 (1.0 g, 4.1 mmol) under nitrogen. The reaction mixture was stirred at 80 degrees for 32 hours. The reaction mixture was cooled to room temperature, and dichloromethane (15 mL) / methyl tert-butyl ether (20 mL) was added to the mixture, and solid precipitated. It was washed with methyl tert-butyl ether (40 mL) to obtain a light brown solid compound 4, which was directly used in the next step.

[0209] Synthesis of compound 5

[0210]

[0211] Trifluoroacetic acid (5 mL) was added dropwise to compound 4 (1 g, 3.45 mmol, crude product) in dichloromethane (10 mL), and the reaction mixture was stirred at room temperature overnight (under nitrogen). The organic phase was spin-dried and solid compound 5 (660 mg, 69.4% 2-step yield) was crystallized from dichloromethane / methanol. m / z (ES + ), [M] + =234.

[0212] Synthesis of compound 6

[0213]

[0214] Sodium bicarbonate (438 mg, 5.21 mmol) and di-tert-butyl dicarbonate (2.27 g, 10.43 mmol) were added to a mixture of compound 5 (610 mg, 2.61 mmol) in tetrahydrofuran / water (1:2, 15 mL) at 0 degrees. The reaction mixture was stirred at room temperature for 2 hours, the solvent was dried and purified by reverse phase to obtain a white solid compound 6 (530 mg, 61%). m / z (ES + ), [M] + =334.

[0215] Synthesis of compound 7

[0216]

[0217] 4-(4,6-Dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM) (74.3 mg, 252 μmol) was added to a solution of compound 6 (56 mg, 168 μmol) and amine (88.2 mg, 168 μmol) in tetrahydrofuran (2.5 mL) and N,N-dimethylformamide (1.5 mL). The reaction mixture was stirred at room temperature for 2 hours under nitrogen. The reaction mixture was added with a cold aqueous solution of sodium dihydrogen phosphate (10 mL), extracted with ethyl acetate (10 mL x 2), and the organic phase was washed with water (20 mL). The aqueous phase was back-extracted with ethyl acetate (10 mL). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the organic phase was spin-dried and purified by reverse phase to obtain a white solid compound 7 (135 mg, 95%). m / z (ES + ), [M] + =842.

[0218] Synthesis of compound 8

[0219]

[0220] Sulfur trioxide pyridine complex (255 mg, 1.6 mmol) was added to compound 7 (135 mg, 0.16 mmol) in N,N-dimethylformamide. The reaction mixture was stirred at 45 degrees for 2 hours under nitrogen conditions and purified by reverse phase to obtain white solid compound 8 (88 mg, 95%). m / z (ES + ), [M+H] + =924.

[0221] Synthesis of Compound I-4

[0222]

[0223] Trifluoroacetic acid (2 mL) was added dropwise to compound 8 (50 mg, 0.054 mmol) in dichloromethane (2 mL) under nitrogen at 0 degrees. The reaction mixture was stirred at 0 degrees for 6 hours. The solution was dried by nitrogen and the solid was freeze-dried under high pressure to obtain a white solid product (13.9 mg, 38.5%). m / z (ES + ), [M+H] + =667; 1 H NMR (400MHz, D2O) δ9.02 (d, J=7.0Hz, 2H), 8.52 (d, J=6.8Hz, 2H), 7.59 (s, 1H), 6.93 (s, 1H), 5.30 (d, J=5.7Hz, 1H ), 4.96 (t, J=6.3Hz, 2H), 4.56 (d, J=5.9Hz, 1H), 3.78 (d, J=6.7Hz, 2H), 3.66 (q, J=7.5, 6.9Hz, 2H), 1.39 (s, 6H).

[0224] Example 5 Synthesis of Compound I-5

[0225]

[0226] Synthesis of compound 2

[0227]

[0228] Under N2 atmosphere, at 0°C, SO3·Py (24 g, 149.1 mmol, 3 eq) and Et3N (34 mL, 302.5 mmol, 6.5 eq) were added sequentially to a mixed solution of (R)-3-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (10 g, 49.7) in DMSO (40 mL): DCM (20 mL). The reaction mixture was stirred at room temperature for 2 h. The mixture was then diluted with NaHCO3 (saturated aqueous solution, 200 mL) and extracted with ether (400 mL x 2). The combined organic phases were washed with HCl (1 mol / L), NaHCO3 (saturated aqueous solution) and NaCl (saturated aqueous solution) in sequence, and then the organic phase was removed by rotary evaporation under reduced pressure to obtain a crude product, Compound 2 (9.37 g, crude product).

[0229] Synthesis of compound 3

[0230]

[0231] Compound 2 (9.37 g, 0.045 mol, 1 eq), hydroxylamine hydrochloride (4.68 g, 0.0678 mol, 1.5 eq), pyridine (10.7 g, 0.135 mol, 3 eq) were added to ethanol (100 mL). The reaction mixture was stirred at room temperature overnight. The solvent was removed by vortexing, diluted with water, and extracted with ethyl acetate (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and vortexed to obtain a crude product. The crude product was further purified by silica gel column (petroleum ether and ethyl acetate) to obtain a yellow oily compound 3 (8.5 g, 85%).

[0232] M / z (ES-), [MH] = 213; base, HPLC tR = 1.069 min.

[0233] Synthesis of compound 4

[0234]

[0235] Compound 3 (9 g, 42 mmol, 1 eq), methyl propiolate (8.8 g, 105 mmol, 2.5 eq), pyridine (10.7 g, 0.135 mol, 3 eq) were added to ethanol (100 mL). The reaction mixture was stirred at room temperature overnight. The solvent was removed by vortexing, diluted with water, and extracted with ethyl acetate (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and vortexed to obtain a crude product. The crude product was further purified by silica gel column (petroleum ether and ethyl acetate) to obtain brown oily compound 4 (7 g, 67.5%).

[0236] M / z (ES+), [M+MeCN+Na]+ = 360; acid, HPLC tR = 0.988 min.

[0237] Synthesis of Compound A-11

[0238]

[0239] A solution of NaOH (0.81 g, 0.02 mol, 2 eq) in water (8 mL) was added to a solution of compound 4 (3 g, 0.01 mol) in MeOH (20 mL). The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was acidified with HCl. The solvent was removed, and the crude product was purified by reverse phase column with acetonitrile and pure water to obtain yellow oily compound A-11 (1.36 g, 45.9%)

[0240] M / z (ES-), [MH]-=281; acid, HPLC tR=0.967min.

[0241] Synthesis of compound 6

[0242]

[0243] A-11 (0.174 g, 6.178 mmol, 1.3 eq) and 4-(4,6-dimethoxytriazin-2-yl)-4-methylmorpholine hydrochloride (0.210 g, 7.129 mol, 1.5 eq) were added to tert-butyl ((((z)-2-(((2R,3S)-2-(aminomethyl)-4-oxazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethyl)amino)-2-methylpropanoate (0. 25g, 4.75mmol, 1eq) in a DMF:THF=3:5 mixed solution, and the resulting mixture was stirred at room temperature for 2h. The resulting solution was concentrated and added to a cold half-saturated NaH2PO4 solution, extracted with ethyl acetate, and the combined organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and rotary evaporated. The mixture was further purified by silica gel chromatography to obtain yellow oily compound 6 (0.3g, 79%). M / z (ES+), [M+H]+=791; acid, HPLC tR=1.130min.

[0244] Synthesis of compound 7

[0245]

[0246] Under nitrogen atmosphere, SO3·Py (0.25 g, 1.5 mmol, 6 eq) was added to a solution of compound 6 (0.2 g, 0.25 mmol, 1 eq) in DMF (0.210 g, 7.129 mol, 1.5 eq), and the resulting mixture was stirred at 45°C for 2 h. The resulting mixture was purified by preparative-HPLC with H2O&MeCN, and the product fractions were directly lyophilized to give the title compound 7 (0.1 g, 40%) as a white solid. M / z (ES-), [MH] - =869; base, HPLC tR = 1.269min.

[0247] Synthesis of Compound I-5

[0248]

[0249] At 0°C, TFA (0.5 mL) was added to a solution of compound 7 (0.05 g, 40%) in DCM (1 mL). The mixture was stirred at 0°C for 3 h. The solvent was blown dry with a stream of nitrogen to give a crude product, which was purified by preparative HPLC (Xselect CSHOBD column, 30*150 mm) using a mixture of water (containing 0.1% FA) and MeCN as eluent. The fractions containing the desired compound were lyophilized to give compound I-5 (4.8 mg) as an off-white solid.

[0250] M / z(ES+), [M+H]+=615; acid, HPLC tR=0.593min.1H NMR (400MHz, D2O) δ6.99 (d, J=15.2Hz, 2H), 5.35 (d, J=5.7Hz, 1H), 4.63 (d, 1H), 3.81-3.66 (m, 4 H), 3.50-3.37 (m, 3H), 2.47 (dt, J=13.7, 7.0Hz, 1H), 2.18 (dd, J=13.5, 7.6Hz, 1H), 1.42 (s, 6H).

[0251] Example 6 Synthesis of Compound I-6

[0252]

[0253] Synthesis of compound 2

[0254]

[0255] Sodium borohydride (5.67 g, 0.149 mol) was added in batches to a tetrahydrofuran (40 mL) solution of N-BOC-3-carboxylic acid azetidine (10 g, 0.0497 mol) at 0 degrees. The reaction mixture was stirred at 0 degrees for 30 minutes, and then a boron trifluoride ether solution (24 mL) was added (dropwise for 1 hour). Stirred for 16 hours under nitrogen. The reaction mixture was quenched by adding ice water, extracted with ethyl acetate (50 mL x 3), the organic phase was dried, and passed through a silica gel column (ethyl acetate / petroleum ether = 1 / 3-1 / 1) to obtain a light yellow oily compound 2 (2.5 g, 27%). m / z (ES + ), [M] + =187.

[0256] Synthesis of compound 3

[0257]

[0258] Sulfur trioxide pyridine complex (6.4 g, 0.04 mol) and triethylamine (8.1 g, 0.08 mol) were added to a solution of compound 2 (2.5 g, 0.0134 mol) in dichloromethane / Dimethyl sulfoxide (5:1, 60 mL). The reaction mixture was stirred at room temperature for 1 hour, and an icy sodium bicarbonate aqueous solution was added to the reaction mixture, and extracted with ether (100 mL x 3). The organic phase was washed with 1 mol hydrochloric acid, saturated sodium bicarbonate aqueous solution, and saturated brine, respectively, and the organic phase was dried over anhydrous sodium sulfate, and the organic phase was spin-dried and purified by column to obtain a light yellow oily compound 3 (1.5 g, 61%). m / z (ES + ), [M] - =184;

[0259] Synthesis of compound 4

[0260]

[0261] Pyridine (2.61 g, 0.033 mol) was added to a solution of compound 3 (2.1 g, 0.011 mol) and hydroxylamine hydrochloride (1.17 g, 0.017 mol) in ethanol (20 mL) at 0 degrees. The reaction mixture was stirred at room temperature for 6 hours. The solvent was dried and purified by silica gel column to obtain a light yellow solid compound 4 (1.0 g, 45.5%), m / z (ES + ), [M] - =199.30.

[0262] Synthesis of compound 5

[0263]

[0264] Bis(trifluoroacetyl)iodobenzene (3.22 g, 10 mmol) was added in batches to a solution of compound 4 (1 g, 5 mmol) and methyl propiolate (1.05 g, 12.5 mmol) in methanol (10 mL) and water (5 mL) at 0 degrees. The reaction mixture was stirred at room temperature for 2 hours, the organic phase was concentrated, water (20 mL) was added, and it was extracted with ethyl acetate (100 mL x 3). The organic phase was washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and the organic phase was dried by spin drying and purified by silica gel column (ethyl acetate / petroleum ether = 1 / 4 to 1 / 1) to obtain a light yellow solid compound 5 (800 mg, 57%). m / z (ES + ), [M+H] + =283.

[0265] Synthesis of compound 6

[0266]

[0267] 2 mol of sodium hydroxide aqueous solution (213 mg, 5.32 mmol) was added to tetrahydrofuran / methanol (9 mL, 2:1) of compound 5 (750 mg, 2.66 mmol) at 0 degrees. The reaction mixture was warmed to room temperature and reacted for 1 hour. The solvent was dried, water was added, and the pH was adjusted to 5 with 1 mol of hydrochloric acid. The obtained solid was filtered to obtain yellow solid compound 6 (690 mg, 96%). m / z (ES + ), [M+H] + =269.

[0268] Synthesis of compound 7

[0269]

[0270] 4-(4,6-Dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (300 mg, 1.017 mmol) was added to a solution of compound 6 (200 mg, 0.746 mmol) and amine (357 mg, 0.678 mmol) in tetrahydrofuran (5 mL) and N,N-dimethylformamide (3 mL). The reaction mixture was stirred under nitrogen for 2 hours. The reaction mixture was added to an icy aqueous solution of sodium dihydrogen phosphate (10 mL), extracted with ethyl acetate (10 mL x 2), and the organic phase was washed with water (20 mL). The aqueous phase was back-extracted with ethyl acetate (10 mL). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the organic phase was spin-dried and purified by reverse phase to obtain a white solid compound 7 (205 mg, 38.9%). m / z (ES + ), [M+H] + =777.

[0271] Synthesis of compound 8

[0272]

[0273] Sulfur trioxide pyridine complex (318 mg, 2.0 mmol) was added to compound 7 (155 mg, 0.2 mmol) in N,N-dimethylformamide (2 ml), and the reaction mixture was stirred for 2 hours under nitrogen at 45 degrees. White solid compound 8 (88 mg, 95%) was obtained by reverse phase purification. m / z (ES + ), [M+H] + =857.

[0274] Synthesis of compound I-6:

[0275]

[0276] Trifluoroacetic acid (2 mL) was added dropwise to compound 8 (50 mg, 0.058 mmol) in dichloromethane (2 mL) under nitrogen at 0 degrees. The reaction mixture was stirred at 0 degrees for 6 hours. The solution was blown dry, the solid was freeze-dried, and purified by reverse phase column to obtain a white solid compound (10.4 mg, 29.8%).

[0277] m / z(ES + ), [M+H] + =601. 1 H NMR (400MHz, D2O) δ6.99 (d, J=8.8Hz, 2H), 5.32 (d, J=5.7Hz, 1H), 4.42 (s, 1H), 4.29-4.40 (m, 5H), 3.84-3.73 (m, 2H), 1.40 (s, 6H).

[0278] Example 7 Synthesis of Compound I-7

[0279]

[0280] Synthesis of compound 2

[0281]

[0282] Benzyl chloride (1.93 g, 15.3 mmol) was added dropwise to 3-benzyloxy-4-pyridone-6-carboxylic acid (1.5 g, 6.1 mmol) and potassium carbonate (2.07 g, 15 mmol) in N,N-dimethylformamide (20 mL). The reaction mixture was reacted at 80 degrees overnight. The reaction solution was cooled to room temperature and ice water was added. Solids precipitated, which were filtered and purified by silica gel column to obtain compound 2 (4 g crude) as a yellow oil.

[0283] m / z (ES+), [M+H]+=426; acid HPLC tR=1.371min.

[0284] Synthesis of compound 3

[0285]

[0286] 1 mol / L potassium hydroxide aqueous solution (11 mL, 11 mmol) was added dropwise to tetrahydrofuran (50 mL) of compound 2 (3.7 g, 8.7 mmol). The reaction mixture was reacted at room temperature for 3 hours. Water (100 ml) was added to the reaction solution, and the pH was adjusted to 2-3 with 1N hydrochloric acid. Solids precipitated, which were filtered, washed with water (3 x 25 mL), and dried to obtain white solid compound 3.

[0287] m / z(ES+), [M+H]+=336.4; acid HPLC tR=0.773min.1H NMR (400MHz, DMSO-d6) δ5.32 (d, J=1.8Hz, 4H), 7.47-7.29 (m, 7H), 7.46 (dd, J=6.6, 1.7Hz, 3H), 7.74 (s, 1H), 8.35 (s, 1H), 12.88 (s, 1H).

[0288] Synthesis of compound 4

[0289]

[0290] Compound 3 ( 800mg , 2.4mmol ),amine( 1.4g , 7.14mmol ), HATU (1.1 g, 2.89 mmol) and DIEA (1.44 g, 10.89 mmol). The reaction mixture was reacted at room temperature for 2 hours. Ethyl acetate (20 mL) / water (20 mL) was added to the reaction solution. The organic phase was washed with saturated brine (20 mL), and the organic phase was concentrated and passed through a column (PE: EA = 0-50%) to obtain a white solid compound 4 (910 mg, 79%).

[0291] m / z (ES+), [M+H]+=514; acid HPLC tR=1.476 min. 1H NMR (methanol-d4, 300 MHz): δ (ppm) 2.47-2.70 (m, 1H), 2.80 (dt, J=12.3, 6.1 Hz, 1H), 4.02-4.33 (m, 3H), 4.35 (dd, J=3.5, 1.3 Hz, 3H), 4.38-4.52 (m, 3H), 5.45-5.86 (m, 4H), 7.61 (d, J=17.4 Hz, 1H), 7.72-8.03 (m, 10H), 8.67 (s, 1H).

[0292] Synthesis of compound 5

[0293]

[0294] At 0 degrees, m-CPBA (350 mg, 2 mmol) was dissolved in dichloromethane (10 mL) and added dropwise to compound 4 ( 510mg , 1mmol) in dichloromethane (5 mL), and the reaction mixture was reacted at room temperature for 2 hours. Dichloromethane (20 mL) and saturated sodium bicarbonate (20 mL) were added to the reaction solution, and the organic phase was washed with sodium chloride (20 mL). The organic phase was concentrated and plated (DCM: MeOH = 10: 1) to obtain white solid compound 5 (320 mg, 61%). m / z (ES+), [M+H]+ = 530; acid HPLC tR = 1.245 min.

[0295] Synthesis of compound 6

[0296]

[0297] Sodium hydroxide aqueous solution (4 mL, 2M) was added dropwise to methanol (6 mL) of compound 5 (310 mg, 0.58 mmol). The reaction solution was reacted at room temperature for 1 hour. The methanol was dried and the aqueous phase was adjusted to pH 2.5 with citric acid. The aqueous phase was extracted with ethyl acetate and the organic phase was dried with anhydrous sodium sulfate to obtain white compound 6 (280 mg). m / z (ES+), [M+H]+=516; acid HPLC tR=1.061 min.

[0298] Synthesis of compound 7

[0299]

[0300] Compound 6 (110 mg, 0.21 mmol) and amine (100 mg, 0.19 mmol) were added to tetrahydrofuran (1.6 mL) and N,N-dimethylformamide (1 mL), and DMTMM (100 mg, 0.34 mmol) was added to the mixture under nitrogen. The reaction mixture was stirred at room temperature for 2 hours and purified by reverse phase to obtain white solid compound 7 (130 mg, 54.6%). m / z (ES+), [M]+=1024; acid HPLC tR=1.679 min.

[0301] Synthesis of compound 8

[0302]

[0303] Sulfur trioxide pyridine complex (200 mg, 1.14 mmol, 11 equiv) was added to compound 7 (108 mg, 0.1 mmol) in N, N-dimethylformamide (3 mL), and the reaction mixture was stirred overnight under nitrogen at room temperature and purified by reverse phase to give a light yellow compound 8 (56 mg, 50%). m / z (ES+), [M]+=1104; acid, HPLC tR=1.579 min.

[0304] Synthesis of Compound I-7

[0305]

[0306] Boron trichloride (1 ml, 1 mol / L dichloromethane solution) was added dropwise to compound 8 (92 mg, 0.083 mmol) in dichloromethane (7 mL) at 0 degrees under nitrogen. The reaction mixture was stirred at 0 degrees for 1 hour, the solvent was blown dry with nitrogen, and ether was added to precipitate solid. The ether was centrifuged to obtain a solid, and the solid was prepared by high pressure to obtain a white solid (12.7 mg, 19.85%).

[0307] 1 H NMR (400MHz, D2O) δ1.43 (s, 3H), 1.44 (s, 3H), 2.16 (dq, J=20.4, 6.8, 5.7Hz, 1H), 2.42 (ddd, J=25.8, 12.6, 6.2Hz, 1H), 3.35-3.54 (m, 2H), 3.54-3.88 (m, 5H), 4.53-4.60 (m, 1H), 5.37 (t, J=5.7Hz, 1H), 6.90-7.09 (m, 3H), 7.87 (d, J=4.6Hz, 1H).m / z (ES+), [M+H] + =768; [MH] - =766; acid, HPLC tR=1.391min.

[0308] Example 8 Synthesis of Compound I-8

[0309]

[0310] Synthesis of compound 1

[0311]

[0312] At 80 ℃, to the TFA (10ml) solution of hexamethylenetetramine (2.2g, 16mmol) of heating, add 1-fluoro-2,3-dimethoxybenzene (1.20g, 7.8mmol) TFA (10ml) solution dropwise.The mixture is heated for 1 hour, then concentrated in vacuo.Ice / water (30ml) is added until the mixture becomes cloudy, the mixture is stirred for 15 minutes, then adjusted to alkalinity with solid sodium carbonate, stirred for 20 minutes, then extracted into ethyl acetate, washed with water, dried and evaporated in vacuo.Purified by silica gel column chromatography, eluted with ethyl acetate (0-50%) and petroleum ether solution, to obtain compound 1 (1.1g) as a white solid. m / z (ES+), [M+H]+=185; acid, HPLC tR=1.040 min. 1H NMR (400 MHz, chloroform-d) δ10.19 (s, 1H), 7.59 (dd, J=8.8, 7.3 Hz, 1H), 6.80 (dd, J=8.8, 1.6 Hz, 1H), 3.95 (d, J=1.4 Hz, 6H).

[0313] Synthesis of compound 2

[0314]

[0315] To a solution of 2-fluoro-3,4-dimethoxybenzaldehyde (1.6 g, 8.69 mmol) in 1,4-dioxane (15 mL) at 0°C was added a solution of sulfamic acid (1.8 g, 19.1 mmol) in water (7 mL) and a solution of NaClO2 (1.72 g, 19.1 mmol) in water (7 mL). After stirring at 0°C for 30 minutes, the mixture was quenched with an aqueous solution of sodium bisulfite (20 mL). The aqueous layer was extracted with ethyl acetate, and the combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 2-fluoro-3,4-dimethoxybenzoic acid (1.9 g, crude) as an off-white solid. m / z (ES+), [MH]+=199; acid, HPLC tR=0.917 min.

[0316] Synthesis of compound 3

[0317]

[0318] To a solution of 2-fluoro-3,4-dimethoxybenzoic acid (1.9 g, 9.5 mmol) in dichloromethane (20 mL) at 0°C was added dropwise BBr3 (5.9 g, 23.7 mmol). After stirring at room temperature for 2 hours, the resulting mixture was slowly poured into MeOH (270 mL). After stirring at room temperature for 2 days, ice water was added to the mixture, and then methanol was evaporated in vacuo. The resulting precipitated solid was collected by filtration, washed with water and dried in vacuo to give 2-fluoro-3,4-dihydroxybenzoate (1.3 g, 80%). [MH]+=185; acid, HPLC tR=0.832 min.

[0319] Synthesis of compound 4

[0320]

[0321] To a solution of methyl 2-fluoro-3,4-dihydroxybenzoate (1 g, 5.3 mmol) in DMF (5 mL) was added K2CO3 (1.85 g, 13 mmol), NaI (0.8 g, 5.3 mmol) and PMBCl (1.9 g, 12 mmol). After stirring at 50°C for 3.5 hours, ice water was added to the mixture. The aqueous layer was extracted with ethyl acetate, and the combined extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude product, which was further purified by silica gel column chromatography, eluted with ethyl acetate (0-50%) and petroleum ether solution to give compound 4 (1.6 g, 70%) as a white solid. [M+Na]+=449; acid, HPLC tR=1.422 min.

[0322] Synthesis of compound 5

[0323]

[0324] To a mixed solution of compound 4 (1 g, 2.3 mmol) in THF (5 mL): MeOH (5 mL): H 2 O (5 mL) was added NaOH (0.187 g), and the resulting mixture was refluxed with stirring for 1.5 h. After the solvent was evaporated in vacuo, HCl (2 mol / L) was added until pH = 3-4, and the precipitated solid was collected by filtration, washed with water and dried in vacuo to give 2-fluoro-3,4-bis((4-methoxybenzyl)oxy)benzoic acid (0.7 g, 73%).

[0325] m / z (ES+), [M+Na]+ = 435; acid, HPLC tR = 0.825 min.

[0326] Synthesis of compound 6

[0327]

[0328] To a solution of 2-fluoro-3,4-bis((4-methoxybenzyl)oxy)benzoic acid (0.2 g, 0.485 mmol) and (R)-3-(pyrrolidin-3-yl)isoxazole-5-carboxylic acid methyl ester hydrochloride (0.095 g, 2.33 mmol) in THF (3 mL) were added HOBt (0.13 g, 0.97 mmol), TEA (0.196 g, 1.94 mmol) and EDC·HCl (0.186 g, 0.97 mml) and stirred at room temperature for 3 hours. The resulting mixture was diluted with water and ethyl acetate. The organic layer was separated, the aqueous layer was extracted with ethyl acetate, and the combined extracts were washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography to give methyl (R)-3-(1-(2-fluoro-3,4-bis((4-methoxybenzyl)oxy)benzoyl)pyrrolidin-3-yl)isoxazole-5-carboxylate (180 mg, 73%) as a white solid.

[0329] m / z(ES+), [M+H]+=591; acid HPLC tR=1.751min

[0330] Synthesis of compound 7

[0331]

[0332] LiOH (0.024 g) was added to a solution of methyl (R)-3-(1-(2-fluoro-3,4-bis((4-methoxybenzyloxy)benzoyl)pyrrolidin-3-yl)isoxazole-5-carboxylate (200 mg, 0.338 mmol) in MeOH:THF:H2O=0.5 ml:0.5 ml:0.5 ml. The reaction mixture was stirred at room temperature for 2 hours. MeOH and THF were removed, and the mixture was acidified to pH=2.5 with HCl (1 mol / L), and the resulting precipitated solid was collected by filtration, washed with water and dried in vacuo to give (R)-3-(1-(2-fluoro-3,4-bis((4-methoxybenzyl)oxy)benzoyl)pyrrolidin-3-yl)isoxazole-5-carboxylic acid (152 mg, 77.9%) as a white solid.

[0333] m / z (ES+), [M+H]+=577; base, HPLC tR=0.979min

[0334] Synthesis of compound 8

[0335]

[0336] In a 10 mL round-bottom flask, a solution of (R)-3-(1-(2-fluoro-3,4-bis((4-methoxybenzyl)oxy)benzoyl)pyrrolidin-3-ylisoxazole-5-carboxylic acid (109 mg, 0.019 mmol) and 2-((((z)-2-((((2S,3R)-2-(aminomethyl)-4-oxazetidin-3-yl)amino)-1-(2-(((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (100 mg, 0.019 mmol) in THF (0.8 mL) and DMF (0.5 mL) was placed. DMTMM ( 84 mg, 0.0285 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was purified by Flash (MeCN and H2O) to give 2-(((((z)-1-)-(2-((tert-butyloxycarbonylcarbonyl)amino)thiazol-4-yl)-2-((((2S),3R)-2-(((3-((R)-1-(2-fluoro-3,4-bis((4-methoxybenzyl)oxy)benzoyl)pyrrolidin-3-yl)isoxazole-5-carboxamido)methyl)-4-oxazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (43 mg, 20.8%) as a white solid.

[0337] m / z (ES+), [M]+=1085; acid; HPLC tR=0.977min.

[0338] Synthesis of compound 9

[0339]

[0340] To a solution of compound 8 (43 mg; 0.0396 mmol) in DMF (1 mL) was added pyridine sulfur trioxide (62.6 mg, 0.396 mmol, 10 eq). The resulting solution was stirred at 45 ° C for 3 hours under nitrogen. The residue was purified by Flash (MeCN and H2O) to give compound 9 (35 mg) as a white solid.

[0341] m / z (ES+), [M]+ = 1165; acid, HPLC tR = 1.518 min.

[0342] Synthesis of Compound I-8

[0343]

[0344] To a solution of compound 9 (35 mg) in dichloromethane (2 ml) was added BrCl3 (0.4 ml) at 0°C. The resulting mixture was stirred at 0°C for 4 hours. The solution was blown dry with a stream of nitrogen and the solid was washed with diethyl ether (3 times). The crude product was further purified by preparative HPLC under the following conditions: column: Xbridge shied RP18OBD column, 19×250 mm, 10 μm; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: from 20B to 35B in 8 minutes; 254 / 220 nm; RT1: 7.70; RT2: ) to give 2-(((((z)-1-(2-aminothiazol-4-yl)-2-(((((2S,3R)-2-((3-((R)-1-(2-fluoro-3,4-dihydroxybenzoyl)pyrrolidin-3-yl)isoxazole-5-carboxamido)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxyethylidene)amino)oxy)-2-methylpropanoic acid (10.8 mg) as an off-white solid.

[0345] m / z (ES+), [M+H]+ = 769; acid, HPLC tR = 0.997 min. 1 H NMR (400MHz, DMSO-d6) δ6.94 (d, J=28.0Hz, 1H), 6.85-6.54 (m, 3H), 5.18 (dd, J=5.7, 4.6Hz, 1H), 4.17 (s, 1H), 3.83 (s, 1H), 3.70 ( s, 1H), 3.61 (d, J=12.6Hz, 1H), 3.583.40 (m, 4H), 3.36 (t, J=6.7Hz, 1H), 2.392.21 (m, 1H), 2.13-1.93 (m, 1H), 1.46-1.35 (m, 6H).

[0346] Example 9 Synthesis of Compound I-9

[0347]

[0348] Synthesis of Compound A-2

[0349]

[0350] Compound A-1 (10 g, 56.5 mmol), Boc2O (30.5 g, 143.5 mmol), Na2CO3 (17.97 g, 169.5 mmol) in a mixed solvent of dioxane (150 mL) / H2O (150 mL). The reaction system was stirred at room temperature for 10 hours. The reaction solution was concentrated, the pH was adjusted to 3 with a 2N hydrochloric acid aqueous solution, extracted with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and dried. The crude product was obtained and used directly in the next step without further purification. [M+H]+=305; acid, HPLC tR=1.315min.

[0351] Synthesis of Compound A-3

[0352]

[0353] Compound A-2 (crude product from step 1) was dissolved in 150 mL of tetrahydrofuran, and BH3.THF (100 mL, 100 mmol) was added dropwise at 0°C. The reaction solution was stirred at room temperature for 5 hours and then reacted overnight. The reaction solution was quenched with H2O (50 mL) and stirred for 30 min. The reaction solution was separated, the organic phase was dried, and concentrated to give a crude oil. The crude product was purified by silica gel column to give a colorless oil A-3 (4 g, two-step yield 14.3%). m / z(ES+), [M+H]+=291; acid HPLC RT=0.754min.1HNMR(300MHz, Chloroform-d)δ1.45(d, J=2.7Hz, 18H), 3.09-3.43(m , 2H), 3.54 (t, J=12.6Hz, 2H), 3.69 (dd, J=2.9, 11.6Hz, 1H), 5.02 (d, J=42.8Hz, 2H).

[0354] Synthesis of Compound A-4

[0355]

[0356] Compound A-3 (4 g, 19.1 mmol, 1 eq) was dissolved in dichloromethane (100 mL), and MsCl (2.8 g, 24.82 mmol) was added dropwise at 0°C. The reaction solution was stirred for 5 minutes, and then triethylamine (5.4 mL, 38.2 mmol) was added dropwise. The reaction solution was stirred at 0°C for 2 hours, and TLC showed that the reaction was completely completed. The reaction solution was diluted with dichloromethane and washed with saturated brine. The organic phase was dried and concentrated to obtain a crude product, which was used directly in the next step without further purification.

[0357] Synthesis of compound 2

[0358]

[0359] Compound 1 (2 g, 9.6 mmol, 1 eq) was dissolved in DMF (100 mL), and then Cs2CO3 (6.24 g, 19 mmol, 2 eq) and 2,3-di((tert-tert-butyl ester)amino)propyl methanesulfonate (7 g, 19 mmol, 2 eq) were added respectively. The reaction solution was stirred at 40°C for 4 hours. Water (50 mL) was added, and the reaction solution was extracted 3 times with 100 mL of ethyl acetate. The organic phase was distilled under reduced pressure, and the residue was purified by silica gel column to obtain yellow solid compound 2 (2.1 g, 45.6%). m / z (ES+), [M+1]+=482.2; acid, HPLC tR=1.343 min.

[0360] Synthesis of compound 3

[0361]

[0362] Compound 2 (2.1 g, 4.37 mmol, 1 eq) was dissolved in DMF (10 mL), and MeI (6.2 g, 43.7 mmol, 10 eq) was added, and then the reaction solution was stirred in a microwave tube at 80°C for 1.5 hours. The final reaction solution was purified by C-18 liquid column (0-50%, 0.5‰ formic acid aqueous solution and acetonitrile) to obtain a mixture of yellow solid compounds 3a and 3b (900 mg, 41.6%). m / z (ES+), [M]+=496.2; acid, HPLC tR=1.089 min.Isomer 2: m / z (ES+), [M]+=496.2; acid, HPLC tR=1.089 min. 1 H NMR (400MHz, DMSO-d6) δ1.14 (s, 9H), 1.40 (s, 9H), 3.19 (d, J = 7.0Hz, 2H), 3.88 (s, 3H), 4.04 (q, J = 7.6Hz, 1H), 4.25 (s, 3H), 4.40 (t, J=13.0Hz, 1H), 4.76 (d, J=14.2Hz, 1H), 8.57 (s, 1H), 9.34 (s, 1H), 9.38 (s, 1H).

[0363] Synthesis of compound 4

[0364]

[0365] Mixture 3 (3a and 3b, 900 mg, 1.81 mmol, 1.00 eq) was dissolved in tetrahydrofuran: water (10 mL: 5 mL), and LiOH (435 mg, 18.1 mmol, 10 eq) was added. The mixture was stirred at room temperature for 1 hour and dried under reduced pressure to obtain yellow solid mixture 4 (4a and 4b, 1.2 g, crude product). The solid was used directly without further purification. m / z (ES+), [M]+ = 482.1; acid, HPLC tR = 1.058 min.

[0366] Synthesis of compound 5

[0367]

[0368] Mixture 4 (4a and 4b, 454 mg, 0.860 mmol, 1 eq), reactant H (500 mg, 1.04 mmol, 1.2 eq) and DMTMM (406 mg, 1.38 mmol, 1.6 eq) were dissolved in DMF / THF (8:5, 10 ml), and the reaction solution was stirred at room temperature for 2 hours. The product was purified by C-18 liquid column (0-60%, 0.5‰ formic acid aqueous solution and acetonitrile) to obtain yellow solid compound 5 (300 mg, 32%) m / z (ES+), [MH]+=990.4; alkali, HPLC tR=0.953 min.

[0369] Synthesis of compound 6

[0370]

[0371] Mixture 5 (5a and 5b, 200 mg, 0.202 mmol, 1 eq), SO3.Py (192 mg, 1.212 mmol, 6 eq) were dissolved in DMF (4 mL) and stirred at 36°C overnight. The reaction solution was adjusted to pH 3 with HCl (2 M), and the product was purified by liquid column (0-100%, 0.5‰ formic acid aqueous solution and acetonitrile) to obtain a white solid mixture 6 (6a and 6b, 80 mg, 37%). m / z (ES+), [M]+ = 1071.6; alkali, HPLC tR = 1.210 min.

[0372] Synthesis of Compound I-9 and Compound I-13

[0373]

[0374] At 0°C, TFA (2 mL) was added dropwise to a DCM (4 mL) solution of mixture 6 (6a and 6b, 80 mg, 0.035 mmol), and the reaction solution was stirred at 0°C for 5 h. After the reaction was complete, the reaction solution was dried under a nitrogen stream, and the residue was quenched in ether and centrifuged. The previous step was repeated 3 times. The residue was lyophilized and purified by liquid column chromatography to obtain compounds I-9 and I-13.

[0375] Compound I-9: m / z (ES+), [M] + =715; acid HPLC RT=3.301min. 1 H NMR (300MHz, D2O) δ1.43 (s, 6H), 3.02 (dd, J=10.0, 13.1Hz, 1H), 3.30 (dd, J=3.8, 13.1Hz, 1H), 3.60 (s, 1H), 3.78 (d, J=6 .4Hz, 2H), 4.23 (s, 3H), 4.48-4.63 (m, 2H), 5.34 (d, J=5.6Hz, 1H), 6.96 (s, 1H), 8.23 ​​(s, 1H), 8.86 (s, 1H), 8.92 (s, 1H).

[0376] Example 10 Synthesis of Compound I-10

[0377]

[0378] Synthesis of compound 2:

[0379]

[0380] Cesium carbonate (6 g, 19.12 mmol) and 2-bromoethane-1-ol (3.58 g, 28.7 mmol) were added to a solution of compound 1 (2 g, 9.56 mmol) in N,N-dimethylformamide (30 mL). The reaction mixture was heated to 50°C overnight, cooled to room temperature, diluted with ice water, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The crude product was purified by column chromatography to obtain yellow solid compound 2 (1.1 g). m / z (ES + ), [M+H] + =254.

[0381] Synthesis of compound 3:

[0382]

[0383] Compound 2 (2 g, 7.9 mmol), di-tert-butyl 1,2-dihydroazodicarboxylate (2.75 g, 11.8 mmol), and triphenylphosphine (4.13 g, 15.8 mmol) were added to tetrahydrofuran (15 mL) under nitrogen protection at 0°C, and diisopropyl azodicarboxylate (3.19 g, 15.8 mmol) was added, and the reaction mixture was stirred at room temperature under nitrogen for 2 h. The residue was purified by column chromatography to obtain a light yellow oily compound 3 (0.7 g, 20.9%). M / z (ES + ), [M+H] + =468.

[0384] Synthesis of compound 4:

[0385]

[0386] To a solution of compound 3 (0.6 g, 1.49 mmol) in N,N-dimethylformamide (3 ml), iodomethane (1.8 g, 12.6 mmol) and potassium carbonate (0.88 g, 7.23 mmol) were added. The mixture was heated to 80 ° C by microwave for 4 h. After the reaction was completed, the mixture was filtered and the filtrate was concentrated. The crude product was washed with dichloromethane to obtain a yellow solid compound 4 (50 mg). m / z (ES + ), [M] + =482.

[0387] Synthesis of compound 5:

[0388]

[0389] To a solution of compound 4 (50 mg, 1.03 mmol) in tetrahydrofuran (0.5 ml) / methanol (1 ml), lithium hydroxide aqueous solution was added and stirred at 0°C for 2 h. After the reaction, the reaction system was concentrated to obtain a crude compound 5 (90 mg). m / z (ES + ), [M] + =468.

[0390] Synthesis of compound 6:

[0391]

[0392] Compound H (112 mg, 0.213 mmol) and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM) (62.8 mg, 0.213 mmol) were added to a solution of compound 5 (50 mg, 0.106 mmol) in N,N-dimethylformamide / tetrahydrofuran (0.5 ml: 0.7 ml). The mixture was stirred at room temperature for 4 hours. The crude product was purified by column chromatography to obtain compound 6 (40 mg) as a colorless oil. m / z (ES+), [M]+ = 976.

[0393] Synthesis of compound 7:

[0394]

[0395] Sulfur trioxide pyridine complex (60 mg) was added to a solution of compound 6 (40 mg) in N,N-dimethylformamide (1 ml), and the reaction mixture was stirred at 0° C. for 4 h. The crude product was purified by column chromatography to obtain compound 7 (15 mg).

[0396] Synthesis of compound I-10:

[0397]

[0398] Trifluoroacetic acid (0.3 ml) was added to a solution of compound 7 (40 mg, 0.106 mmol) in dichloromethane (1 ml). The reaction mixture was stirred at 0°C for 3 h. The reaction solution was purified by reverse phase column chromatography to obtain compound I-10 (0.5 mg). m / z (ES+), [M+H] + =701.

[0399] Example 11 Synthesis of Compound I-11

[0400]

[0401] Synthesis of compound 2

[0402]

[0403] Compound 1 (1 g, 2.62 mmol) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (5 mL) was slowly added dropwise, and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, it was concentrated to obtain a crude yellow oil compound 2 (1.51 g) which was used directly in the next step without purification. Compound 1 contains two configurations, one of which disappears during the hydrolysis process in the third step. The presence of two configurations can be detected in the second step analysis. m / z (ES+), [M] + =281; acid HPLC RT =0.174min.

[0404] Synthesis of compound 3

[0405]

[0406] Compound 2 (1.51 g, 2.69 mmol) was dissolved in acetonitrile, triethylamine (1.09 g, 10.76 mmol) was added dropwise, and then raw material A (874 mg, 2.82 mmol) was slowly added. The reaction solution was stirred at 40°C for 2 hours and then dried by spin drying to obtain a crude yellow oil compound 3 (3 g) which was used directly in the next step without purification. m / z (ES+), [M] + =523; acid HPLC RT=1.104min. 1 H NMR (400 MHz, methanol-d4) δ 1.52 (d, J = 1.6 Hz, 18H), 2.26 (dt, J = 33.5, 6.7, 6.7 Hz, 2H), 3.34-3.61 (m, 5H), 4.00 (s, 2H), 4.26 (s, 3H), 7.77 (d, J = 1.8 Hz, 1H), 8.27-8.31 (m, 1H), 8.32 (d, J = 0.8 Hz, 1H).

[0407] Synthesis of compound 4

[0408]

[0409] Compound 3 (3 g, 5.74 mmol) was dissolved in methanol, lithium hydroxide (413 mg, 17.21 mmol) was dissolved in water (5 mL) and slowly added dropwise to the above methanol solution. The reaction solution was stirred at room temperature for 2 hours, concentrated, added with a small amount of water, and the pH value was adjusted to 3-4 with hydrochloric acid (1 M). Freeze-dried to obtain a crude yellow solid compound 4 (2 g) which was used directly in the next step without purification. During the post-treatment of the hydrolysis reaction, it was found that the product lost a Boc protecting group. m / z (ES+), [M] + =409; acid HPLC RT = 0.763min. 1 H NMR (400 MHz, methanol-d4) δ 1.55 (s, 9H), 2.36 (d, J = 29.7 Hz, 2H), 3.47-3.77 (m, 4H), 4.32 (s, 3H), 7.90 (s, 1H), 8.20 (s, 1H), 8.23 ​​(d, J = 1.3 Hz, 1H).

[0410] Synthesis of compound 5

[0411]

[0412] Compound 4 (1 g, 1.14 mmol) was dissolved in N,N-dimethylformamide / tetrahydrofuran (6 mL / 9 mL), and raw material B (500 mg, 0.95 mmol) and DMTMM (560 mg, 1.9 mmol) were slowly added. The reaction solution was stirred at room temperature for 6 hours and directly purified by C18 column to obtain yellow solid compound 5 (200 mg, yield 40.6%). m / z (ES+), [M] + =917; Alkaline HPLC RT = 2.055min. 1 H NMR (400 MHz, methanol-d4) δ 1.49-1.57 (m, 33H), 2.32 (d, J = 8.4 Hz, 2H), 3.49 (t, J = 6.7, 6.7 Hz, 2H), 3.59 (dd, J = 14.0, 6.1 Hz, 1H), 3.78 (dd, J = 14.0, 6.9 Hz, 1H), 4.12 (q, J = 6.4, 6.3, 6.3Hz, 1H), 4.27 (s, 3H), 4.65 (t, J=7.4, 7.4Hz, 2H), 5.23 (dd, J=5.8, 2. 9Hz, 1H), 7.39 (d, J = 3.9Hz, 1H), 8.29 (s, 1H), 9.01 (s, 1H), 9.07 (d, J = 14.1Hz, 1H).

[0413] Synthesis of compound 6

[0414]

[0415] Compound 5 (200 mg, 0.218 mmol) was dissolved in N,N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (345 mg, 2.18 mmol) was slowly added, the reaction solution was stirred at 40°C overnight, and directly purified by C18 column to obtain yellow solid compound 6 (35 mg, yield 20.5%). m / z (ES+), [M] + =998; alkali HPLC RT = 2.015min.

[0416] Synthesis of Compound I-11

[0417]

[0418] Compound 8 (35 mg, 0.035 mmol) was dissolved in dichloromethane (4 mL), and nitrogen was replaced three times. Trifluoroacetic acid (2 mL) was slowly added dropwise at 0°C under nitrogen protection. The reaction solution was stirred at 0°C for 7 hours. After the reaction was completed, the reaction solution was blown dry with a nitrogen stream, and the residue was washed with ether and centrifuged, which was repeated three times. The crude product was freeze-dried and purified by high pressure preparation to obtain a light yellow solid compound I-11 (7.7 mg, yield 29.6%). m / z (ES+), [M] + =741; acid HPLC RT =5.916min. 1 H NMR (400MHz, D2O) δ1.41 (s, 6H), 2.22-2.32 (m, 2H), 3.33 (t, J=6.7Hz, 2H), 3.80 (d, J=6.4Hz, 2H), 4.19 ( s, 3H), 4.60 (t, J=6.5Hz, 3H), 5.36 (d, J=5.7Hz, 1H), 6.97 (s, 1H), 8.24 (s, 1H), 8.82 (d, J=17.2Hz, 2H).

[0419] Example 12 Synthesis of Compound I-12

[0420]

[0421] Synthesis of compound 2

[0422]

[0423] Compound 1 (3.13 g, 15 mmol, 1.00 eq) was dissolved in N,N-dimethylformamide (30 mL). N-Boc-3-amino Propyl bromide (3.6 g, 15 mmol, 1.00 eq) and potassium carbonate (6 g, 15 mmol, 1 eq) were added to the reaction solution, and the reaction mixture was reacted at room temperature for 3 hours. The solid was filtered off, 100 ml of water was added to the organic phase, and extracted with ethyl acetate (2 x 200 mL). The organic phase was dried over anhydrous sodium sulfate and the organic phase was spin-dried to obtain a light-colored oily compound 2 (5 g, Yield: 91.2%). m / z (ES+), [M+H]+=367; acid, HPLC tR=0.986 min. 1H NMR (methanol-d4, 400 MHz): δ (ppm) 1.47 (s, 9H), 2.08 (dd, J=13.9, 7.1 Hz, 2H), 3.11 (t, J=6.6 Hz, 2H), 3.94 (s, 3H), 4.28 (t, J=6.9 Hz, 2H), 8.05 (d, J=0.8 Hz, 1H), 8.34 (d, J=5.5 Hz, 2H).

[0424] Synthesis of compound 3

[0425]

[0426] Trifluoroacetic acid (10 mL) was added dropwise to compound 2 (2.4 g, 6.55 mmol, 1.00 eq) in dichloromethane (20 mL), and the reaction mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated to give compound 3 (4 g crude) as a yellow oil. m / z (ES+), [M+H]+=267; acid, HPLC tR=0.833 min.

[0427] Synthesis of compound 4

[0428]

[0429] Compound 3 (4 g crude, 6.55 mmol, 1.00 eq). HATU (3.7 g, 13.11 mmol, 2 eq), acid (2.2 g, 6.55 mmol, 1. eq), DIEA (5.1 g, 40 mmol, 6 eq) were added to N, N-dimethylformamide (20 ml) at 0 degrees. The reaction mixture was reacted at room temperature for 2 hours. 50 mL of water was added to the reaction solution and extracted with ethyl acetate (2 x 100 mL). The organic phase was dried by column (PE / EA = 1 / 1-0 / 1). White compound 4 (2.5 g, 65.4% for 2 steps) was obtained. m / z (ES+), [M+H]+ = 584; acid, HPLC tR = 1.069 min. 1H NMR (methanol-d4, 300MHz): δ (ppm) 2.34 (p, J=6.5Hz, 2H), 3.60 (t, J=6.3Hz, 2H), 3.97 (s, 3H), 4.42 (t, J=6.5Hz, 2H), 5.35 (d, J=5.1Hz, 4H), 7.37-7.67 (m, 10H), 7.84 (d, J=1.8Hz, 2H), 8.05 (d, J=0.7Hz, 1H), 8.21 (s, 1H), 8.32-8.43 (m, 1H).

[0430] Synthesis of compound 5

[0431]

[0432] A solution of m-CPBA (1 g, 5.8 mmol, 6 eq) in dichloromethane (20 mL) was added dropwise to compound 4 ( 500mg , 0.86mmol) in dichloromethane (5 mL). The reaction mixture was stirred at room temperature for 5 hours, then heated to 45 degrees and continued to react for 2 hours. The reaction mixture was concentrated and plated to obtain white compound 5 (160 mg, 31.2%). m / z (ES+), [M+H]+=600; acid HPLC tR=1.918 min.

[0433] Synthesis of compound 6

[0434]

[0435] Compound 5 (450 mg, 0.75 mmol, 1.00 eq) was added to a mixed solution of N, N-dimethylformamide (6 mL) and iodomethane (3 mL), and the reaction mixture was reacted at 80 degrees in a microwave for 2 hours. The reaction mixture was directly purified by reverse phase to obtain white compound 6 (130 mg, 28.2%). m / z (ES+), [M]+=614; acid HPLC tR=1.142 min.

[0436] Synthesis of compound 7

[0437]

[0438] A solution of lithium hydroxide (50 mg, 1.78 mmol, 9 eq) in water (2 mL) was added dropwise to a solution of compound 6 (130 mg, 0.21 mmol) in methanol (5 mL), and the reaction mixture was reacted at room temperature for 2 hours. The methanol was dried by spin drying, the pH was adjusted to 2.5 with 1N hydrochloric acid, and the solid was filtered and dried to obtain a white compound 7 (200 mg crude) m / z (ES+), [M]+=600; acid, HPLC tR=1.490 min.

[0439] Synthesis of compound 8

[0440]

[0441] Compound 7 (200 mg crude, 0.21 mmol) and amine (110 mg, 0.21 mmol) were added to tetrahydrofuran (1.6 mL) and N,N-dimethylformamide (1 mL). DMTMM (100 mg, 0.34 mmol) was added to the mixture under nitrogen. The reaction mixture was stirred at room temperature for 2 hours and purified by reverse phase to give white solid compound 8 (110 mg, 47.5%). m / z (ES-), [MH] = 1108; acid HPLC tR = 2.375 min, 1H NMR (methanol-d4, 400MHz): δ (ppm) 1.47 (s, 9H), 1.52 (d, J = 6.9Hz, 16H), 2.36 (s, 2H) ), 3.51-3.69(m, 3H), 3.74(dd, J=14.0, 7.0Hz, 1H), 3.95-4.12(m, 1H), 4.26( s, 3H), 4.67 (s, 2H), 5.19 (d, J = 4.5Hz, 1H), 5.25 (d, J = 10.9Hz, 3H), 7.32-7.5 5(m, 10H), 7.78(s, 1H), 8.08(s, 1H), 8.29(s, 2H), 8.89(s, 1H), 9.07(s, 1H).

[0442] Synthesis of compound 9

[0443]

[0444] Sulfur trioxide pyridine complex (200 mg, 1.14 mmol, 11 eq) was added to compound 8 (110 mg, 0.1 mmol, 1.00 eq) in N,N-dimethylformamide (3 mL), and the reaction mixture was stirred overnight under nitrogen at room temperature and purified by reverse phase to obtain a light yellow solid compound 9 (30 mg, 25.4%). m / z (ES+), [M]+ = 1189; acid, HPLC tR = 1.137 min.

[0445] Synthesis of Compound I-12

[0446]

[0447] Boron trichloride (0.25 mL, 10.00 eq) was added dropwise to compound 9 (30 mg, 0.025 mmol, 1.00 equiv) in dichloromethane (2 mL) under nitrogen at 0 degrees, and the reaction mixture was stirred at 0 degrees for 4 hours. The reaction mixture was blown dry with nitrogen, and solids were precipitated by adding ether, which was centrifuged and washed several times with ether. The obtained solid was subjected to high pressure preparation (Atlantis preparative T3 OBD column, 19*250mm 10u; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 5B to 33B in 12 minutes; 254 / 220 nm) to obtain white solid compound I-12 (7.6 mg, 35.3%). m / z (ES+), [M]+=852; acid, HPLC tR=0.557min.1H NMR (D2O, 400MHz): δ (ppm) 1.53 (d, J = 3.8Hz, 6H), 2.43 (s, 2H), 3.72 (s, 2H), 3.89 (s, 2H), 4.21 (s, 3H), 4.30 (d, J = 3.7Hz, 3H), 5.45 ( t, J=4.8Hz, 1H), 7.07 (d, J=3.9Hz, 1H), 7.40 (d, J=4.6Hz, 1H), 7.76 (d, J=4.3Hz, 1H), 8.22 (d, J=4.3Hz, 1H), 8.83 (d, J=37.6Hz, 2H).

[0448] Example 13 Synthesis of Compound I-13

[0449]

[0450] The synthesis method is shown in Example 9.

[0451] Compound I-13: m / z (ES+), [M] + =715; acid HPLC RT =5.196min. 1 H NMR (400MHz, D2O) δ1.51 (s, 6H), 3.24-3.50 (m, 2H), 3.77 (d, J=9.4Hz, 2H), 4.17-4.18 (m, 4H), 4.60-4.68 (m, 2H), 4.70-4. 77 (m, 1H), 5.35 (dd, J=3.0, 6.1Hz, 1H), 7.04 (d, J=4.0Hz, 1H), 8.28 (d, J=3.2Hz, 1H), 8.50 (d, J=3.9Hz, 1H), 8.65 (s, 1H).

[0452] Example 14 Synthesis of Compound I-14

[0453]

[0454] Synthesis of compound 2:

[0455]

[0456] Compound 1 (100 mg, 0.149 mmol) and compound A (115 mg, 0.224 mmol) were dissolved in N, N-dimethylformamide (1.5 mL), and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (88 mg, 0.298 mmol) was slowly added. The reaction solution was stirred at room temperature under nitrogen protection for 2 hours, and then quenched with potassium hydrogen phosphate solution (10 mL), extracted with ethyl acetate (10 mL x 3), and the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, concentrated, purified by reverse phase column, and freeze-dried to obtain white solid compound 2 (78 mg, 44.8%). m / z (ES + ), [M] + =1167.

[0457] Synthesis of compound 3:

[0458]

[0459] Compound 2 (78 mg, 0.0668 mmol) was dissolved in N, N-dimethylformamide (4 mL), sulfur trioxide pyridine complex (106 mg, 0.668 mmol) was slowly added, and the reaction mixture was stirred at 45°C under nitrogen protection for 2 hours, purified by reverse phase column, and freeze-dried to obtain white solid compound 3 (70 mg, 84%). m / z (ES+), [M] + =1247.

[0460] Synthesis of compound I-14:

[0461]

[0462] Compound 3 (70 mg, 0.056 mmol) was dissolved in dichloromethane (5 mL), and a dichloromethane solution of boron trichloride (1 M, 66 mg, 0.561 mmol) was slowly added dropwise under an ice bath and nitrogen protection. The reaction solution was stirred for 4 hours under ice bath conditions. After the reaction was completed, the reaction solution was blown dry with a nitrogen stream. The reaction residue was washed with ether and centrifuged, and the process was repeated three times. The crude product was purified by reverse phase column chromatography and freeze-dried to obtain a white solid compound compound I-14 (5.2 mg, 12.1%). m / z (ES + ), [M+H] + =769. 1H NMR (400MHz, D2O) δ7.85 (d, J=5.1Hz, 1H), 6.94 (d, J=7.8Hz, 2H), 5.32 (s, 1H), 4.53 (s, 1H), 3.97 -3.89 (m, 1H), 3.58-3.70 (m, 6H), 3.41 (s, 1H), 2.41 (m, 1H), 2.11 (m, 1H), 1.48 (d, J=3.6Hz, 6H).

[0463] Example 15 Synthesis of Compound I-15

[0464]

[0465] Synthesis of compound 2:

[0466]

[0467] Compound 1 (150 mg, 0.224 mmol) was dissolved in tetrahydrofuran (2.5 mL), and then compound A (162 mg, 0.336 mmol) dissolved in N, N-dimethylformamide (1.5 mL) and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (132 mg, 0.448 mmol) were added in sequence under nitrogen protection, and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was removed by rotary evaporation, and a saturated sodium dihydrogen phosphate solution (10 mL) was added, and the mixture was extracted twice with ethyl acetate (10 mL x 2), and the organic phase was washed with water (20 mL). The aqueous phase was extracted with ethyl acetate (10 mL). The combined organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the crude product obtained by vacuum rotary drying was purified by reverse phase column chromatography to obtain a white solid compound 2 (50 mg, 19.7%).

[0468] Synthesis of compound 3:

[0469]

[0470] Compound 2 (50 mg, 0.0441 mmol) was dissolved in dry N,N-dimethylformamide (4 mL), and then sulfur trioxide pyridine complex (70 mg, 0.441 mmol) was added. The reaction solution was stirred at 45°C for two hours under nitrogen protection. After the reaction was completed, the reaction solution was directly purified by reverse phase column to obtain white solid compound 3 (40 mg, 74.8%). m / z (ES + ), [M+H] + =1214.

[0471] Synthesis of compound I-15:

[0472]

[0473] Compound 3 (40 mg, 0.033 mmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (2 mL) was added dropwise under nitrogen protection at 0°C, and the mixture was stirred at 0°C for 6 hours. The reaction solution was spin-dried and freeze-dried to obtain a crude product, which was purified by reverse phase column chromatography to obtain a white solid product I-15 (3.8 mg, 16.1%). m / z (ES + ), [M] + =716; 1 H NMR (400MHz, D2O) δ8.86 (s, 1H), 8.81 (s, 1H), 8.15 (s, 1H), 5.28 (d, J = 5.5Hz, 1H), 4.52-4.41 (m, 3H), 4.18 (s, 3H), 3.83 (dd, J=14.3, 6.5Hz, 1H), 3.57 (dd, J=14.3, 6.9Hz, 1H), 3.50 (s, 1H), 3.29-3.20 (m, 1H), 2.99-2.89 (m, 1H), 1.41 (s, 6H).

[0474] Example 16 Synthesis of Compound I-16

[0475]

[0476] Synthesis of compound 2:

[0477]

[0478] Compound 1 (210 mg, 0.314 mmol) was dissolved in tetrahydrofuran (5.0 mL), and compound A (173 mg, 0.471 mmol) dissolved in N, N-dimethylformamide (3.0 mL) and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (185 mg, 0.628 mmol) were added in sequence under nitrogen protection, and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was vortexed, saturated sodium dihydrogen phosphate solution (10 mL) was added, and then extracted twice with ethyl acetate (10 mL x 2). The organic phase was washed with water (20 mL), and the aqueous phase was extracted with ethyl acetate (10 mL). The combined organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and vacuum dried to obtain a crude product, which was purified by reverse phase column chromatography to obtain a white solid compound 2 (53 mg, 16.6%). m / z (ES + ), [MH] + =1018.

[0479] Synthesis of compound 3:

[0480]

[0481] Compound 2 (50 mg, 0.0441 mmol) was dissolved in dry N,N-dimethylformamide (4 mL), and then sulfur trioxide pyridine complex (78 mg, 0.49 mmol) was added. The reaction liquid was reacted at 45°C for two hours under nitrogen protection. After the reaction was completed, the reaction liquid was purified by reverse phase column to obtain white solid compound 3 (25 mg, 46.5%). m / z (ES + ), [MH] + =1098.

[0482] Synthesis of compound I-16:

[0483]

[0484] Compound 3 (25 mg, 0.023 mmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (2 mL) was added dropwise at 0°C under nitrogen protection, and the reaction was stirred at 0°C for 6 hours. The reaction solution was spin-dried and freeze-dried to obtain a crude product, which was purified by reverse phase column chromatography to obtain a white solid product I-16 (2.0 mg, 12.6%). m / z (ES + ), [M+H] + =701. 1 H NMR (400MHz, D2O) δ8.83 (s, 1H), 8.76 (s, 1H), 8.14 (s, 1H), 5.28 (d, J = 5.5Hz, 1H), 4.58 (s, 2H), 4.50 (s, 1H), 4.15 (s, 3 H), 3.82 (dd, J=14.3, 6.6Hz, 1H), 3.57 (dd, J=14.3, 6.9Hz, 1H), 3.14-3.06 (m, 2H), 2.33 (p, J=7.6Hz, 2H), 1.40 (s, 6H).

[0485] Example 17 Synthesis of Compound I-17

[0486]

[0487] Synthesis of compound 1:

[0488]

[0489] In a 10 mL round-bottom flask, under nitrogen protection, to a solution of (R)-4,5-bis(benzyloxy)-2-(3-(5-carboxyisoxazol-3-yl)pyrrolidine-1-carbonyl)pyridine 1-oxide (324 mg, 0.63 mmol) and compound A-1 (400 mg, 0.63 mmol) in tetrahydrofuran (3.2 mL) and N,N-dimethylformamide (2 mL), 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (278 mg, 0.945 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The mixture was purified by reverse phase column chromatography to obtain compound 1 (500 mg, 57%) as a white solid. m / z (ES + ), [M+H] + =1132.

[0490] Synthesis of compound 2:

[0491]

[0492] In a 10 mL round-bottom flask, sulfur trioxide pyridine (600 mg, 3.8 mmol) was added to a solution of compound 1 (500 mg, 0.442 mmol) in N,N-dimethylformamide (3 mL). The resulting solution was stirred at 45°C for 3 hours. The reaction solution was purified by reverse phase column chromatography to obtain a light yellow solid compound 2 (350 mg, 65.4%).

[0493] m / z(ES + ), [M+H] + =1212.

[0494] Synthesis of compound I-17:

[0495]

[0496] Boron trichloride (5 ml, 5 mmol) was added to a dichloromethane (10 mL) solution of compound 2 (340 mg, 0.28 mmol) at 0°C, and the resulting mixture was stirred at 0°C for 4 hours under nitrogen protection. After the reaction was completed, the solution was blown dry with a stream of N nitrogen, and the solid was washed three times with ether and centrifuged to obtain a crude product. The crude product was purified by reverse phase column chromatography to obtain an off-white solid I-17 (61.8 mg). m / z (ES + ), [M+H] + =766. 1H NMR (400MHz, D2O): δ (ppm) 1.42 (t, J=10.1Hz, 4H), 2.20 (ddd, J=21.0, 13.5, 7.1Hz, 1H), 2.35-2.64 (m, 1H), 3.33-4. 15 (m, 7H), 4.55-4.68 (m, 1H), 5.41 (t, J=5.6Hz, 1H), 6.86-7.13 (m, 2H), 7.16 (d, J=3.1Hz, 1H), 7.94 (d, J=5.3Hz, 1H)

[0497] Example 18 Synthesis of Compound I-18

[0498]

[0499] Synthesis of compound 2

[0500]

[0501] 2-Chloro-3,4-dimethoxybenzaldehyde (20.06 g, 100 mmol) was dissolved in dioxane (300 mL), Sulfamic acid A solution of 21.36 g, 220 mmol) in water (200 mL) and a solution of NaClO2 (19.9 g, 220 mmol) in water (100 mL) were added dropwise to the reaction solution at 0 degrees. The reaction mixture was reacted at 0 degrees for 30 minutes. Sodium bisulfite The reaction was quenched with an aqueous solution (200 mL) of (45.8 g, 440 mmol). The reaction solution was extracted with ethyl acetate, and the organic phase was washed with water and saturated brine, respectively. The organic phase was dried over anhydrous sodium sulfate and spin-dried to give compound 2 (21.7 g, 100%). m / z (ES+), [MH]+ = 215; acid, HPLC tR = 0.673 min. 1H-NMR (DMSO-d6) δ: 13.04 (br s, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.11 (d, J = 8.9 Hz, 1H), 3.89 (s, 3H), 3.74 (s, 3H).

[0502] Synthesis of compound 3

[0503]

[0504] Boron tribromide (24 mL, 253 mmol) was added dropwise to compound 2 (21.7 g, 100 mmol) in dichloromethane (180 mL) at 0 degrees, and the reaction mixture was reacted at room temperature for 2 hours. Methanol (270 mL) was slowly added to the reaction solution, and the reaction was continued for two days. Ice water was added to the reaction solution, and the methanol was spin-dried to obtain a solid precipitated. The solid was filtered and dried to obtain compound 3 (18.9 g, 93%). [M+H] + = 203; acid, HPLC tR = 0.987 min. 1H-NMR (DMSO-d6) δ: 10.50 (br s, 1H), 9.39 (br s, 1H), 7.22 (d, J = 8.5 Hz, 1H), 6.78 (d, J = 8.5 Hz, 1H), 3.76 (s, 3H).

[0505] Synthesis of compound 5

[0506]

[0507] Potassium carbonate (32.4 g, 23.4 mmol), sodium iodide (14 g, 93.5 mmol) and 4-Methoxybenzyl chloride (33.5g, 215mmol) was added to N, N-dimethylformamide (140mL) of compound 3 (18.9g, 93.5mmol), and the reaction mixture was reacted at 50 degrees for 3.5 hours. Water (500mL) and IPE (200mL) were added to the reaction solution. Solid precipitated, the solid was filtered and dissolved in tetrahydrofuran (230mL) and methanol (180mL), 2mol / L sodium hydroxide (125mL, 250mmol) was added to the reaction solution, and the reaction mixture was refluxed for 1.5 hours. The solvent was dried, IPE and 2mol / L hydrochloric acid (135mL, 270mmol) were added to the mixture, solid precipitated, filtered and dried to obtain compound 5 (19.6g, 48.5%). m / z (ES+), [M+Na]+=451; acid, HPLC tR=1.393min.

[0508] Synthesis of compound 6

[0509]

[0510] Compound 5 (1 g, 2.33 mmol), amine (541 mg, 2.33 mmol), HOBt (630 mg, 4.66 mmol), triethylamine (940 mg, 9.32 mmol) and EDC·HCl (895 mg, 4.66 mml) were added to 50 ml of tetrahydrofuran, and the reaction mixture was reacted at room temperature for 3 hours. Water and ethyl acetate were added to the mixture, the aqueous phase was separated and extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the organic phase was spin-dried and purified by column to obtain compound 6 (720 mg, 52%) as a yellow oil m / z (ES+), [M]+=607; acid HPLC tR=1.308 min

[0511] Synthesis of compound 7

[0512]

[0513] An aqueous solution of lithium hydroxide (4 ml, 2 mol / L) was added dropwise to a solution of compound 6 (440 mg, 0.73 mmol) in methanol (6 ml). The reaction mixture was reacted at room temperature for 2 hours. The methanol was dried by spin drying, the aqueous phase was adjusted to pH 2.5 with hydrochloric acid (1 mol / L), the aqueous phase was extracted with ethyl acetate, and the organic phase was concentrated to give a white compound 7 (650 mg, 92.4%). m / z (ES+), [M]+=593; acid HPLC tR=1.654 min

[0514] Synthesis of compound 8

[0515]

[0516] Compound 7 (323 mg, 0.54 mmol) and compound H-1 (286 mg, 0.54 mmol) were added to tetrahydrofuran (1.6 mL) and N,N-dimethylformamide (1 mL). DMTMM (240 mg, 0.81 mmol) was added to the mixture under nitrogen. The reaction mixture was stirred at room temperature for 2 hours and purified by reverse phase to obtain white solid compound 8 (350 mg, 53.8%). m / z (ES+), [M]+=1101; acid HPLC tR=1.996 min.

[0517] Synthesis of compound 9

[0518]

[0519] Sulfur trioxide pyridine complex (350 mg, 2.21 mmol, 7 eq) was added to compound 8 (350 mg, 0.318 mmol, 1.00 eq) in N,N-dimethylformamide (3 mL), and the reaction mixture was stirred for 3 hours under nitrogen at 45 degrees. Reverse phase purification gave a light yellow solid compound 9 (270 mg, 72%). m / z (ES+), [M]+ = 1181; acid, HPLC tR = 1.200 min.

[0520] Synthesis of Compound I-18

[0521]

[0522] Boron trichloride (0.63 ml, 0.63 mmol) was added dropwise to compound 9 (50 mg, 0.042 mmol, 1.00 eq) in dichloromethane (2 mL) under nitrogen at 0 degrees. The reaction mixture was stirred at 0 degrees for 4 hours. The solvent was dried with nitrogen, ether was added and centrifuged three times, and the solid was prepared by high pressure (XSelect CSH preparative C18 OBD column, 19*250 mm, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 25 mL / mm; gradient: 5B to 30B in 10 minutes; 254 / 220 nm;) to obtain white solid I-18 (7.0 mg). m / z (ES+), [M]+=785; acid, HPLC tR=0.673 min. 1 H NMR (D2O, 400MHz): δ (ppm) 1.11-1.62 (m, 6H), 2.00-2.48 (m, 2H), 3.25-3.39 (m, 2H), 3.54-3 .95 (m, 5H), 4.45-4.60 (m, 1H), 5.33 (t, J=5.9Hz, 1H), 6.67-6.95 (m, 3H), 6.98-7.08 (m, 1H).

[0523] Example 19 Synthesis of Compound I-19

[0524]

[0525] Synthesis of compound 2

[0526]

[0527] Sulfonyl chloride (10.51 g, 77.8 mmol) was added dropwise 3,4-Dihydroxybenzoic acid(5g, 32.46mmol) in acetic acid (20mL). The reaction mixture was stirred at 50 degrees overnight. The reaction solution was cooled and crystallized with (ethyl acetate / n-hexane) to obtain compound 2 (2g, 27%). [M] + = 223; acid, HPLC tR = 0.659min.

[0528] Synthesis of compound 3

[0529]

[0530] 4-Methoxybenzyl chloride (5.6g, 36mmol) was added to compound 2 (2g, 9mmol), potassium carbonate (6.5g, 47mmol), sodium iodide (1.35g, 9mmol) in N, N-dimethylformamide (50ml). The reaction mixture was stirred at 50 degrees for 6 hours. Water (50mL) was added to the reaction solution, extracted with ethyl acetate (100ml), the organic phase was washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, and dried by column to obtain compound 3 (4.88g, 93%). [M+Na+ACN]+=646; ​​acid, HPLC tR=2.274min.

[0531] Synthesis of compound 4

[0532]

[0533] 8 ml of sodium hydroxide (2 mol / L, 16 mmol) was added dropwise to a solution of compound 3 (2.4 g, 4.12 mmol) in tetrahydrofuran (8 mL) and methanol (6 mL). The reaction mixture was refluxed for 1.5 hours. The solvent was dried, and a solution of IPE and 2 mol / L hydrochloric acid (8.5 mL, 17 mmol) was added to the mixture, filtered to obtain a solid, and dried to obtain compound 4 (1.57 g, 82.6%). m / z (ES+), [M+Na]+=486; acid, HPLC tR=1.505 min.

[0534] Synthesis of compound 5

[0535]

[0536] Compound 4 (462 mg, 1 mmol), amine (232 mg, 1 mmol), HOBt (275 mg, 2 mmol), triethylamine (412 mg, 4 mmol) and EDC·HCl (384 mg, 2 mml) were added to tetrahydrofuran (5 ml), and the reaction mixture was reacted at room temperature for 3 hours. Water was added to the mixture, extracted with ethyl acetate three times, the organic phase was washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, and the organic phase was spin-dried and passed through a column to obtain a yellow oily compound 6 (318 mg, 50%). m / z (ES+), [M+H]+=641; acid HPLC tR=1.955 min

[0537] Synthesis of compound 6

[0538]

[0539] Lithium hydroxide aqueous solution (1 ml, 2 mol / L) was added dropwise to compound 6 (318 mg, 0.5 mmol) in methanol (3 ml). The reaction mixture was reacted at room temperature for 2 hours. The methanol was dried by spin drying, and the aqueous phase was adjusted to pH 2.5 with hydrochloric acid (1 mol / L). The aqueous phase was extracted with ethyl acetate, and the organic phase was dried by spin drying to obtain white compound 7 (276 mg, 88.7%) as a white solid m / z (ES+), [M+H]+=627; acid HPLC tR=1.793 min

[0540] Synthesis of compound 7

[0541]

[0542] Compound 6 (276 mg, 0.44 mmol) and amine (232 mg, 0.44 mmol) were added to tetrahydrofuran (1.6 mL) and N,N-dimethylformamide (1 mL). DMTMM (200 mg, 0.66 mmol) was added to the mixture under nitrogen. The reaction mixture was stirred at room temperature for 2 hours and purified by reverse phase to obtain white compound 7 (270 mg, 55%). m / z (ES+), [M]+=1136; acid HPLC tR=2.094 min.

[0543] Synthesis of compound 8

[0544]

[0545] Sulfur trioxide pyridine complex (300 mg, 1.89 mmol, 8 eq) was added to compound 7 (270 mg, 0.238 mmol, 1.00 eq) in N,N-dimethylformamide (3 mL), and the reaction mixture was stirred for 3 hours under 45° nitrogen conditions. The light yellow solid compound 8 (200 mg, 69%) was obtained by reverse phase purification. m / z (ES+), [M]+=1216; acid, HPLC tR=1.199 min.

[0546] Synthesis of Compound I-19

[0547]

[0548] Boron trichloride (0.63 ml, 0.63 mmol) was added dropwise to compound 8 (50 mg, 0.042 mmol, 1.00 eq) in dichloromethane (2 mL) under nitrogen conditions at 0 degrees. The reaction mixture was stirred at 0 degrees for 4 hours, the solvent was blown dry with nitrogen, and washed three times by centrifugation with ether. The solid was prepared by high pressure (column: XSelect CSH preparative C18OBD column, 19*250 mm, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 5B to 30B in 10 minutes; 254 / 220 nm;) to obtain white solid compound I-19 (1.9 mg). m / z (ES+), [M]+=819; acid, HPLC tR=0.740 min. 1 H NMR (D2O, 400MHz): δ (ppm) 1.31-1.62 (m, 6H), 2.00-2.48 (m, 2H), 3.25-3.95 (m, 7H) ), 4.45-4.60 (m, 1H), 5.33 (t, J=5.9Hz, 1H), 6.71-6.95 (m, 2H), 6.98-7.08 (m, 1H)

[0549] Example 20 Synthesis of Compound I-20

[0550]

[0551] Synthesis of compound 2

[0552]

[0553] Compound 1 (2.1 g, 9 mmol), N,N-diisopropylethylamine (3.48 g, 27 mmol) and N-Boc-bromoethylamine (2.02 g, 9 mmol) were dissolved in acetonitrile (20 mL), and the reaction solution was stirred at 60°C for 2 hours, cooled to room temperature and dried by spin drying, and purified by silica gel plate to obtain yellow oily compound 2 (1.26 g, yield 41.2%). m / z (ES+), [M+1] = 340; acid HPLC RT = 1.137 min. 1 H NMR (300MHz, DMSO-d6) δ1.43 (s, 9H), 1.90-2.08 (m, 1H), 2.33 (ddt, J=6.7, 9.8, 13.2Hz, 1H), 2.55-2.85 ( m, 5H), 3.04 (dd, J=8.0, 9.6Hz, 1H), 3.21 (t, J=6.8Hz, 2H), 3.47-3.66 (m, 1H), 3.97 (s, 3H), 7.09 (s, 1H).

[0554] Synthesis of compound 3

[0555]

[0556] Compound 2 (1.26 g, 3.71 mmol) was dissolved in methanol (10 mL), and a methanol solution of hydrogen chloride (4 M, 20 mL) was slowly added. The reaction solution was stirred at room temperature for 8 hours and then dried by rotation. The crude brown oil compound 3 (1.19 g) was used directly in the next step without purification. m / z (ES+), [M+H]+-240; acid HPLC RT-0.523 min.

[0557] Synthesis of compound 4

[0558]

[0559] The raw material A (1.85 g, 4.31 mmol) was dissolved in N, N-dimethylformamide (20 mL), HATU (3.28 g, 8.62 mmol), N, N-diisopropylethylamine (2.22 g, 17.24 mmol) and compound 3 (1.19 g, 4.31 mmol) were slowly added, the reaction solution was stirred at room temperature for 3 hours, quenched with water, extracted with ethyl acetate three times, the organic phase was washed with saturated brine three times, dried, spin-dried, and purified by silica gel column to obtain a light yellow solid compound 4 (1.75 g, yield 62.9%). m / z (ES+), [M]+=650; acid HPLC RT=1.775 min.

[0560] Synthesis of compound 5

[0561]

[0562] Compound 4 (1.5 g, 2.3 mmol) was dissolved in N, N-dimethylformamide (20 mL), iodomethane (327 mg, 2.3 mmol) was slowly added dropwise to the solution, the reaction solution was stirred at 80°C for 4 hours, directly purified by C18 column, and freeze-dried to obtain yellow oily compound 5 (860 mg, yield 56.2%). m / z (ES+), [M] + =665; acid HPLC RT=1.557min.

[0563] Synthesis of compound 6

[0564]

[0565] Compound 5 (860 mg, 1.29 mmol) was dissolved in methanol / tetrahydrofuran (5 mL / 5 mL), and 1 M sodium hydroxide aqueous solution (2.5 mL, 2.58 mmol) was slowly added dropwise. The reaction solution was stirred at room temperature for 3 hours, concentrated, and dissolved in water. The aqueous solution was adjusted to pH 3-4 with 1 M hydrochloric acid and freeze-dried to obtain a crude yellow solid compound 6 (850 mg) which was used directly in the next step without purification. m / z (ES+), [M] + =651; acid HPLC RT=1.474min.

[0566] Synthesis of compound 7

[0567]

[0568] Compound 6 (850 mg, 1.31 mmol) and compound H-1 (690 mg, 1.31 mmol) were dissolved in N, N-dimethylformamide / tetrahydrofuran (6 mL / 9 mL), and DMTMM (773 mg, 2.62 mmol) was slowly added. The reaction solution was stirred at room temperature for 2 hours, directly purified by C18 column, and freeze-dried to obtain yellow solid compound 7 (388 mg, yield 25.5%). m / z (ES+), [M] + =1159; acid HPLC RT=2.217min.

[0569] Synthesis of compound 8

[0570]

[0571] Compound 7 (150 mg, 0.13 mmol) was dissolved in N,N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (205 mg, 1.3 mmol) was slowly added, the reaction solution was stirred at 45°C for 6 hours, directly purified by C18 column, and freeze-dried to obtain yellow solid compound 8 (60 mg, yield 37.5%). m / z (ES+), [M] + =1239; acid HPLCRT =2.250min.

[0572] Synthesis of Compound I-20

[0573]

[0574] Compound 8 (60 mg, 0.048 mmol) was dissolved in dichloromethane (3 mL), and the nitrogen was replaced three times. A dichloromethane solution of boron trichloride (1 M, 2 mL) was slowly added dropwise under an ice bath and nitrogen protection. The reaction solution was stirred for 4 hours under an ice bath. After the reaction was completed, the reaction solution was blown dry with a nitrogen stream, and the residue was washed with ether and centrifuged, which was repeated three times. The crude product was freeze-dried and purified by high pressure preparation. Compound I-20 (2 mg, yield 4.9%) was obtained as an off-white solid. m / z (ES+), [M] + =843; acid HPLC RT =0.981min. 1 H NMR (400MHz, D2O) δ1.47 (d, J=5.6Hz, 6H), 2.44-2.62 (m, 1H), 2.82 (d, J=10.4Hz, 1H), 3.31 (d, J=13.3Hz, 3H), 3.72-4 .00 (m, 9H), 4.08-4.25 (m, 2H), 4.52-4.67 (m, 1H), 5.41 (dd, J=2.5, 5.7Hz, 1H), 6.85-7.00 (m, 2H), 7.00-7.08 (m, 2H).

[0575] Example 21 Synthesis of Compound I-21

[0576]

[0577] Synthesis of compound 3:

[0578]

[0579] 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (100 mg, 0.34 mmol) was added to a mixed solvent of THF (1.6 mL) / DMF (1 mL) of compound 1 (110 mg, 0.21 mmol) and compound H-1 (100 mg, 0.19 mmol) under nitrogen protection, and the reaction system was stirred at room temperature for 2 hours. The reaction mixture was directly purified by reverse phase column to obtain a white solid 2 (130 mg, 54.6%). m / z (ES + ), [M] + =1024.

[0580] Synthesis of compound 4:

[0581]

[0582] SO3.Py (200 mg, 1.14 mmol) was added to compound 2 (108 mg, 0.1 mmol) in N,N-dimethylformamide (3 mL) at 0°C, and the reaction system was stirred at room temperature for 20 hours. The reaction solution was directly purified by reverse phase column to obtain a light yellow solid 3 (56 mg, 50%). m / z (ES + ), [M] + =1104.

[0583] Synthesis of compound I-21:

[0584]

[0585] Boron trichloride (1 mol / l dichloromethane solution) was added to a dichloromethane solution (7 mL) of compound 4 (92 mg, 0.083 mmol) at 0°C under nitrogen protection, and the reaction system was stirred at 0°C for 1 hour. The solvent was blown dry with nitrogen, ether was added, centrifuged, the supernatant was removed, the solid was purified with a reverse phase column, and the product was directly freeze-dried to obtain a white solid final product I-21 (12.7 mg, 19.85%). 1 H NMR (400MHz, D2O) δ1.32-1.55 (m, 6H), 2.16 (dq, J=20.4, 6.8, 5.7Hz, 1H), 2.42 (ddd, J=25.8, 12.6, 6.2Hz, 1H), 3.35-3.54 (m, 2H), 3.54-3.88 (m, 5H), 4.53-4.60 (m, 1H), 5.37 (t, J=5.7Hz, 1H), 6.90-7.09 (m, 2H), 7.01-7.04 (m, 1H), 7.87 (d, J=4.6Hz, 1H).m / z (ES + ), [M+H] + =768; [MH]- =766.

[0586] Example 22 Synthesis of Compound I-22

[0587]

[0588] Synthesis of compound 1

[0589]

[0590] Raw material 1 (140 mg, 0.27 mmol) and compound A (170 mg, 0.27 mmol) were added to tetrahydrofuran (3.2 mL) and N,N-dimethylformamide (2 mL). DMTMM (120 mg, 0.4 mmol) was added to the mixture under nitrogen, and the reaction mixture was stirred at room temperature for 2 hours. White compound 1 (150 mg, 49%) was obtained by reverse phase purification. m / z (ES+), [M]+=1132; acid HPLC tR=1.91 min.

[0591] Synthesis of compound 2

[0592]

[0593] Sulfur trioxide pyridine complex (200 mg, 1.266 mmol, 9.7 eq) was added to compound 1 (150 mg, 0.132 mmol, 1.00 eq) in N,N-dimethylformamide (3 mL), and the reaction mixture was stirred for 3 hours under nitrogen at 45 degrees. Reverse phase purification gave a light yellow compound 2 (120 mg, 78%) m / z (ES+), [M]+=1212; acid, HPLC tR=1.843 min.

[0594] Synthesis of Compound I-22

[0595]

[0596] Boron trichloride (1 ml, 1 mmol) was added dropwise to compound 2 (70 mg, 0.058 mmol, 1.00 eq) in dichloromethane (2 mL) under nitrogen at 0 degrees. The reaction mixture was stirred at 0 degrees for 4 hours, the solvent was blown dry with nitrogen, the solid was washed three times by centrifugation with ether, and the solid was prepared by high pressure (column: Atlantis preparative T3 OBD column, 19*250mm 10u; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 10B to 25B in 10 minutes; 254 / 220 nm;) to obtain white compound I-22 (11.2 mg). m / z (ES+), [M+H]+=766; acid, HPLC tR=0.869 min. 1 H NMR (DMSO-d6, 400MHz): δ (ppm) 1.18-1.42 (m, 4H), 2.06 (d, J=7.8Hz, 1H), 2.37 (d, J=7.7Hz, 1H), 3.44-3.46 (m, 3 H), 3.55-3.60(m, 3H), 3.85-3.90(m, 1H), 4.03-4.27(m, 1H), 5.19-5.25(m, 1H), 6.71-7.15(m, 3H), 7.95(s, 1H).

[0597] Example 23 Synthesis of Compound I-23

[0598]

[0599] Synthesis of compound 2

[0600]

[0601] Compound 1 (428 mg, 1 mmol) and raw material 1 (232 mg, 1 mmol) were dissolved in tetrahydrofuran (5 ml), and HOBt (275 mg, 2 mmol), triethylamine (412 mg, 4 mmol) and EDC·HCl (384 mg, 2 mml) were added in sequence, and the reaction solution was stirred at room temperature for 3 hours. After the reaction was completed, the reaction solution was diluted with water and ethyl acetate, respectively, and then extracted with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous magnesium sulfate, and finally concentrated and dried. The crude product was purified by silica gel column to obtain the final product yellow oil 2 (606 mg, 50%). m / z (ES+), [M]+=607; acid HPLC tR=1.180 min

[0602] Synthesis of compound 3

[0603]

[0604] Compound 2 (303 mg, 0.5 mmol) was dissolved in methanol (3.0 ml) and tetrahydrofuran (3.0 ml), and then lithium hydroxide aqueous solution (1 ml, 2 mol / L) was added, and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, methanol and tetrahydrofuran were spun out, and the remaining aqueous solution was adjusted to pH 2.5 with hydrochloric acid (1 mol / L). Then it was extracted with ethyl acetate, and the organic phase was dried to obtain the final product 3 (262 mg, 88.7%) as a white solid. m / z (ES+), [M]+ = 593; acid HPLCtR = 1.104 min

[0605] Synthesis of compound 4

[0606]

[0607] Compound 3 (261 mg, 0.44 mmol) and compound A (279 mg, 0.44 mmol) were dissolved in tetrahydrofuran (1.6 mL) and N,N-dimethylformamide (1 mL). DMTMM (200 mg, 0.66 mmol) was slowly added and nitrogen protection was performed. The reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the crude product was purified by reverse phase column to obtain a white solid final product 4 (293 mg, 55%). m / z (ES+), [M+H]+=1210; acid HPLC tR=2.528 min.

[0608] Synthesis of compound 5

[0609]

[0610] Compound 4 (288 mg, 0.238 mmol, 1.0 eq) was dissolved in N, N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (300 mg, 1.89 mmol, 8.0 eq) was slowly added, and the reaction solution was stirred at 45°C for 3 hours. After the reaction was completed, the crude product was purified by reverse phase column to obtain the final product 5 (211 mg, 69%) as an off-white solid. m / z (ES+), [M+H]+=1290; acid, HPLC tR=1.275 min.

[0611] Synthesis of Compound I-23

[0612]

[0613] Compound 5 (50 mg, 0.042 mmol, 1.00 eq) was dissolved in dichloromethane (2 mL), the reaction flask was replaced with nitrogen three times, a dichloromethane solution of boron trichloride (0.63 ml, 0.63 mmol) was slowly added dropwise in an ice bath and under nitrogen protection, the reaction solution was stirred for 4 hours in an ice bath, the reaction solution was blown dry with a nitrogen stream, the residue was washed with ether and centrifuged, repeated three times, the obtained crude product was freeze-dried, and purified by high pressure preparation to obtain compound I-23 (4.1 mg) as a light gray solid. m / z (ES+), [M]+=783; acid, HPLC tR=1.054 min. 1 H NMR (400MHz, DMSO-d6) δ8.60 (s, 1H), 7.07-6.69 (m, 3H), 6.64 (dd, J=8.2, 5.0Hz, 1H), 5.21 (t, J=5.4Hz, 1H), 4.25-4.1 0 (m, 1H), 3.50 (s, 5H), 3.32-3.19 (m, 1H), 2.40-2.24 (m, 1H), 2.04 (ddd, J=19.8, 12.4, 7.3Hz, 1H), 1.52-1.04 (m, 4H).

[0614] Example 24 Synthesis of Compound I-24

[0615]

[0616] Synthesis of compound 2

[0617]

[0618] Compound 1 (1.9 g, 8.2 mmol), N,N-diisopropylethylamine (3.17 g, 24.6 mmol) and N-Boc-bromoethylamine (1.84 g, 8.2 mmol) were dissolved in acetonitrile (10 mL), and the reaction solution was stirred at 60°C for 2 hours, cooled to room temperature and dried by spin drying, and purified by silica gel plate to obtain yellow oily compound 2 (800 mg, yield 28.7%). m / z (ES+), [M+1] = 340, acid HPLC RT = 0.803 min. 1 H NMR (300 MHz, methanol-d4) δ 1.43 (s, 9H), 1.98 (ddd, J = 7.2, 13.2, 14.4 Hz, 1H), 2.33 (ddt, J = 6.7, 9.8, 13.2 Hz, 1H), 2.54-2.81 (m, 5H), 3.03 (dd, J = 8.0, 9.6 Hz, 1H), 3.21 (t, J = 6.8 Hz, 2H), 3.55 (ddt, J = 6.7, 7.9, 9.8 Hz, 1H), 3.93 (s, 3H), 7.09 (s, 1H).

[0619] Synthesis of compound 3

[0620]

[0621] Compound 2 (800 mg, 2.36 mmol) was dissolved in methanol (5 mL), and a methanol solution of hydrogen chloride (4 M, 10 mL) was slowly added. The reaction solution was stirred at room temperature for 8 hours and then dried by rotation. The crude brown semi-solid compound 3 (750 mg) was used directly in the next step without purification. m / z (ES+), [M+H]+=240, acid HPLC RT=0.506 min. 1 H NMR (300 MHz, methanol-d4) δ 2.35 (s, 1H), 2.65 (s, 1H), 3.46 (t, J = 7.0 Hz, 3H), 3.68 (t, J = 7.0 Hz, 3H), 3.95 (s, 6H), 7.25 (s, 1H).

[0622] Synthesis of compound 4

[0623]

[0624] The raw material A (750 mg, 2.72 mmol) was dissolved in N, N-dimethylformamide (10 mL), HATU (2.07 g, 5.44 mmol), N, N-diisopropylethylamine (1.40 g, 10.88 mmol) and compound 3 (1.17 g, 2.72 mmol) were slowly added, and the reaction solution was stirred at room temperature for 3 hours, quenched with water, extracted with ethyl acetate three times, and the organic phase was washed with saturated brine three times, dried, spin-dried, and purified by silica gel column to obtain a light yellow solid compound 4 (680 mg, yield 44.4%, ee value 96.94%). m / z (ES+), [M]+=650, acid HPLC RT=1.400 min. 1 H NMR (300 MHz, methanol-d4) δ 1.90-2.09 (m, 1H), 2.22-2.44 (m, 1H), 2.69-2.96 (m, 5H), 2.97-3.09 (m, 1H), 3.54 (dt, J = 7.5, 13.4 Hz, 3H), 3.77 (s, 3H), 3.81 (s, 3H), 3.8 9(s, 3H), 4.92(s, 2H), 5.11(s, 2H), 6.77-6.85(m, 2H), 6.92-6.98(m, 2H), 7.11 (d, J=9.9Hz, 2H), 7.19 (d, J=8.5Hz, 1H), 7.25-7.32 (m, 2H), 7.36-7.44 (m, 2H).

[0625] Synthesis of compound 5

[0626]

[0627] Compound 4 (680 mg, 1.05 mmol) was dissolved in N,N-dimethylformamide (10 mL), and iodomethane (746 mg, 5.25 mmol) was slowly added dropwise. The reaction solution was stirred at 80°C for 4 hours, directly purified by C18 column, and freeze-dried to obtain yellow oily compound 5 (570 mg, yield 82%). m / z (ES+), [M] + =665, acid HPLC RT=1.681min. 1 H NMR (300MHz, methanol-d4) δ2.51 (dt, J=7.7, 14.5Hz, 1H), 2.81 (dd, J=7.7, 14.7Hz, 1H), 3.34 (d, J=5.6Hz, 3H), 3.67-4.03 (m, 16H), 4.08-4.29 (m, 2H), 4.94(d, J=2.5Hz, 2H), 5.12(s, 2H), 6.77-6.85(m, 2H), 6.91-6.99(m, 2H ), 7.14 (dd, J=2.6, 8.6Hz, 1H), 7.18-7.32 (m, 4H), 7.40 (d, J=8.5Hz, 2H).

[0628] Synthesis of compound 6

[0629]

[0630] Compound 5 (300 mg, 0.45 mmol) was dissolved in methanol / tetrahydrofuran (2.5 mL / 2.5 mL), and 1 M sodium hydroxide aqueous solution (1 mL, 0.92 mmol) was slowly added dropwise. The reaction solution was stirred at room temperature for 3 hours, concentrated, and the residue was dissolved in water. The aqueous solution was adjusted to pH 3-4 with 1 M hydrochloric acid, and freeze-dried. The crude yellow solid compound 6 (350 mg) was used directly in the next step without purification. m / z (ES+), [M] + =651, acid HPLC RT=1.100min.

[0631] Synthesis of compound 7

[0632]

[0633] Compound 6 (350 mg, 0.54 mmol) and raw material B (343 mg, 0.54 mmol) were dissolved in N, N-dimethylformamide / tetrahydrofuran (2 mL / 3 mL), and DMTMM (319 mg, 1.08 mmol) was slowly added. The reaction solution was stirred at room temperature for two hours, purified by C18 column, and freeze-dried to obtain yellow solid compound 7 (150 mg, yield 22%). m / z (ES+), [M] + =1267, acid HPLC RT = 1.275min. 1 H NMR (400 MHz, methanol-d4) δ 1.40-1.64 (m, 13H), 2.39 (td, J = 7.1, 14.0, 14.5 Hz, 1H), 2.61-2.84 (m, 1H), 3.25 (s, 1H), 3.42-3.54 (m, 1H), 3.60-4.18 (m, 17H), 4.93 (d, J = 6.4 Hz, 2H), 5.11 (d, J=6.6Hz, 2H), 5.26 (dd, J=4.8, 8.3Hz, 1H), 6.74-6.83 (m, 2H), 6.87 (d, J=4.4Hz, 1H), 6.94 (dq, J=2.6, 3.1, 9.7Hz, 3H), 7.13 (dd, J=6.5, 8.6Hz, 1H), 7.17-7.48 (m, 16H), 8.27 (s, 2H).

[0634] Synthesis of compound 8

[0635]

[0636] Compound 7 (150 mg, 0.12 mmol) was dissolved in N,N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (380 mg, 2.4 mmol) was slowly added, the reaction solution was stirred at 45°C for 6 hours, and purified by C18 column to obtain yellow solid compound 8 (60 mg, yield 37.7%). m / z (ES+), [M] + =1347, acid HPLC RT = 2.236min.

[0637] Synthesis of Compound I-24

[0638]

[0639] Compound 8 (40 mg, 0.03 mmol) was dissolved in dichloromethane (3 mL), and the nitrogen was replaced three times. A dichloromethane solution of boron trichloride (1 M, 0.6 mL) was slowly added dropwise at 0°C under nitrogen protection. The reaction solution was stirred for 4 hours in an ice bath. After the reaction was completed, the reaction solution was blown dry with a nitrogen stream, and the residue was washed with ether and centrifuged, which was repeated three times. The crude product was freeze-dried and purified by high pressure preparation to obtain an off-white solid compound I-24 (4.2 mg, yield 16.8%). m / z (ES+), [M] + =841, acid HPLC RT=1.118min. 1 H NMR (400MHz, DMSO-d6) δ1.26 (d, J=27.5Hz, 4H), 2.23-2.36 (m, 1H), 2.62-2.71 (m, 1H), 3.20 (d, J=2.0Hz, 3H), 3.37-3.44 (m, 1H), 3.56-3.62 (m, 1H), 3.62-3. 69 (m, 3H), 3.69-3.84 (m, 4H), 4.11 (ddd, J=6.1, 10.9, 22.6Hz, 3H), 5.22 (dd, J =1.4, 5.7Hz, 1H), 6.78 (d, J = 7.5Hz, 2H), 6.83 (s, 1H), 7.21 (d, J = 17.6Hz, 1H).

[0640] Example 25 Synthesis of Compound I-25

[0641]

[0642] Synthesis of compound 1:

[0643]

[0644] Compound 2 (200 mg, 0.388 mmol) and compound A (246 mg, 0.388 mmol) were dissolved in N, N-dimethylformamide / tetrahydrofuran (2 mL / 3.2 mL), and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (170 mg, 0.58 mmol) was slowly added. The reaction solution was stirred at room temperature for 2 hours and purified by reverse phase column chromatography to obtain an off-white solid compound 1 (300 mg, 68.3%). m / z (ES + ), [M+H] + =1133.

[0645] Synthesis of compound 2:

[0646]

[0647] Compound 1 (150 mg, 0.132 mmol) was dissolved in N,N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (200 mg, 1.266 mmol) was slowly added, the reaction solution was stirred at 45°C for 3 hours, and the light yellow solid compound 2 (128 mg, 78%) was obtained by purification by reverse phase column chromatography. m / z (ES + ), [M] + =1212.60.

[0648] Synthesis of compound I-25:

[0649]

[0650] Compound 2 (70 mg, 0.058 mmol) was dissolved in dichloromethane (2 mL), and a dichloromethane solution of boron trichloride (1 M, 1 mL) was slowly added dropwise under ice bath conditions and nitrogen protection. The reaction solution was stirred for 4 hours under ice bath, and the reaction solvent was blown dry with a nitrogen stream. The residue was washed with ether and centrifuged, and the process was repeated three times. The crude product was purified by reverse phase column chromatography to obtain an off-white solid compound I-25 (2.8 mg, 6.3%). m / z (ES + ), [M+H] + =766.25. 1 H NMR (400MHz, DMSO-d6) δ (ppm) 1.18-1.42 (m, 4H), 2.06 (d, J = 7.8Hz, 1H), 2.37 (d, J = 7.7Hz, 1H), 3.44-3.46 (m, 3H), 3.55-3. 60 (m, 3H), 3.85-3.90 (m, 1H), 4.03-4.27 (m, 1H), 5.19-5.25 (m, 1H), 6.85 (d, J=3.0Hz, 1H), 7.08-6.92 (m, 2H), 7.95 (s, 1H).

[0651] Example 26 Synthesis of Compound I-26

[0652]

[0653] Synthesis of compound 1

[0654]

[0655] N-Chlorosuccinimide (12.98 g, 97.24 mmol) was added 2-(2(tert-Butyloxycarbonyl)amino)thiazol-4-yl- 2-Oxyacetic acid(22g, 81mmol) in N,N-dimethylformamide (200ml), the reaction mixture was reacted at 50 degrees for 3 hours. After cooling to room temperature, water was added to the reaction solution, the aqueous phase was extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, the organic phase was spin-dried and passed through a silica gel column to obtain yellow oily compound 1 (16.1g, 65%). m / z (ES+), [M+Na]+=329; acid HPLC tR=1.11min

[0656] Synthesis of compound 2

[0657]

[0658] Compound 1 (1.93 g, 6.29 mmol) was added to ethyl acetate (20 ml) of amine (1 g), and the reaction mixture was stirred at room temperature for 2 hours. The reaction solution was spin-dried and passed through a silica gel column to obtain compound 2 (2.77 g crude) as a yellow solid. m / z (ES+), [M+H]+=464; acid HPLC tR=1.442 min.

[0659] Synthesis of compound 4

[0660]

[0661] Compound 2 (2 g crude, 3 mmol) was dissolved in a mixed solvent of dichloromethane (18 mL) and N,N-dimethylformamide (9 mL), HOBt (434 mg, 3.2 mmol) and DCC (661 mg, 3.2 mmol) were added to the reaction solution at 0 degrees (N2), and the reaction mixture was stirred at 0 degrees for 2 hours. Dichloromethane (14 mL) and triethylamine (1.072 g, 10 mmol) were added to the reaction solution at 0 degrees. Amine (330 mg, 2.84 mmol) was dissolved in N,N-dimethylformamide (10 mL) and added dropwise to the reaction mixture at 0 degrees. The reaction mixture was reacted overnight (0 degrees to room temperature). NaH2PO4 (100 mL) was added to the reaction solution, extracted with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the organic phase was spin-dried and passed through a silica gel column to obtain compound 4 (1.63 g, 76%) as a white solid. m / z (ES+), [M]+=562; acid HPLC tR=1.712 min.

[0662] Synthesis of compound 5

[0663]

[0664] Triethylamine (0.6 g, 6 mmol) was added dropwise to compound 4 (1.12 g, 2 mmol) in dichloromethane (15 mL) at 0 degrees (N2), and MSCl (343 mg, 3 mmol) was added dropwise to the reaction solution at 0 degrees. The reaction mixture was reacted at 0 degrees for 30 minutes. Ice water (15 mL) was added to the reaction solution, the organic phase was separated, the organic phase was washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, and the organic phase was spin-dried to obtain a brown solid compound 5. m / z (ES+), [M]+=640; acid HPLC tR=1.843 min.

[0665] Synthesis of compound 6

[0666]

[0667] TBAA (1.7 g, 6 mmol) was added to N,N-dimethylformamide (15 mL) of compound 5 (1.3 g, 2 mmol), and the reaction mixture was stirred overnight at 62 degrees N2. The reaction solution was quenched with cold 4% NaHCO3 solution (200 mL), and the aqueous phase was extracted with ethyl acetate (150 mL x 2). The organic phase was washed with NaCl, dried over anhydrous sodium sulfate, and the organic phase was spin-dried and passed through a silica gel column to obtain a light brown solid compound 6 (561 mg, 48%). m / z (ES+), [M]+=587; acid HPLC tR=1.895 min.

[0668] Synthesis of compound 7

[0669]

[0670] Pd / C (60 mg, 0.566 mmol) was added to tetrahydrofuran (20 mL) of compound 6 (561 mg, 0.96 mmol), and the reaction mixture was reacted at room temperature under H2 for 2 hours. Pd / C was filtered off and the filtrate was dried to give white solid compound 7 (480 mg, 89.6%). m / z (ES+), [M]+=561; acid HPLC tR=1.514 min.

[0671] Synthesis of compound 8

[0672]

[0673] Compound 7 (400 mg, 0.776 mmol) and amine (430 mg, 0.767 mmol) were added to tetrahydrofuran (1.6 ml) and N, N-dimethylformamide (1 ml), and DMTMM (340 mg, 1.15 mmol) was added to the reaction system. The reaction was stirred at room temperature under nitrogen for 2 hours, and reverse phase purification was performed to obtain compound 8 (368 mg, 45.3%) as a white solid. m / z (ES+), [M+Na+H]+=1058; acid HPLC tR=1.974 min

[0674] Synthesis of compound 9

[0675]

[0676] Sulfur trioxide pyridine complex (500 mg, 3.16 mmol) was added to a solution of compound 7 (368 mg, 0.348 mmol, 1.00 equiv) in N,N-dimethylformamide (3 mL), and the reaction mixture was stirred at 45°C for 4 hours under nitrogen conditions. White solid compound 8 was obtained by reverse phase purification. m / z (ES+), [M]+=1138; acid HPLC tR=1.900 min.

[0677] Synthesis of Compound I-26

[0678]

[0679] 1 mol / L boron trichloride (0.5 mL) in dichloromethane was added dropwise to compound 9 (50 mg, 0.044 mmol) in dichloromethane (2.5 mL) at 0 degrees under nitrogen. The reaction mixture was reacted at 0 degrees for 1 hour, the solvent was dried, ether was added for washing and centrifugation, and the solid obtained by centrifugation was prepared (C18 column: Atlantis preparative T3 OBD column, 19*250mm 10u; mobile phase A: water (0.1% formic acid), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 25B to 35B in 7 minutes; 254 / 220 nm) to obtain a white solid product I-26 (3.8 mg) m / z (ES+), [M]+=802; acid HPLC tR=0.676 min. 1H NMR (D2O, 400MHz): δ (ppm) 1.50 (s, 6H), 2.11 (ddd, J=20.9, 13.0, 7.3Hz, 1H), 2.39 (ddd, J=25.0, 12.1, 5.8Hz, 1H), 3.43 (dq, J=18.5, 6. 1Hz, 2H), 3.55-3.80 (m, 4H), 3.80-4.08 (m, 1H), 4.52 (t, J=6.0Hz, 1H), 5.29 (t, J=5.5Hz, 1H), 6.80-7.06 (m, 2H), 7.87 (d, J=2.1Hz, 1H).

[0680] Example 27 Synthesis of Compound I-27

[0681]

[0682] Synthesis of compound 1:

[0683]

[0684] To a solution of 2-chloro-3,4-bis((4-methoxybenzyl)oxy)benzoic acid (1 g, 2.33 mmol) and (R)-3-(pyrrolidin-3-yl)isoxazole-5-carboxylic acid methyl ester hydrochloride (541 mg, 2.33 mmol) in tetrahydrofuran (50 ml) were added 1-hydroxybenzotriazole (630 mg, 4.66 mmol), triethylamine (940 mg, 9.32 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (895 mg, 4.66 mol), and stirred at room temperature for 3 hours. The reaction system was diluted with water and ethyl acetate. The organic layer was separated, the aqueous layer was extracted with ethyl acetate, the combined extracts were washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The crude product was purified by column chromatography to give compound 1 (720 mg, 52%) as a yellow oil. m / z (ES+), [M] + =607.

[0685] Synthesis of compound 2:

[0686]

[0687] A lithium hydroxide aqueous solution (4 ml, 2 mol / L) was added to a methanol (6 ml) solution of compound 1 (440 mg, 0.73 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction system was concentrated to remove methanol, acidified to pH = 2.5 with hydrochloric acid solution (1 mol / L), and the aqueous phase was extracted with ethyl acetate. The combined organic phases were concentrated to give a white solid compound 2 (650 mg, 92.4%). m / z (ES+), [M] + =593.

[0688] Synthesis of compound 3:

[0689]

[0690] In a 10mL round-bottom flask, add a tetrahydrofuran / N,N-dimethylformamide solution (1.6mL / 1mL) of compound 2 (323mg, 0.54mmol) and compound H (286mg, 0.54mmol). Add 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (240mg, 0.81mmol) under nitrogen. The reaction mixture was stirred at room temperature for 2h. After the reaction, the crude product was purified by column chromatography to obtain a white solid compound 3 (350mg, 53.8%). m / z (ES + ), [M] + =1101.

[0691] Synthesis of compound 4:

[0692]

[0693] Sulfur trioxide pyridine complex (350 mg, 2.21 mmol) was added to a solution of compound 3 (350 mg, 0.318 mmol) in N,N-dimethylformamide (3 mL). The reaction system was stirred at 45° C. for 3 hours. The reaction mixture was purified by reverse phase column chromatography to obtain compound 4 (270 mg, 72%).

[0694] m / z(ES+), [M] + =1181.

[0695] Synthesis of compound I-27:

[0696]

[0697] Boron trichloride solution (0.7 ml) was added to a dichloromethane solution of compound 4 (780 mg, 0.66 mmol). The reaction mixture was stirred at 0 ° C for 4 hours under a nitrogen environment, and the solvent was blown dry with a nitrogen stream. The remaining solid was washed with ether (3 times) and centrifuged. The crude product was purified by reverse phase column chromatography to obtain an off-white solid compound I-27 (149 mg). m / z (ES + ), [MH] + =783.

[0698] 1H NMR (400MHz, DMSO-d6) δ6.92 (d, J=31.5Hz, 1H), 6.84-6.71 (m, 2H), 6.61 (dd, J=8.2, 6.0Hz, 1H), 5.17 (t, J=5.5Hz, 1H), 4.20 -4.10 (m, 1H), 3.84-3.39 (m, 5H), 3.34-3.10 (m, 2H), 2.01 (d, J=16.8Hz, 1H), 1.39 (dd, J=6.5, 4.9Hz, 6H), 1.12-1.02 (m, 1H).

[0699] Example 28 Synthesis of Compound I-28

[0700]

[0701] Synthesis of compound 1:

[0702]

[0703] Compound H (1 g, 3.56 mmol) was dissolved in tetrahydrofuran (30 mL), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.367 g, 7.11 mmol), 1-hydroxybenzotriazole (0.961 g, 7.11 mmol), triethylamine (1.438 g, 14.23 mmol) were added, and then 2-chloro-3,4-di(4-methoxybenzyl)benzoic acid (1.523 g, 3.56 mmol) was added. The reaction solution was stirred at room temperature for 2 hours and purified by reverse phase column to obtain white solid compound 1 (600 mg, 24.4%). [MH] + =691.

[0704] Synthesis of compound 2:

[0705]

[0706] Compound 1 (200 mg, 0.289 mmol) was dissolved in tetrahydrofuran / water solution (10 mL), and lithium hydroxide (13.9 mg, 0.579 mmol) was added at 0°C. The reaction solution was stirred at room temperature for 1 hour. The tetrahydrofuran was removed by rotary evaporation, and the residue was freeze-dried to obtain white solid compound 2 (160 mg, crude product), which was used directly in the next step without purification. m / z (ES + ), [MH] + =677.

[0707] Synthesis of compound 3:

[0708]

[0709] Compound 2 (160 mg, 0.263 mmol), reactant A (180 mg, 0.284 mmol) and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (139 mg, 0.473 mmol) were dissolved in tetrahydrofuran / N,N-dimethylformamide solution (3.2 mL: 2 mL) at room temperature. The reaction solution was stirred at room temperature for 2 hours and purified by reverse phase column chromatography to obtain white solid compound 3 (40 mg, 13.1%). m / z (ES + ), [M+H] + =1294.

[0710] Synthesis of compound 4:

[0711]

[0712] Sulfur trioxide pyridine complex (71 mg, 0.39 mmol) was added to a solution of compound 3 (50 mg, 0.039 mmol) in dry N,N-dimethylformamide (3 mL), and the reaction system was stirred at room temperature for 20 hours. The crude product was purified by reverse phase column chromatography to obtain a light yellow solid compound 4 (30 mg, 56.5%). m / z (ES + ), [M] + =1374.

[0713] Synthesis of compound I-28:

[0714]

[0715] Compound 4 (30 mg, 0.022 mmol) was dissolved in dichloromethane (2 mL) in a 10 mL round-bottom flask, and a boron trichloride solution (0.22 mL) was added dropwise at 0°C. The reaction system was stirred at 0°C for 4 hours. After the reaction was completed, the solvent was dried under a nitrogen stream, and ether was added to the residue. The solid crude product was obtained by centrifugation, and was purified by reverse phase column chromatography to obtain a white solid compound I-28 (3.8 mg, 20.1%). m / z (ES + ), [M+H] + =869. 1H NMR (400MHz, DMSO-d6) δ9.21 (d, J=26.6Hz, 2H), 8.23 ​​(s, 1H), 6.86 (s, 1H), 6.80-6.73 (m, 2H), 5.21 (d, J=5.6Hz, 1H), 4.54 (t, J=6.9Hz , 2H), 4.17 (s, 4H), 3.30 (t, J=6.4Hz, 2H), 2.16 (t, J=6.8Hz, 1H), 2.16 (t, J=6.8Hz, 1H), 2.16 (t, J=6.8Hz, 2H), 1.32 (d, J=11.5Hz, 4H).

[0716] Example 29 Synthesis of Compound I-29

[0717]

[0718] Synthesis of compound 1

[0719]

[0720] The raw material A (20 g, 0.06 mol) was dissolved in tetrahydrofuran (50 mL), and borane tetrahydrofuran solution (300 mL) was slowly added dropwise in an ice bath. The reaction solution was stirred in an ice bath for 4 hours, and the reaction solution was slowly added dropwise into ice water to quench, extracted with ethyl acetate 3 times, and the organic phase was collected and washed with saturated brine 3 times, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column to obtain an off-white solid compound 1 (9.4 g, yield 49%). m / z (ES+), [M+Na]+=347, acid HPLC RT=1.156 min. 1 H NMR (400 MHz, chloroform-d) δ 1.44 (s, 9H), 3.14-3.41 (m, 2H), 3.41-3.79 (m, 4H), 4.94 (s, 1H), 5.09 (s, 2H), 5.37 (d, J = 8.3 Hz, 1H), 7.28-7.39 (m, 5H).

[0721] Synthesis of compound 2

[0722]

[0723] Compound 1 (2 g, 6.2 mmol) and triethylamine (1.25 g, 12.4 mmol) were dissolved in dichloromethane (20 mL), and methylsulfonyl chloride (1.07 g, 9.3 mmol) was slowly added dropwise in an ice bath. The reaction solution was stirred in an ice bath for 1 hour, quenched with water, extracted with dichloromethane 3 times, and the organic phase was collected and washed 3 times with saturated brine, dried over anhydrous sodium sulfate, and spin-dried. The crude yellow solid compound 2 (2.33 g) was used directly in the next step without purification. m / z (ES+), [M+Na]+=425, acid HPLC RT=1.242 min.

[0724] Synthesis of compound 3

[0725]

[0726] Raw material B (500 mg, 2.15 mmol) and triethylamine (1.3 g, 12.9 mmol) were dissolved in acetonitrile (10 mL) and stirred for 20 minutes, then compound 2 (1.73 g, 4.3 mmol) was slowly added, the reaction solution was stirred at 60°C overnight, concentrated, and purified by silica gel plate to obtain yellow oily compound 3 (360 mg, yield 33.3%). m / z (ES+), [M+H]+=503, acid HPLC RT=1.522 min.

[0727] Synthesis of compound 4

[0728]

[0729] Compound 3 (360 mg, 0.72 mmol) was dissolved in ethyl acetate (3 mL), and a solution of hydrogen chloride in ethyl acetate (4 M, 20 mL) was slowly added. The reaction solution was stirred at room temperature for 2 hours, concentrated, and freeze-dried. The crude yellow solid compound 4 (400 mg) was used directly in the next step without purification. m / z (ES+), [M+H]+=403, acid HPLC RT=0.875 min.

[0730] Synthesis of compound 5

[0731]

[0732] The raw material C (373 mg, 0.87 mmol), HATU (661 mg, 1.74 mmol) and N, N-diisopropylethylamine (449 mg, 3.48 mmol) were dissolved in DMF (5 mL), and then compound 4 (380 mg, 0.87 mmol) was slowly added. The reaction solution was stirred at room temperature for 3 hours, quenched with water and extracted with ethyl acetate 3 times. The organic phase was collected, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, purified by C18 column, and freeze-dried to obtain a light yellow solid compound 5 (320 mg, yield 45.3%, ee value 100%). m / z (ES+), [M]+=813, acid HPLC RT=2.011 min. 1 H NMR (400MHz, chloroform-d) δ1.25 (s, 1H), 1.93 (s, 1H), 2.31 (s, 1H), 2.71 (s, 4H), 3.00 (s, 1H), 3.55 (s, 2H), 3.80 (s, 4H), 3.83 (s , 3H), 3.94 (s, 4H), 4.94 (s, 2H), 5.04-5.17 (m, 4H), 6.79-6.87 (m, 3H), 6.92 (dd, J=2.0, 8.7Hz, 3H), 7.28-7.41 (m, 10H).

[0733] Synthesis of compound 6

[0734]

[0735] Compound 5 (300 mg, 0.37 mmol) was dissolved in methanol / tetrahydrofuran (5 mL / 5 mL), and 0.5 M aqueous lithium hydroxide solution (3 mL, 1.48 mmol) was slowly added dropwise. The reaction solution was stirred at room temperature for 3 hours, concentrated, and the residue was dissolved in water. The pH value was adjusted to 3-4 with 1 M hydrochloric acid, and freeze-dried. The crude white solid compound 6 (270 mg) was directly used in the next step without purification. m / z (ES+), [M]+=799, acid HPLC RT=1.753 min.

[0736] Synthesis of compound 7

[0737]

[0738] Compound 6 (250 mg, 0.31 mmol) was dissolved in N,N-dimethylformamide / tetrahydrofuran (2 mL / 3 mL), and DMTMM (274 mg, 0.93 mmol) was slowly added. The reaction solution was stirred at room temperature for 2 hours, purified by C18 column, and freeze-dried to obtain white solid compound 7 (190 mg, yield 46.4%). m / z (ES+), [M]+=1307, acid HPLC RT=1.946 min.

[0739] Synthesis of compound 8

[0740]

[0741] Compound 7 (180 mg, 0.14 mmol) was dissolved in N,N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (442 mg, 2.8 mmol) was slowly added, the reaction solution was stirred at 45°C for 3 hours, purified by C18 column, and freeze-dried to obtain yellow solid compound 8 (145 mg, yield 75.9%). m / z (ES+), [M]+=1387, acid HPLC RT=3.419 min.

[0742] Synthesis of Compound I-29

[0743]

[0744] Compound 8 (65 mg, 0.047 mmol) was dissolved in dichloromethane (2 mL), the reaction flask was replaced with nitrogen three times, and a dichloromethane solution of boron trichloride (1 M, 0.5 mL) was slowly added dropwise in an ice bath and under nitrogen protection. The reaction solution was stirred for 2 hours in an ice bath, and the reaction solution was blown dry with a nitrogen stream. The residue was washed with ether and centrifuged, and the process was repeated three times. The crude product was freeze-dried and purified by high pressure preparation to obtain compound I-29 (3.1 mg, yield 7.7%) as a light gray solid. m / z (ES+), [M]+=857, acid HPLC RT=0.928 min. 1 H NMR (400MHz, DMSO-d6) δ1.37 (d, J=6.0Hz, 6H), 1.74 (s, 1H), 2.16-2.30 (m, 1H), 2.55-2.65 (m, 2H), 2.73 (t, J=11.4Hz, 1H), 2.86 (d, J=27. 6Hz, 2H), 3.39 (d, J=25.0Hz, 5H), 3.61 (s, 2H), 4.15 (s, 1H), 5.15 (d, J=5.6Hz, 1H), 6.71-6.81 (m, 2H), 6.85 (d, J=8.3Hz, 1H), 6.93 (s, 1H).

[0745] Example 30 Synthesis of Compound I-30

[0746]

[0747] Synthesis of compound 1

[0748]

[0749] The raw material A (5g, 23.23mmol) was dissolved in tetrahydrofuran (100mL), triethylamine (4.69g, 46.46mmol) and isobutyl chloroformate (3.8g, 27.87mmol) were slowly added under ice bath conditions, and stirred for 20 minutes under ice bath conditions. Then ammonia water was added, and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate (30mL), then washed twice with saturated citric acid solution (2 x 20mL), and then washed twice with saturated sodium carbonate solution (2 x 20mL). Finally, the organic phase was dried over anhydrous sodium sulfate, concentrated, and dried to obtain a crude yellow oil (2.39g, 49%). MS (ESI): m / z = 214

[0750] Synthesis of compound 2

[0751]

[0752] Compound 1 (0.76 g, 3.55 mmol) was dissolved in dry toluene (20 mL), Lawesson's reagent (0.71 g, 1.77 mmol) was added at room temperature, and then nitrogen was used for protection. The reaction solution was stirred at 80°C for 16 hours overnight. After the reaction was completed, the reaction solution was diluted with ethyl acetate (30 mL), and then washed twice with saturated sodium carbonate solution (2 x 20 mL) and saturated brine (2 x 20 mL). Finally, the organic phase was dried over anhydrous sodium sulfate, concentrated, and spin-dried, and the crude product was purified by silica gel column (petroleum ether / ethyl acetate = 6:1) to obtain the final brown oil product (230 mg, 28%). MS (ESI): m / z = 231.

[0753] Synthesis of compound 3

[0754]

[0755] Compound 2 (360 mg, 0.1 mmol) and raw material B (150 mg, 0.1 mmol) were dissolved in toluene (10 mL) and the reaction solution was stirred at 90°C for 16 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate (30 mL), and then washed twice with water (2 x 20 mL) and saturated brine (2 x 20 mL). Finally, the organic phase was dried over anhydrous sodium sulfate, concentrated, and spin-dried. The crude product was purified by normal phase column to obtain the final product (100 mg, 20%) as a brown oil. MS (ESI): m / z = 326.

[0756] Synthesis of compound 4

[0757]

[0758] Compound 3 (326 mg, 1.0 mmol) was dissolved in ethyl acetate (10.0 ml), and then hydrogen chloride (2.0 ml, 4.0 M / L) was added under ice bath conditions, and then the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the organic phase was concentrated to obtain crude product 4 (200 mg, 88%). MS (ESI): m / z = 227

[0759] Synthesis of compound 5

[0760]

[0761] Compound C (428 mg, 1 mmol) and compound 4 (226 mg, 1 mmol) were dissolved in DMF (5 ml), and then HOBt (275 mg, 2 mmol), DIEA (516 mg, 4 mmol) and EDC·HCl (384 mg, 2 mml) were added in sequence, and the reaction solution was reacted at room temperature for 3 hours. After the reaction was completed, the reaction solution was diluted with water and ethyl acetate respectively, and then extracted with ethyl acetate. The organic phases were combined, washed with saturated brine, dried with anhydrous magnesium sulfate, and finally concentrated and dried. The crude product was purified by silica gel column to obtain the final product as a yellow solid (426 mg, 67%). m / z (ES+), [M]+=637.

[0762] Synthesis of compound 6

[0763]

[0764] Compound 5 (318 mg, 0.5 mmol) was dissolved in methanol (5.0 ml) and tetrahydrofuran (5.0 ml), and then lithium hydroxide aqueous solution (10 ml, 2 mol / L) was added, and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, methanol and tetrahydrofuran were spun out, and the remaining aqueous solution was adjusted to pH 2.5 with hydrochloric acid (1 mol / L). Then, it was extracted with ethyl acetate, and the organic phase was spun dry to obtain the final product compound 6 (295 mg, 97%) as a white solid. m / z (ES+), [M]+ = 609.

[0765] Synthesis of compound 7

[0766]

[0767] Compound 6 (267 mg, 0.44 mmol) and compound H (231 mg, 0.44 mmol) were dissolved in tetrahydrofuran (1.6 mL) and N,N-dimethylformamide (1 mL). DMTMM (200 mg, 0.66 mmol) was slowly added and nitrogen protection was performed. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the crude product was purified by reverse phase column to obtain a white solid final product (270 mg, 55%). m / z (ES+), [M]+ = 1117.

[0768] Synthesis of compound 8

[0769]

[0770] Compound 7 (265 mg, 0.238 mmol, 1.0 eq) was dissolved in N, N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (300 mg, 1.89 mmol, 8.0 eq) was slowly added, and then the reaction solution was stirred at .450°C for 3 hours. After the reaction was completed, the crude product was purified by reverse phase column to obtain the final product 8 (185 mg, 69%) as a white solid. m / z (ES+), [M]+ = 1197;

[0771] Synthesis of Compound I-30

[0772]

[0773] Compound 8 (20 mg, 0.017 mmol, 1.00 eq) was dissolved in dichloromethane (2 mL), the reaction flask was replaced with nitrogen three times, a dichloromethane solution of boron trichloride (0.63 ml, 0.63 mmol) was slowly added dropwise in an ice bath and under nitrogen protection, the reaction solution was stirred for 2 hours in an ice bath, the reaction solution was blown dry with a nitrogen stream, the residue was washed with ether and centrifuged, and the process was repeated three times, the crude product was freeze-dried, and purified by high pressure preparation to obtain compound I-30 (4.1 mg) as a light gray solid. m / z (ES+), [M]+=801. 1 H NMR (400MHz, DMSO-d6) δ8.05 (d, J=21.2Hz, 1H), 6.95-6.72 (m, 2H), 6.63 (dd, J=8. 1, 4.7Hz, 1H), 5.19 (t, J=5.3Hz, 1H), 4.25-4.11 (m, 1H), 385-3.90 (m, 1H), 3.63 (d, J=6.2Hz, 2H), 3.58-3.44(m, 2H), 3.36(dd, J=10.6, 6.4Hz, 1H), 3.25(t, J=7.0Hz, 1H), 2.40 (dd, J=15.3, 8.9Hz, 1H), 2.24-2.04 (m, 1H), 1.42 (dd, J=9.6, 4.1Hz, 6H).

[0774] Example 31 Synthesis of Compound I-31

[0775]

[0776] Synthesis of compound 1:

[0777]

[0778] To a solution of tert-butyl carbamate (3-amino-2-hydroxypropyl) (5 g, 26.3 mmol, 1 eq) in dichloromethane (100 mL) were added triethylamine (5.3 g, 52.6 mmol, 2 eq) and Cbz-Cl (5.36 g, 31.5 mmol, 1.2 eq). The mixture was stirred at room temperature for 3 h. The obtained residue was diluted with water and ethyl acetate. The organic layer was separated, and the combined extracts were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The obtained residue was purified by silica gel chromatography to obtain compound 1 (6.2 g, 72.9%) as a colorless oil. m / z (ES+), [M+H]+=325; acid, HPLC tR=0.87 min.

[0779] Synthesis of compound 2:

[0780]

[0781] At 0°C, TEA (2.99 g, 29.6 mol, 1.5 eq) was added to a solution of compound 1 (6.2 g, 19 mmol, 1 eq) in DCM (100 mL), and methanesulfonyl chloride (3.39 g, 29.6 mol, 1.5 eq) was added dropwise. The resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was washed with hydrochloric acid solution (1 M) and sodium bicarbonate (aqueous solution, 5%) in sequence, and the organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give a colorless oily compound 2 (6.2 g, 81%). m / z (ES+), [M+Na]+=425; acid, HPLCtR=1.229 min.

[0782] Synthesis of compound 3:

[0783]

[0784] Sodium azide (2.1 g, 30 mmol, 2 eq) was added to a solution of compound 2 (6.2 g, 16 mmol, 1 eq) in DMF (50 mL). The resulting mixture was stirred at 70°C for 4 h. Ice water was added to the resulting mixture, extracted with ethyl acetate, and the combined extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give compound 3 (6.1 g, crude) as a colorless oil. m / z (ES+), [M+Na]+=372; acid, HPLC tR=1.301 min.

[0785] Synthesis of compound 4:

[0786]

[0787] To a solution of compound 3 (6.1 g, 17.4 mmol, 1 eq) in MeOH (50 mL), triphenylphosphine (6.86 g, 26.2 mol, 1.5 eq) and H2O (15 ml) were added. The resulting mixture was stirred at 70°C for 4 h. The solution was evaporated and the resulting mixture was washed with petroleum ether 3 times to give compound 4 (7 g, crude product). m / z (ES+), [M+H]+=324; acid, HPLC tR=1.599 min.

[0788] Synthesis of compound 5:

[0789]

[0790] To a DMF (50 mL) solution of compound 4 (7 g, crude product), TEA (5.78 g, 57.3 mmol, 3 eq) and 5-bromo-2-chloropyrimidine (7.3 g, 382 mmol, 2 eq) were added. The resulting mixture was stirred at 45 ° C for 3 h. Ice water was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel chromatography to obtain a brown oil compound 5 (3 g, 3-step total yield of 37.7%). m / z (ES+), [M+H]+ = 481; acid, HPLC tR = 0.968 min.

[0791] Synthesis of compound 6:

[0792]

[0793] In a solution of compound 5 (3 g, 6.26 mmol) in 1,4-dioxane (50 mL), diboric acid pinacol ester (3.18 g, 12.5 mmol, 2 eq), potassium acetate (1.22 g, 12.5 mmol, 2 eq) and Pd(dppf)Cl2 (0.458 g, 6.26 mmol, 0.1 eq) were added. The reaction system was replaced with nitrogen protection and heated at 80°C for 2 hours. After the reaction was completed, the filtrate was filtered and concentrated under vacuum. The crude product was purified on a silica gel column using ethyl acetate / petroleum ether to obtain a yellow oily compound 6 (1.2 g, yield: 36.37%). m / z (ES+), [M+H]+=528; alkali, HPLC tR=1.055 min.

[0794] Synthesis of compound 7:

[0795]

[0796] To a solution of compound 6 (0.4 g, 0.759 mmol) in 1,4-dioxane: water = 5 mL: 0.5 mL, 2-bromothiazole-5-carboxylic acid methyl ester (0.218 g, 0.986 mmol, 1.3 eq), potassium phosphate (0.48 g, 2.27 mmol, 3 eq) and Pd(dppf)Cl2 (0.111 g, 0.152 mmol, 0.2 eq) were added. The reaction system was replaced with nitrogen protection and heated at 80°C for 3 hours. After the reaction was completed, the reaction mixture was concentrated under vacuum. The crude product was purified on a silica gel column using ethyl acetate / petroleum ether to obtain a yellow oily compound 7 (0.11 g, 26.8%). m / z (ES+), [M+H]+ = 543; acid, HPLC tR = 1.316 min.

[0797] Synthesis of compound 8:

[0798]

[0799] To a solution of compound 7 (0.3 g, 0.55 mmol, 1 eq) in DMF (1 mL) was added iodomethane (0.39 g, 2.76 mmol, 5 eq), and the reaction system was heated at 45°C for 3 hours. After the reaction was completed, the reaction mixture was concentrated under vacuum. The crude product was purified by C18 reverse chromatography to give a white solid compound 8 (260 mg, 81%), m / z (ES+), [M]+=557; acid, HPLC tR=0.774 min.

[0800] Synthesis of compound 9:

[0801]

[0802] HCl / EA (4M) solution (3 mL) was added to a solution of compound 8 (0.26 g) in ethyl acetate (3 mL) at 0°C, and the reaction system was stirred at 0°C for 3 hours. After the reaction, petroleum ether was added to dilute the system and a precipitate was generated. The filter cake was filtered and dried to obtain a yellow solid compound 9 (180 mg, 84.5%). m / z (ES+), [M]+ = 457; acid, HPLC tR = 0.902 min.

[0803] Synthesis of compound 10:

[0804]

[0805] HATU (0.449 g, 1.18 mmol, 3 eq), DIEA (0.152 g, 1.18 mmol, 3 eq), and compound 9 (0.18 g, 0.393 mmol, 1 eq) were added to a DMF (2 mL) solution of 2-chloro-3,4-bis((4-methoxybenzyl)oxy)benzoic acid (0.185 g, 0.433 mmol, 1.1 eq). The reaction system was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was poured into ice water and extracted with ethyl acetate. The crude product obtained by concentrating the combined organic phases was purified on a silica gel column using ethyl acetate / petroleum ether to obtain a yellow solid compound 10 (300 mg, 88%). m / z (ES+), [M]+=868; acid, HPLC tR=0.748 min.

[0806] Synthesis of compound 11:

[0807]

[0808] A solution of lithium hydroxide solid (0.039 g, 1.38 mmol, 4 eq) and water (0.6 mL) was added to a solution of compound 10 (300 mg, 0.346 mmol, 1 eq) in methanol (3 mL). The reaction system was stirred at room temperature for 2 hours. Methanol was removed by rotary evaporation, and the residue was acidified to pH = 3 with hydrochloric acid solution (1 mol / L). The system was extracted with ethyl acetate, and the organic phase was concentrated to obtain yellow solid compound 11 (200 mg, 67.7%), m / z (ES+), [M]+ = 854; acid, HPLC tR = 1.204 min.

[0809] Synthesis of compound 12:

[0810]

[0811] To a solution of compound 11 (220 mg, 0.257 mmol) in THF (1.6 mL) and DMF (1 mL) were added intermediate H (149 mg, 0.283 mmol, 1.1 eq) and DMTMM (114 mg, 0.386 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 2 h. The mixture was purified by preparative HPLC to give compound 12 (20 mg, 53.8%) as a white solid. m / z (ES+), [M]+ = 1362; acid, HPLC tR = 1.330 min.

[0812] Synthesis of compound 13:

[0813]

[0814] In a 10 mL round-bottom flask, sulfur trioxide pyridine complex (20 mg) was added to a DMF (1 mL) solution of compound 12 (20 mg). The reaction system was stirred at 45°C for 3 hours. After the reaction, the mixture was directly purified by preparative HPLC to obtain white solid compound 13 (12 mg, 56%). m / z (ES+), [M]+ = 1443; acid, HPLC tR = 1.415 min.

[0815] Synthesis of compound I-31:

[0816]

[0817] At 0°C, boron trichloride solution (0.2 mL) was added to a solution of compound 13 (12 mg) in dichloromethane (1 mL). The reaction system was stirred at 0°C for 4 hours under nitrogen protection. After the reaction, the residual boron trichloride was removed with a nitrogen stream. The crude product was purified by preparative liquid phase: column: XSelect CSH preparative C18OBD column, 19*250 mm, 5 um; mobile phase A: water (0.1% FA), mobile phase B: CAN; flow rate: 25 mL / min; gradient: 5B to 30B in 7 minutes; 254 / 220 nm; white solid compound I-31 (2 mg, 26.4%) was obtained. m / z (ES+), [M]+=912; 1 H NMR (400MHz, DMSO-d6): δ (ppm) 1.36 (t, J=6.9Hz, 6H), 3.23 (d, J=35.4Hz, 3H), 3.41-3.55 (m, 2H), 3.61 (s, 3H), 4.17-4.32(m, 2H), 5.16(d, J=5.5Hz, 1H), 6.66-6.81(m, 3H), 7.97(s, 1H), 8.19(s, 1H), 8.27(s, 3H).

[0818] Example 32 Synthesis of Compound I-32

[0819]

[0820] Compound Synthesis Steps Reference Example 24

[0821]

[0822] m / z (ES+), [M]+=843; acid HPLC tR=0.801min. 1 H NMR (D2O, 400MHz): δ (ppm) 1.42 (d, J = 5.6Hz, 6H), 2.49 (tt, J = 13.5, 7.6Hz, 1H), 2.70-2.89 (m, 1H), 3.25 (d, J = 12.6Hz, 3H), 3. 66-3.96 (m, 9H), 3.99-4.24 (m, 2H), 4.57 (p, J=6.2Hz, 1H), 5.35 (dd, J=5.7, 3.4Hz, 1H), 6.76-6.97 (m, 2H), 6.94-7.04 (m, 2H).

[0823] Example 33 Synthesis of Compound I-33

[0824]

[0825] Synthesis of compound 1

[0826]

[0827] In a 50 mL single-necked bottle, SM1 (1.2 g, 4.27 mmol, 1.00 equiv) and SM2 (1.83 g, 4.27 mmol, 1 equiv) were added to a tetrahydrofuran (10 mL) solution of DIPEA (1.65 g, 12.81 mmol, 3.00 equiv) and HATU (2.6 g, 6.83 mmol, 1.6 equiv). The reaction mixture was stirred at room temperature for 2 hours, quenched with water, extracted with ethyl acetate, and the solvent was dried and purified by reverse phase column to obtain 700 mg of crude compound 1, m / z (ES+), [MH]+=691; acid HPLC tR=0.801 min.

[0828] Synthesis of compound 2

[0829]

[0830] A solution of LiOH (2 mL, 2 mol / L) was added dropwise to a solution of intermediate 1 (300 mg, 0.43 mmol) in THF (3 mL). The reaction mixture was reacted at room temperature for 2 hours. The tetrahydrofuran was dried by spin drying. The pH of the solution was adjusted to about 2.5 with HCl (1 mol / L). The aqueous phase was extracted with ethyl acetate and dried by spin drying to obtain a white solid compound 2 (60 mg, 20%). m / z (ES+), [MH]+=677; acid HPLC tR=2.545 min.

[0831] Synthesis of compound 3

[0832]

[0833] In a 10 mL round-bottom flask, compound 2 (60 mg, 0.088 mmol) and intermediate H (47 mg, 0.088 mmol) were dissolved in a mixed solvent of THF (1.6 mL) and DMF (1 mL). Under nitrogen protection, DMTMM (39 mg, 0.132 mmol) was added, and the reaction solution was stirred at room temperature for 2 hours. The reaction system was directly purified by reverse phase to obtain white solid compound 3 (45 mg, 42.8%). m / z (ES+), [M+H]+=1186; acid HPLC tR=1.287 min.

[0834] Synthesis of compound 4:

[0835]

[0836] In a 10 mL round-bottom flask, compound 3 (40 mg, 0.034 mmol, 1.00 eq) was dissolved in DMF (2 mL), and then SO3.Py (120 mg, 0.76 mmol, 22 eq) was added. The reaction system was reacted at 45 ° C for 3 hours. The reaction solution was directly purified by reverse phase column to obtain a light yellow solid 4 (25 mg, 62%). m / z (ES+), [MH] + = 1265; acid, HPLC tR = 1.201 min.

[0837] Synthesis of compound I-33:

[0838]

[0839] In a 25mL round-bottom flask, compound 4 (25mg, 0.02mmol, 1.00eq) was dissolved in dichloromethane (2mL), and BCl3 (0.5mL, 0.5mmol) was added at 0℃ under nitrogen protection. The reaction system was stirred at 0℃ for 4 hours. After the reaction was completed, the dichloromethane was blown dry with nitrogen, the solid was washed with ether, and purified by high pressure preparation. The purification conditions were: column: Sunfire preparative C18OBD column, 10um, 19*250mm; mobile phase A: water (0.1% FA), mobile phase B: CAN; flow rate: 20mL / min; gradient: 5B to 10B in 0.5 minutes; 254 / 220nm; the off-white solid final product I-33 (2.1mg) was obtained. m / z(ES+), [M+H]+=869; acid, HPLC tR=0.87min. 1 H NMR (D2O, 400MHz): δ (ppm) 1.68 (d, J=4.5Hz, 6H), 2.48 (s, 3H), 3.66 (s, 2H), 3.96 (s, 2H), 4.40 (s, 3H), 4.65 (t, J=5 .9Hz, 2H), 5.50 (d, J=5.5Hz, 1H), 7.02 (d, J=8.1Hz, 1H), 7.05-7.17 (m, 2H), 8.47 (s, 1H), 9.08 (s, 1H), 9.18 (s, 1H).

[0840] Example 34 Synthesis of Compound I-34

[0841]

[0842] Synthesis of compound 2:

[0843]

[0844] Compound 1 (452 ​​mg, 2.0 mmol) was dissolved in dry N, N-dimethylformamide (10 mL), and then triethylamine (606 mg, 6.0 mmol) and compound N-Boc-bromoethylamine (535.2 mg, 2.4 mmol) were added at room temperature, and the reaction solution was stirred at 60°C for 3 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed with saturated sodium carbonate solution (2 x 20 mL), and then the organic phase was dried over anhydrous sodium sulfate and spin-dried to obtain a crude product. The yellow oil compound 2 (400 mg, 49%) was obtained by purification with a silica gel column. m / z (ES+), [M]+ = 370.

[0845] Synthesis of compound 3:

[0846]

[0847] Compound 2 (380 mg, 1.02 mmol) was dissolved in dry ethyl acetate (10 mL), 5.0 mL HCl (4.0 M in EA) was added at room temperature, and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was directly spin-dried to obtain brown solid compound 3 (300 mg, 95.5%) which could be used directly in the next step without purification. m / z (ES+), [M]+ = 269.

[0848] Synthesis of compound 4:

[0849]

[0850] Compound SM2 (428 mg, 1 mmol) and compound 3 (269 mg, 1 mmol) were dissolved in N, N-dimethylformamide (5 mL), and HOBt (275 mg, 2 mmol), DIEA (516 mg, 4 mmol) and EDC·HCl (384 mg, 2 mmol) were added at room temperature. After the addition was completed, the reaction solution was stirred at room temperature for 3 hours. After the reaction was completed, the reaction solution was diluted with water and ethyl acetate, respectively, and then extracted with ethyl acetate. The organic phases were combined, washed with saturated brine, dried with anhydrous magnesium sulfate, and finally concentrated and dried. The crude product was purified by silica gel column to obtain the final product, yellow solid compound 4 (360 mg, 48%). m / z (ES+), [M]+ = 680.

[0851] Synthesis of compound 5:

[0852]

[0853] Compound 4 (340 mg, 0.5 mmol) was dissolved in dry acetonitrile (10 mL), and then iodomethane (355 mg, 2.5 mmol) was added at room temperature. After completion, the reaction solution was stirred at 60°C for 3 hours. After completion of the reaction, the reaction solution was directly spin-dried to obtain a crude product of compound 5 (300 mg, 95.5%). m / z (ES+), [M]+ = 694.

[0854] Synthesis of compound 6:

[0855]

[0856] Compound 5 (347 mg, 0.5 mmol) was dissolved in methanol (5.0 mL) and tetrahydrofuran (5.0 mL), and then lithium hydroxide aqueous solution (10 mL, 1.5 mol / L) was added, and the reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, methanol and tetrahydrofuran were spun out, and the remaining aqueous solution was adjusted to pH 2.5 with hydrochloric acid (1 mol / L). Then it was extracted with ethyl acetate, and the organic phase was spun dry to obtain the final product 6 (200 mg, 97%) as a white solid. m / z (ES+), [M+H]+=668.

[0857] Synthesis of compound 7:

[0858]

[0859] Compound 6 (200 mg, 0.30 mmol) and intermediate H (158 mg, 0.30 mmol) were dissolved in tetrahydrofuran (1.6 mL) and N,N-dimethylformamide (1 mL). DMTMM (132 mg, 0.45 mmol) was slowly added and nitrogen protection was performed. The reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the crude product was purified by reverse phase column to obtain white solid compound 7 (200 mg, 57%) m / z (ES+), [M]+=1174.

[0860] Synthesis of compound 8:

[0861]

[0862] Compound 7 (200 mg, 0.17 mmol, 1.0 eq) was dissolved in dry N,N-dimethylformamide (3 mL), sulfur trioxide pyridine complex (537 mg, 3.4 mmol, 20.0 eq) was added at room temperature, and the reaction system was stirred at 45°C for 3 hours. After the reaction was completed, the reaction system was purified with a reverse phase column to obtain a white solid compound 8 (165 mg, 69%). m / z (ES+), [M]+ = 1255.

[0863] Synthesis of compound I-34:

[0864]

[0865] Compound 8 (100 mg, 0.0797 mmol, 1.00 eq) was dissolved in dichloromethane (2 mL), and the reaction system was replaced with nitrogen three times. A dichloromethane solution of boron trichloride (0.63 mL, 0.63 mmol) was slowly added dropwise in an ice bath and under nitrogen protection. The reaction solution was stirred for 2 hours in an ice bath, and the reaction solution was dried with a nitrogen stream. The residue was washed with ether and centrifuged, and the reaction was repeated three times. The crude product was freeze-dried and purified by high-pressure preparation to obtain white solid compound I-34 (22.7 mg, 33%). m / z(ES+), [M]+=859; acid 1H NMR (400MHz, DMSO-d6) δ8.13 (d, J=4.8Hz, 1H), 6.79 (pd, J=8.2, 3.9Hz, 3H), 6.03 (d, J=4.7Hz, 1H), 5.66 (d, J=4.3Hz, 1H), 5.17 (d, J=5.5Hz, 1H), 4.19 (q, J=6.2Hz, 1H), 3.70-3.49 (m, 4H), 3.33 (d, J=29.1Hz, 4H), 3.15-2.56 (m, 6H), 1.40 (d, J=7.4Hz, 6H).

[0866] Example 35 Synthesis of Compound I-35

[0867]

[0868] Synthesis of compound 2:

[0869]

[0870] Compound 1 (4.5 g, 19.3 mmol), N,N-diisopropylethylamine (10 g, 77.2 mmol) and N-Boc-bromoethylamine (4.3 g, 19.3 mmol) were dissolved in acetonitrile (80 mL), the reaction solution was stirred at 60°C for 2 hours, cooled to room temperature and dried by rotation, the residue was dissolved in ethyl acetate, washed with saturated brine 3 times, dried, concentrated, and purified by silica gel column to obtain yellow oily compound 2 (4.1 g, yield 62.4%). m / z (ES+), [M+H] = 340; acid HPLC RT = 1.354 min.

[0871] Synthesis of compound 3:

[0872]

[0873] Compound 2 (4.1 g, 12.1 mmol) was dissolved in ethyl acetate (20 mL), and a solution of hydrogen chloride in ethyl acetate (4 M, 50 mL) was slowly added dropwise. The reaction solution was stirred at room temperature for 2 hours and then dried by spin drying. The obtained brown oily compound 3 (3.9 g, crude product) was used directly in the next step without purification. m / z (ES+), [M+H] = 240; acid HPLC RT = 0.708 min.

[0874] Synthesis of compound 4:

[0875]

[0876] Compound B (5.92 g, 13.8 mmol) was dissolved in N, N-dimethylformamide (50 mL), HATU (10.5 g, 27.6 mmol), N, N-diisopropylethylamine (7.12 g, 55.2 mmol) and compound 3 (3.8 g, 13.8 mmol) were slowly added, the reaction solution was stirred at room temperature for 2 hours, quenched with water, extracted with ethyl acetate three times, the organic phase was washed with saturated brine three times, dried, spin-dried, and purified by silica gel column to obtain brown solid compound 4 (6.1 g, yield 68.5%). m / z (ES+), [M]+=650; acid HPLC RT=1.471 min.

[0877] Synthesis of compound 5:

[0878]

[0879] Compound 4 (2 g, 3 mmol) was dissolved in tetrahydrofuran (50 mL), and an aqueous solution of sodium hydroxide (6 mL, 1 M, 6 mmol) was slowly added dropwise. The reaction solution was stirred at room temperature for 2 hours, concentrated, and the residue was dissolved in water, and the pH value was adjusted to 3-4 with 1 M hydrochloric acid. After freeze-drying, yellow solid compound 5 (1.9 g, crude product) was obtained. m / z (ES+), [M]+=636; acid HPLC RT=1.709 min.

[0880] Synthesis of compound 6:

[0881]

[0882] Compound 5 (1.6 g, 2.5 mmol) and intermediate H (1.32 g, 2.5 mmol) were dissolved in N, N-dimethylformamide (20 mL), and DMTMM (1.48 g, 5 mmol) was slowly added. The reaction solution was stirred at room temperature for 2 hours, and directly subjected to reverse phase purification without post-treatment, and freeze-dried to obtain a light yellow solid compound 6 (1.67 g, yield 57.5%). m / z (ES+), [M]+ = 1144; acid HPLC RT = 2.367 min.

[0883] Synthesis of compound 7:

[0884]

[0885] Compound 6 (1.67 g, 1.46 mmol) was dissolved in N, N-dimethylformamide (20 mL), sulfur trioxide pyridine complex (4.64 g, 29.2 mmol) was slowly added, the reaction solution was stirred at 45°C for 2 hours, directly subjected to reverse phase purification without post-treatment, and freeze-dried to obtain off-white solid compound 7 (1.45 g, 81.4% yield). m / z (ES+), [M+H]+=1225; acid HPLC RT=2.484 min.

[0886] Synthesis of compound I-35:

[0887]

[0888] Compound 7 (300 mg, 0.25 mmol) was dissolved in dichloromethane (5 mL), the reaction flask was replaced with nitrogen three times, and a dichloromethane solution of boron trichloride (1.75 mL, 1.75 mmol) was slowly added dropwise in an ice bath and under nitrogen protection. The reaction solution was stirred for 2 hours in an ice bath, and the reaction solution was blown dry with a nitrogen stream. The residue was washed with ether and centrifuged, and the reaction was repeated three times. The crude product was purified by high pressure preparation and freeze-dried to obtain compound I-35 (59.9 mg, yield 29.6%) as a white solid. m / z (ES-), [M+H]+=829; acid HPLC RT=0.796 min. 1 H NMR (400MHz, DMSO-d6) δ1.40 (s, 6H), 2.28 (s, 1H), 2.62 (d, J = 23.6Hz, 1H), 3.52 (t, J = 6.1Hz, 3H), 3.69-3.78 (m, 4H), 3.83 (d d, J=7.4, 14.5Hz, 2H), 3.90 (s, 2H), 4.57 (q, J=6.0Hz, 1H), 5.33 (d, J=5.6Hz, 1H), 6.83 (d, J=8.4Hz, 1H), 6.92-6.99 (m, 3H).

[0889] Example 36 Synthesis of Compound I-36

[0890]

[0891] Synthesis of compound 1

[0892]

[0893] 2-Chloro-3,4-bis((4-methoxybenzyl)oxy)benzoic acid (10 g, 23.3 mmol), triethylamine (2.8 g, 28 mmol), diphenylphosphoryl azide (8 g, 28 mmol), 9-fluorenemethanol (6.8 g, 35 mmol) and piperidine (10 g, 116.5 mmol) were added to toluene (100 ml). The reaction mixture was stirred at 100 degrees for 16 hours, concentrated, added with water, and then extracted with ethyl acetate. The organic phase was washed with 2M hydrochloric acid, saturated sodium bicarbonate aqueous solution, and saturated brine, dried over anhydrous sodium sulfate, and spin-dried to give an off-white solid compound 1 (6 g, 64%). m / z (ES+), [M+H]+=400, acid.

[0894] Synthesis of compound 2

[0895]

[0896] Compound 1 (8 g, 20 mmol), 2-bromoacetaldehyde (4.89 g, 40 mmol) and N,N-diisopropylethylamine (766 mg, 5.94 mmol) were added to methanol (20 ml), and the reaction mixture was stirred at room temperature for 2 hours. Then sodium cyanoborohydride (3.789 g, 60 mmol) and acetic acid (0.5 ml) were added to the reaction solution. The reaction mixture was stirred at room temperature for 18 hours, then quenched with water, extracted with ethyl acetate (2x100 mL), and dried by column to obtain compound 2 (3 g, 29.5%). m / z (ES+), [M+H]+=507, acid.

[0897] Synthesis of compound 3

[0898]

[0899] Compound 2 (1 g, 1.98 mmol), amine hydrochloride (459 mg, 1.98 mmol) and N,N-diisopropylethylamine (766 mg, 5.94 mmol) were added to acetonitrile (20 ml), stirred for 5 hours under nitrogen at 60 degrees, and the reaction solution was concentrated and purified by column to obtain compound 3 (500 mg, 40.5%). m / z (ES+), [M+H]+=623, acid.

[0900] Synthesis of compound 4

[0901]

[0902] Lithium hydroxide (288 mg, 10.3 mmol) was added to a mixed solvent of methanol (5 mL) / tetrahydrofuran (5 mL) / water (5 mL) of compound 4 (1.6 g, 2.57 mmol), and the reaction was carried out at room temperature for 3 hours. The reaction system was purified by reverse phase to obtain compound 4 (1.4 g, 22.3%). m / z (ES+), [M]+=608, acid.

[0903] Synthesis of compound 5

[0904]

[0905] Compound 4 (1.4 g, 2.3 mmol) and intermediate H (1.21 g, 2.3 mmol) were dissolved in a mixed solvent of tetrahydrofuran (12 mL) and N,N-dimethylformamide (8 mL) and stirred for 10 minutes. 4-(4,6-dimethoxytriazine-2-yl)-4-methyl Morpholine hydrochloride (718 mg, 3.45 mmol) was added to the reaction solution, and the reaction mixture was stirred for 1.5 hours under nitrogen at room temperature. The reaction system was concentrated and purified by reverse phase to obtain white solid compound 5 (900 mg, 35%). m / z (ES+), [M+H]+=1117.

[0906] Synthesis of compound 6

[0907]

[0908] Compound 5 (900 mg, 0.8 mmol, 1.00 eq) was dissolved in N,N-dimethylformamide (15 mL), sulfur trioxide pyridine complex (2.0 g, 11.4 mmol) was added to the reaction solution under nitrogen protection, and the reaction mixture was stirred at room temperature for 2 hours, and purified by reverse phase to obtain white solid compound 6 (420 mg, 94%). (ES+), [M+H]+=1197;

[0909] Synthesis of Compound I-36

[0910]

[0911] Boron trichloride (5 mL) was added to compound 6 (400 mg, 0.334 mmol, 1.00 eq) in dichloromethane (10 mL) at 0 degrees under nitrogen. The reaction mixture was stirred at 0 degrees for 6 hours, the reaction solvent was dried by nitrogen flow, washed with ether and centrifuged four times to obtain a solid, which was prepared by high pressure liquid phase (column: Xselect CSH OBD column 30*150mm 5um, n; mobile phase A: water (0.1% FA), mobile phase B: CAN; flow rate: 60 mL / min; gradient: 5% B to 30% B, 30% B in 7 minutes; wavelength: 254 / 220 nm; to obtain an off-white solid compound I-36 (72.3 mg, 27%). (ES+), [M+H]+=800. 1 H NMR (400MHz, DMSO-d6): δ (ppm) 1.41 (d, J = 6.2Hz, 6H), 2.14 (s, 1H), 3.04-3.21 (m, 4H), 3.41 (d, J = 37.7Hz, 8H), 3.8 5 (d, J=13.1Hz, 1H), 5.20 (d, J=5.7Hz, 1H), 6.10 (d, J=8.7Hz, 1H), 6.60 (d, J=8.7Hz, 1H), 6.74 (s, 1H), 7.07 (s, 1H).

[0912] Example 37 Synthesis of Compound I-37

[0913]

[0914] Synthesis of compound 1:

[0915]

[0916] Under nitrogen, compound SM (550 mg, 1.33 mmol), triethylamine (336 mg, 3.36 mmol) and aldehyde (550 mg, 1.33 mmol) were added to methanol (10 mL), and the reaction mixture was stirred at room temperature for 5 hours. Sodium borohydride (152 mg, 4 mmol) was added in batches at 0 degrees, and the reaction was allowed to react at room temperature for 3 hours. The reaction mixture was purified by reverse phase to obtain white solid compound 1 (260 mg, 10.3%). m / z (ES+), [M]+=636, acid.

[0917] Synthesis of compound 2:

[0918]

[0919] Lithium hydroxide (30 mg, 1.25 mmol) was added to a mixed solvent of methanol (2 mL) / tetrahydrofuran (2 mL) / water (4 mL) of compound 1 (260 mg, 0.41 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 3 hours. Reverse phase purification gave white solid compound 2 (200 mg, 78%). m / z (ES+), [M]+=622, acid.

[0920] Synthesis of compound 3

[0921]

[0922] Compound 2 (340 mg, 0.55 mmol) and intermediate H (287 mg, 0.55 mmol) were added to tetrahydrofuran (6 mL) and N, N-dimethylformamide (4 mL), stirred at room temperature for 10 minutes, then 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (200 mg, 0.96 mmol) was added, and the reaction mixture was stirred at room temperature under nitrogen for 1.5 hours. The reaction solution was concentrated and purified by reverse phase to obtain white solid compound 3 (110 mg, 17.7%). m / z (ES+), [M]+=1130, acid.

[0923] Synthesis of compound 4

[0924]

[0925] Compound 3 (110 mg, 0.53 mmol), di-tert-butyl dicarbonate (346 mg, 1.59 mmol) and triethylamine (267 mg, 2.65 mmol) were dissolved in dichloromethane (5 mL). The reaction mixture was stirred at room temperature for 4 hours. The solvent was concentrated and purified by reverse phase to give a white solid compound 4 (100 mg, 15.3%) (ES+), [M]+=1230, acid.

[0926] Synthesis of compound 5:

[0927]

[0928] Sulfur trioxide pyridine complex (200 mg, 1.14 mmol) was added to compound 4 (100 mg, 0.081 mmol, 1.00 eq) in N,N-dimethylformamide (3 mL) under nitrogen, and the reaction mixture was stirred at room temperature for 2 hours and purified by reverse phase to obtain white solid compound 5 (100 mg, 93.8%). (ES+), [M+H]+=1311;

[0929] Synthesis of compound I-37:

[0930]

[0931] Boron trichloride (2 mL) was added dropwise to a dichloromethane (4 mL) solution of compound 5 (100 mg, 0.076 mmol, 1.00 eq) under nitrogen protection at 0-5 degrees. The reaction mixture was stirred at 0 degrees for 6 hours, the solvent was blown dry by nitrogen flow, washed with ether and centrifuged four times to obtain a solid, which was prepared by high pressure liquid phase (column: XSelect CSH preparative C18 OBD column, 19*250 mm, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 25 mL / min; 254 / 220 nm; to obtain an off-white solid compound I-37 (4.5 mg, 7.2%). (ES+), [M+H]+=814;. 1 H NMR (DMSO-d6, 400MHz): δ (ppm) 1.42 (d, J=6.6Hz, 6H), 1.80-2.00 (m, 1H), 2.18-2.38 (m, 1H), 2.43 (s, 3H), 2.65-2.89 (m, 4H), 3.00 (t, J=10. 1Hz, 3H), 3.78 (dd, J=14.3, 4.3Hz, 1H), 4.12 (d, J=6.5Hz, 3H), 5.22 (d, J=5.7Hz, 1H), 6.62-6.84 (m, 2H), 6.89 (d, J=8.3Hz, 1H), 7.03 (s, 1H).

[0932] Example 38 Synthesis of Compound I-38

[0933]

[0934] Synthesis of compound 2:

[0935]

[0936] Compound 1 (500 mg, 1.9 mmol) was dissolved in N, N-dimethylformamide (10 mL), N, N-diisopropylethylamine (1.47 g, 11.4 mmol) and compound A (1.47 g, 3.8 mmol) were slowly added, the reaction solution was stirred at 60°C overnight, the reaction was quenched with water, extracted with ethyl acetate three times, the organic phases were combined, washed with saturated brine three times, dried over anhydrous sodium sulfate, concentrated, and purified using a silica gel plate to obtain a yellow oily compound 2 (250 mg, yield 24%). m / z (ES+), [M+H] + =533; acid HPLC RT=1.181min.

[0937] Synthesis of compound 3:

[0938]

[0939] Compound 2 (250 mg, 0.47 mmol) was dissolved in a small amount of ethyl acetate (3 mL), and a solution of hydrogen chloride in ethyl acetate (4 M, 10 mL) was slowly added dropwise. The reaction solution was stirred at room temperature for 2 hours and concentrated to obtain a yellow solid compound 3 (210 mg, crude). m / z (ES+), [M+H] + =433; acid HPLC RT =0.964min.

[0940] Synthesis of compound 4:

[0941]

[0942] Compound B (193 mg, 0.45 mmol) was dissolved in DMF (3 mL), HATU (342 mg, 0.9 mmol) and DIEA (232 mg, 1.8 mmol) were slowly added, and the mixture was stirred for 10 minutes. Compound 3 (210 mg, 0.45 mmol) was then slowly added. The reaction solution was stirred at room temperature for 2 hours, and the reaction was quenched with water, extracted with ethyl acetate (3*20 mL), and the organic phases were combined, washed with saturated brine, dried, concentrated, purified using a silica gel plate, and freeze-dried to obtain a light yellow solid compound 4 (150 mg, yield 39%). m / z (ES+), [M+H] + =845, acid HPLC RT=2.284min.

[0943] Synthesis of compound 5:

[0944]

[0945] Compound 4 (150 mg, 0.18 mmol) was dissolved in N, N-dimethylformamide (3 mL), iodomethane (126 mg, 0.9 mmol) was slowly added, and the reaction solution was stirred at 80°C for 3 hours. The reaction solution was directly purified by reverse phase without post-treatment and freeze-dried to obtain yellow solid compound 5 (100 mg, yield 65%). m / z (ES+), [M] + =857; acid HPLC RT=1.640min.

[0946] Synthesis of compound 6:

[0947]

[0948] Compound 5 (100 mg, 0.117 mmol) was dissolved in tetrahydrofuran (3 mL), and an aqueous solution of lithium hydroxide (1.2 mL, 0.5 M, 0.585 mmol) was slowly added dropwise. The reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated, and the residue was dissolved in water. The pH value of the aqueous phase was adjusted to 3-4 with 1 M HCl, and freeze-dried to obtain a light yellow solid compound 6 (110 mg, crude product). m / z (ES+), [M] + =829, acid HPLC RT=1.690min.

[0949] Synthesis of compound 7:

[0950]

[0951] Compound 6 (90 mg, 0.11 mmol) and intermediate H (58 mg, 0.11 mmol) were dissolved in N, N-dimethylformamide (2 mL), and DMTMM (65 mg, 0.22 mmol) was slowly added. The reaction solution was stirred at room temperature for 2 hours. The reaction solution was directly subjected to high pressure preparation and freeze-dried to obtain white solid compound 7 (23 mg, yield 15.8%). m / z (ES+), [M] + =1337, acid HPLCRT=2.723min.

[0952] Synthesis of compound 8:

[0953]

[0954] Compound 7 (20 mg, 0.015 mmol) was dissolved in N, N-dimethylformamide (2 mL), sulfur trioxide pyridine complex (48 mg, 0.3 mmol) was slowly added, and the reaction solution was stirred at 45°C for 2 hours. Without post-treatment, it was directly purified by C18 column, and freeze-dried to obtain white solid compound 8 (18 mg, yield 85.7%). m / z (ES+), [M+H] + =1420; acid HPLC RT=2.726min.

[0955] Synthesis of compound I-38:

[0956]

[0957] Compound 8 (18 mg, 0.013 mmol) was dissolved in dichloromethane (1 mL), the reaction system was replaced with nitrogen three times, and a dichloromethane solution of boron trichloride (1 M, 0.5 mL) was slowly added dropwise in an ice bath and under nitrogen protection, and the reaction solution was stirred in an ice bath for 2 hours. After the reaction was completed, the reaction solution was blown dry with a nitrogen stream, and the reaction residue was washed with ether and centrifuged, which was repeated three times. The crude product was purified by high pressure preparation (column: X Select CSH preparative C18 OBD column, 19*250 mm, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 10% B to 30% B in 7 minutes; 254 / 220 nm; a white solid compound (2 mg, yield 18.1%) was obtained. m / z (ES+), [M] + =887; acid HPLC RT =0.772min.

[0958] Example 39 Synthesis of Compound I-39

[0959]

[0960] Synthesis of compound 1:

[0961]

[0962] In a 50mL single-necked flask, SM1 (1.2g, 4.26mmol, 1.43eq) was dissolved in DMF (12mL) with magnetic stirring, and SM2 (1.0g, 2.98mmol, 1.0eq), HATU (2.1g, 5.54mmol, 1.86eq), and N,N-diisopropylethylamine (1.7g, 12.78mmol, 4.29eq) were added. After the addition, the mixture was stirred at room temperature for 2 hours. After the reaction was completed, ice water (120mL) was added dropwise to the system, and the solid was precipitated. The solid was filtered, and the filter cake was washed with water (20mL x 2) and dried to obtain an off-white solid compound 1 (crude product, 2.2g, purity 88%). MS = 557.2 (M+H) +

[0963] Synthesis of compound 2:

[0964]

[0965] In a 50mL single-necked flask, magnetic stirring was used to dissolve compound 1 (2.0g, 3.6mmol, 1.0eq) in a mixed solution of methanol (12mL) and tetrahydrofuran (12mL), and 2M lithium hydroxide aqueous solution (4mL) was added dropwise. After the addition, the mixture was stirred at room temperature for 2 hours. After the reaction was completed, the reaction system was concentrated, water (10mL) was added, and the pH was adjusted to 2 with 2N hydrochloric acid solution. The solid was precipitated, filtered, and the filter cake was washed with water (20mLx 2) and then dried to obtain a crude off-white solid compound 2 (1.85g, purity 91%, yield: 94.9%). MS = 543.2 (M+H) +

[0966] Synthesis of compound 3:

[0967]

[0968] In a 50mL four-necked flask, magnetic stirring, under N2 protection, compound 2 (1.3g, 2.40mmol, 1.0eq) was dissolved in a mixed solution of DMF (5mL) and tetrahydrofuran (9.8mL), then intermediate H (1.51g, 2.88mmol, 1.2eq) was added, and then DMTMM (1.10g, 3.60mmol, 1.5eq) was added, and stirred at room temperature for 2 hours. After the reaction was completed, water (100mL) was added to the system, extracted with dichloromethane (100mL x 3), washed with saturated brine, dried, concentrated, and purified on a silica gel column (dichloromethane / methanol = 20:1) to obtain a light yellow solid compound 3 (1.02g, purity 93%, yield: 40.8%). MS = 1051.4 (M+H) +

[0969] Synthesis of compound 4:

[0970]

[0971] Under nitrogen protection, compound 3 (500.0 mg, 0.48 mmol, 1.0 eq) was dissolved in DMF (5 mL), and SO3.DMF (364.3 mg, 2.38 mmol, 5.0 eq) was added, and stirred at room temperature overnight. After the reaction was completed, the system was added dropwise to 50 mL of ice water, solids were precipitated, filtered, and the filter cake was freeze-dried to obtain white solid compound 4 (501.0 mg, purity 91%, yield 93%). MS = 1131.4 (M+H) +

[0972] Synthesis of compound I-39:

[0973]

[0974] Under nitrogen protection, compound 4 (200.0 mg, 0.194 mmol, 1.0 eq) was dissolved in dichloromethane (4 mL), cooled to -15 ° C, and a dichloromethane solution of boron trichloride was added dropwise, and stirred at -15 ° C for 1 hour. After the reaction was completed, potassium bicarbonate was added in batches at -15 ° C, and then 0.2 mL of water and 12 mL of methyl tert-butyl ether were added, stirred for 30 min, and then filtered under nitrogen protection, the filter cake was rinsed with methyl tert-butyl ether, and dried with nitrogen. The filter cake was slurried with 1.2 mL of methyl tert-butyl ether and 1.2 mL of ethanol for 1 hour, filtered, and the filter cake was dried with nitrogen, and the preparative liquid phase was purified to obtain an off-white solid compound I-39 (42 mg, purity: 98%, yield: 29.9%).

[0975] MS=795.1(M+H) + , 1 HNMR (400MHz, DMSO-d6): δ (ppm) 10.61 (brs, 1H), 9.90 (brs, 1H), 9.34 (d, J = 8.4Hz, 1H), 8.75-8.66 (m, 2H), 7.98 (s, 1H), 7.48 (s, 1H), 7 .26(s, 2H), 7.09(s, 1H), 6.73(s, 1H), 5.23-5.19(m, 1H), 4.12(s, 1H), 3.82-3.33(m, 4H), 2.10-2.07(m, 2H), 1.43(s, 3H), 1.41(s, 3H).

[0976] Example 40 Synthesis of Compound I-40

[0977]

[0978] Synthesis of compound 1:

[0979]

[0980] SM1 (500 mg, 1.42 mmol), DMTMM (592 mg, 2.13 mmol), and DIPEA (733 mg, 5.68 mmol) were dissolved in DMF (50 mL). After nitrogen replacement, the system was heated to 50°C, and a DMF (5 mL) solution of SM2 (628 mg, 2.13 mmol) was added dropwise in batches. After stirring at 50°C for 2 hours, the solution gradually became clear, and HATU (500 mg, 1.31 mmol) was added. The heating was stopped and the mixture was stirred at room temperature overnight. The DMF was removed by concentration under reduced pressure, and ethyl acetate and water were added. The organic phase was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (DCM / MeOH) to obtain pure compound 1 (710 mg, purity 93%, yield 87%), LCMS: [M+H] + =573.

[0981] Synthesis of compound 2:

[0982]

[0983] Compound 1 (710 mg, 1.24 mmol) was dissolved in THF / MeOH (7 mL / 7 mL) solution, 1 M lithium hydroxide solution (2 mL) was added at room temperature, and stirred at room temperature for 3 h. The reaction was completed. The reaction solution was concentrated under reduced pressure to remove the organic solvent, and then 2 M hydrochloric acid was added to adjust the pH to 2. A large amount of insoluble matter was precipitated. The mixture was extracted with ethyl acetate three times, and the organic phase was concentrated under reduced pressure to obtain a crude compound 2 (480 mg, purity 93%, yield 69%). LCMS: [M+H] + =559.

[0984] Synthesis of compound 3:

[0985]

[0986] Compound 2 (350 mg, 0.627 mmol) and intermediate H (264 mg, 0.502 mmol) were dissolved in a DMF / THF mixed solvent, and DMTMM (203 mg, 0.690 mmol) was added. The mixture was stirred at room temperature for 2 hours under nitrogen protection. The reaction was completed, and the tetrahydrofuran was removed by concentration under reduced pressure. Water and ethyl acetate were added, and the liquids were separated. The organic phase was concentrated under reduced pressure and purified by normal phase column chromatography (DCM / MeOH system) to obtain pure compound 3 (330 mg, purity 95%, yield 49%), LCMS: [M+H] + =1067.

[0987] Synthesis of compound 4:

[0988]

[0989] Compound 3 (120 mg, 0.113 mmol) was dissolved in anhydrous DMF (3 mL), and sulfur trioxide pyridine complex (286 mg, 1.180 mmol) was added. After nitrogen protection, the temperature was raised to 45 ° C and stirred overnight. After the mid-control reaction was completed, water was added to the system, and ethyl acetate was extracted twice. The organic phases were combined and concentrated under reduced pressure, and purified by normal phase column chromatography (DCM / MeOH system) to obtain solid compound 4 (77 mg, purity 96%, yield 60%). LCMS: [M+H] + =1146.

[0990] Synthesis of compound I-40:

[0991]

[0992] Compound 4 (77 mg, 0.067 mmol) was dissolved in dichloromethane (2 mL), and the reaction flask was replaced with nitrogen three times. The system was cooled to below -20°C, and BCl3.DCM solution (0.92 mL) was slowly added dropwise, with the internal temperature not higher than -20°C. After the addition was completed, stirring was continued at -20°C for 1 hour. After the mid-control reaction was completed, solid NaHCO3 (492 mg) was added to the system in batches at -20°C, followed by water (77 mg), and then methyl tert-butyl ether TBME (4.5 mL) was slowly added to the system, and stirring was continued for 30 min at -5°C. The mixture was filtered under nitrogen protection, and the filter cake was rinsed with a small amount of TBME, and then dried with nitrogen. The solid was slurried with TBME (1.2 mL) / EtOH (1.2 mL) at room temperature for 1 h, filtered, and then dried with nitrogen to obtain 400 mg of a solid crude product, which was purified by high pressure preparation to obtain pure compound I-40 (24.2 mg, purity 98.8%, yield 45%), LCMS: [M+H] + =811.

[0993] 1 H NMR (CD3OD-d4, 400MHz): δ (ppm) 1.61 (s, 6H), 2.25-2.34 (m, 1H), 2.51-2.62 (m, 1H), 3.57-3.59 (m, 2H), 3.67-3.81 (m, 2H) , 3.81-3.98 (m, 7H), 4.47 (dd, J=12.0, 8.0Hz, 1H), 5.39-5.40 (m, 1H), 6.97 (s, 1H), 7.01 (s, 1H), 7.71 (s, 1H), 7.93 (s, 1H).

[0994] Example 41 Synthesis of Compound I-41

[0995]

[0996] Synthesis of compound 1:

[0997]

[0998] SM1 (6.0 g, 26.4 mmol, 1.0 eq), N-Boc-3-aminoethyl bromide (6.5 g, 29.1 mmol, 1.1 eq) and triethylamine (5.4 g, 52.8 mmol, 2.0 eq) were added to acetonitrile (60 mL), and the mixture was heated to 50°C and stirred overnight. After the reaction was completed, the solvent was concentrated under reduced pressure, ethyl acetate was added to dissolve, and the mixture was washed with water. The crude product obtained after the solvent was concentrated was purified by column chromatography to obtain compound 1 (2.2 g, purity 93%, yield 23%).

[0999] Synthesis of compound 2:

[1000]

[1001] Compound 1 (2.2 g, 5.9 mmol, 1.0 eq) was dissolved in 1,4-dioxane (10 mL), and hydrogen chloride / dioxane solution (10 mL) was added at room temperature, and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness under reduced pressure to obtain compound 2 (3.0 g, purity 93%), which was directly used in the next step reaction.

[1002] Synthesis of compound 3:

[1003]

[1004] Compound 2 (1.6 g, 5.9 mmol, 1.0 eq), SM2 (2.1 g, 4.7 mmol, 0.8 eq), EDCI (2.3 g, 11.8 mmol, 2.0 eq), HOBT (1.6 g, 11.8 mmol, 2.0 eq) and N, N-diisopropylethylamine (3.1 g, 23.7 mmol, 4.0 eq) were dissolved in DMF (20 mL) and stirred at room temperature overnight. After the reaction was completed, ethyl acetate and water were added to the system, and the organic phase was backwashed with water after separation, and the organic phase was concentrated under reduced pressure to obtain a crude compound 3 (3.4 g, purity 85%, yield 85%), which was directly used in the next step without purification.

[1005] Synthesis of compound 4:

[1006]

[1007] Compound 3 (3.4 g, 5.0 mmol, 1.0 eq.) was dissolved in tetrahydrofuran / methanol solution (30 mL / 30 mL), 2 M lithium hydroxide solution was added at room temperature, and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure to remove the organic solvent, and 6 M hydrochloric acid was added to adjust the pH to 3-4, extracted with dichloromethane (containing 10% methanol), backwashed with water, and the organic phase was concentrated under reduced pressure to obtain oily compound 4 (2.8 g, purity 85%, yield 99%).

[1008] Synthesis of compound 5:

[1009]

[1010] Compound 4 (2.8 g, 4.3 mmol, 1.0 eq.) and intermediate H (1.8 g, 3.4 mmol, 0.8 eq.) were dissolved in a DMF / tetrahydrofuran mixed solution (12 mL / 18 mL) and stirred at room temperature for 1 hour under nitrogen protection. After the reaction was completed, water and ethyl acetate were added to the system, and the liquids were separated. The aqueous phase was back-extracted once with ethyl acetate. The combined organic phase was washed with water and then concentrated to dryness under reduced pressure. The crude product was purified by reverse phase column (acetonitrile / water system) to obtain white solid compound 5 (1.0 g, purity 95%, yield 20%).

[1011] Synthesis of compound 6:

[1012]

[1013] Compound 5 (1.0 g, 0.86 mmol, 1.0 eq.) was dissolved in DMF (10 mL), sulfur trioxide pyridine complex (2.2 g, 13.8 mmol, 16.0 eq.) was added, the temperature was raised to 45°C under nitrogen protection and stirred overnight. After the reaction was completed, water and ethyl acetate were added to the system, the liquids were separated, the aqueous phase was back-extracted once with ethyl acetate, the combined organic phase was back-washed with water, the organic phase was concentrated under reduced pressure and purified by column chromatography (dichloromethane / methanol system) to obtain white solid compound 6 (0.7 g, purity 98%, yield 65%).

[1014] Synthesis of compound I-41:

[1015]

[1016] Compound 6 (0.7 g, 0.56 mmol, 1.0 eq) was dissolved in dichloromethane (16 mL), the reaction system was replaced with nitrogen 3 times and cooled to below -20 ° C, BCl3.DCM solution was slowly added dropwise, the internal temperature was not higher than -20 ° C, and stirring was continued at -20 ° C for 1 hour after the addition was completed. After the reaction was completed, solid sodium bicarbonate (4.5 g) was added to the system in batches at -20 ° C, and then water (0.7 g) was added. After the reaction was quenched, methyl tert-butyl ether (42 mL) was slowly added to the system, and stirring was continued at -5 ° C for 30 minutes, and filtered under nitrogen protection. The filter cake was rinsed with a small amount of methyl tert-butyl ether and dried with nitrogen. The crude product was slurried with methyl tert-butyl ether (6 mL) / ethanol (3 mL) at room temperature for 1 hour, filtered, and dried with nitrogen. The obtained product was prepared by high pressure to obtain pure compound I-41 (253 mg, purity 97%, yield 53%). (ES+), [M+H] + =845; 1H NMR (400MHz, DMSO-d6): δ (ppm) 10.07 (s, 1H), 9.37 (d, J = 8.4Hz, 1H), 9.29 (s, 1H) , 8.49 (dd, J=7.2, 3.6Hz, 1H), 8.38 (t, J=5.7Hz, 1H), 8.15 (s, 1H), 7.27 (s, 2H), 6. 86 (d, J=8.2Hz, 1H), 6.83-6.64 (m, 2H), 5.22 (dd, J=8.4, 5.6Hz, 1H), 4.15 (dt, J= 9.7, 5.0Hz, 2H), 3.84-3.69 (m, 2H), 3.57 (d, J=6.0Hz, 3H), 1.45 (d, J=9.0Hz, 6H).

[1017] Example 42 Synthesis of Compound I-42

[1018]

[1019] Synthesis of compound 1:

[1020]

[1021] SM1 (3.7 g, 14.0 mmol, 1.0 eq.), SM2 (6.0 g, 14.0 mmol, 1.0 eq.), HATU (5.9 g, 15.4 mmol, 1.1 eq.) were dissolved in DMF (40 mL), N, N-diisopropylethylamine (5.4 g, 42.0 mmol, 3.0 eq.) was added, and stirred at room temperature for 1 hour. After LCMS detection, the reaction was completed, and water and ethyl acetate were added to the system. After separation, the aqueous phase was back-extracted once. The organic phases were combined, backwashed with water, and the organic phase was concentrated under reduced pressure to obtain solid compound 1 (13.3 g, purity 80%), which was directly used in the next step reaction.

[1022] Synthesis of compound 2:

[1023]

[1024] Compound 1 (13.3 g, 197 mmol, 1.0 eq.) was dissolved in tetrahydrofuran / methanol solution (100 mL / 100 mL), 2 M lithium hydroxide solution (200 mL) was added at room temperature and stirred for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure to remove the organic solvent, 6 M hydrochloric acid was added to adjust the pH to 3-4, the precipitated solid was collected by suction filtration, the filter cake was rinsed with water, and dried to obtain an off-white solid compound 2 (13.7 g, purity 80%, yield 99%).

[1025] Synthesis of compound 3:

[1026]

[1027] Compound 2 (6.8 g, 10.27 mmol, 1.0 eq.) and intermediate H (4.1 g, 7.7 mmol, 0.75 eq.) were dissolved in a DMF / tetrahydrofuran mixed solution (27 mL / 40 mL) and stirred at room temperature for 1 hour under nitrogen protection. After the reaction was completed, water and ethyl acetate were added to the system, the liquid was separated, the aqueous phase was back-extracted once with ethyl acetate, the combined organic phase was back-washed with water, the organic phase was concentrated under reduced pressure and purified by column chromatography (dichloromethane / methanol system) to obtain a white solid compound 3 (6.5 g, purity 97%, yield 54%).

[1028] Synthesis of compound 4:

[1029]

[1030] Compound 3 (1.0 g, 0.85 mmol, 1.0 eq.) was dissolved in DMF (10 mL), sulfur trioxide pyridine complex (1.4 g, 8.5 mmol, 10 eq.) was added, the temperature was raised to 45°C under nitrogen protection and stirred overnight. After the reaction was completed, water and ethyl acetate were added to the system, the liquids were separated, the aqueous phase was back-extracted once with ethyl acetate, the combined organic phase was back-washed with water, the organic phase was concentrated to dryness under reduced pressure and purified by column chromatography (dichloromethane / methanol system) to obtain white solid compound 4 (0.8 g, purity 97%, yield 72%).

[1031] Synthesis of compound I-42:

[1032]

[1033] Compound 4 (1.0 g, 0.81 mmol, 1.0 eq) was dissolved in dichloromethane (24 mL), the reaction system was replaced with nitrogen for 3 times and then cooled to below -20 ° C, BCl3.DCM solution was slowly added dropwise, the internal temperature was not higher than -20 ° C, and stirring was continued at -20 ° C for 1 hour after the addition was completed. After the reaction was completed, solid sodium bicarbonate (6.4 g) was added to the system in batches at -20 ° C, followed by water (1 g), and then methyl tert-butyl ether (60 mL) was slowly added to the system, and stirring was continued at -5 ° C for 30 minutes, and filtered under nitrogen protection, the filter cake was rinsed with a small amount of methyl tert-butyl ether, and dried with nitrogen. The solid was slurried with methyl tert-butyl ether (8 mL) / ethanol (4 mL) at room temperature for 1 hour, filtered, and the filter cake was dried with nitrogen. The crude product was prepared by high pressure to obtain compound I-42 (288 mg, purity 95%, yield 41%). (ES+), [M+H] + =856; 1H NMR (400MHz, DMSO-d6): δ (ppm) 9.46 (d, J=8.5Hz, 1H), 8.48 (s, 1H), 8.43 (dd, J=7.0, 3.4 Hz, 1H), 8.25 (t, J=5.7Hz, 1H), 8.13 (s, 1H), 8.02 (s, 1H), 5.28 (dd, J=8.5, 5.6Hz, 1H), 4 .26 (t, J=6.8Hz, 2H), 4.23-4.09 (m, 1H), 3.76 (dt, J=12.9, 6.5Hz, 1H), 3.52 (ddd, J=13. 9, 8.3, 3.3Hz, 1H), 3.22 (q, J=6.4Hz, 2H), 2.06 (t, J=6.8Hz, 2H), 1.51 (d, J=10.4Hz, 6H).

[1034] Example 43 Synthesis of Compound I-43

[1035]

[1036] Synthesis of compound 1:

[1037]

[1038] 3L four-necked flask, magnetic stirring, add NaOH (96.8g, 2.32mol), water (2200mL), dissolve, add SM1 (300g, 2.11mol) at room temperature, stir to dissolve, stir under ice water bath, yellow insoluble matter precipitates, add 37% HCHO (197g, 2.43mol), after 25min of addition, naturally warm to room temperature and stir overnight. TLC (DCM / MeOH=10 / 1, UV254nm) shows that the raw material SM1 has reacted, cool in -5 degrees low temperature tank, mechanically stir, add concentrated hydrochloric acid (219mL, 2.628mol) dropwise to make pH~1, continue to stir at low temperature after addition, precipitate insoluble matter, continue to stir at -5 degrees for 1.5hrs, filter by suction, collect the filtrate separately, wash the filter cake with petroleum ether (250mLx2), drain overnight, and obtain 268g of light yellow solid. The aqueous filtrate was concentrated to precipitate insoluble matter, then stirred in an ice-water bath for 1 hour, filtered, washed with petroleum ether (250 mL x 2), the filter cake was collected, and rotary evaporation was performed to obtain yellow solid compound 1 (81.7 g, yield 96%). MS = 172.81 (M+H) + .

[1039] Synthesis of compound 2:

[1040]

[1041] A 3L four-necked flask was mechanically stirred, and compound 1 (349.7 g, 2.03 mol) and water (1170 mL) were added. If the solution was not clear, zinc powder (266 g, 4.06 mol) was added at room temperature, and concentrated HCl (609 mL, 7.31 mol) was added dropwise. The internal temperature gradually increased, and the mixture was heated in a water bath at 40 degrees. During the addition, the internal temperature was between 40 and 60 degrees. The addition of concentrated hydrochloric acid was completed in about 1.5 hours. Immediate LC-MS monitoring showed that compound 1 had reacted completely. After the reaction mixture was cooled, it was filtered through filter paper, washed with water (50 mL), and the filtrate was transferred to a 3L four-necked flask and stirred in a -5 degree cooling tank. After 40 minutes, insoluble matter was precipitated. After cooling and stirring for a total of 3 hours, the mixture was filtered and filtered. The filter cake was filtered overnight. The filter cake was collected and dehydrated by rotary evaporation to obtain yellow solid compound 2 (144 g, yield 45%), MS = 156.81 (M + H) + .

[1042] Synthesis of compound 3:

[1043]

[1044] A 3L four-necked flask was mechanically stirred, potassium carbonate (178g, 1.287mol) and water (804mL) were added to dissolve, compound 2 (134g, 0.858mol) and methanol (1876mL) were added at room temperature, BnCl (119.5g, 0.944mol) was added dropwise at room temperature, and the addition was completed in 10min. The internal temperature did not increase significantly, and the mixture was stirred at room temperature at 25 degrees overnight. The reaction solution was transferred to a single-necked bottle and concentrated to remove methanol. Ice water was added to the residue to a total volume of about 3500mL. The precipitated substance was an oily substance, which was extracted with ethyl acetate (800mLx3), dried over anhydrous sodium sulfate, and the filtrate was dried to obtain a brown oily compound 3 (192g, yield 91%), MS = 246.92 (M+H) + .

[1045] Synthesis of compound 4:

[1046]

[1047] In a 500mL four-necked flask A, add chromium trioxide (13.76g, 0.138mol) and water (19mL), stir to dissolve, cool to -10 degrees, add concentrated sulfuric acid (12.1mL) dropwise to precipitate insoluble matter, add water (8.5mL) to dilute, and continue stirring at -10 degrees.

[1048] In another 500mL four-necked flask B, add compound 3 (22.6g, 0.092mol) and acetone (465mL), dissolve clearly, ice-salt bath -5 degrees, slowly drip the mixture in flask A into reaction flask B, keep the internal temperature <10 degrees, and drip it in 20 minutes. After dripping, naturally warm up to room temperature and stir overnight. The reaction mixture is transferred to a single-necked bottle, and the acetone is removed by rotary evaporation. Water (1000mL) is added to the residue, and a viscous yellow oil is precipitated. It is extracted with ethyl acetate (200mLx3), and the organic phase is dried over anhydrous sodium sulfate overnight. The filtrate is concentrated by rotary evaporation to obtain 20.7g of yellow solid. The mixture was stirred and slurried with n-pentane / dichloromethane = 3 / 1 (150 mL) for 6 hours, filtered, and the filter cake was washed with n-pentane / dichloromethane = 3 / 1 (20 mL x 2). The filter cake was collected and rotary evaporated to dryness to obtain a yellow solid compound 4 (11.5 g, yield 48%), MS = 261.01 (M+H) + .

[1049] Synthesis of compound 5:

[1050]

[1051] Compound 4 (11.5 g) and 25% ammonia water (92 mL) were added to a 200 mL glass sealed tube. After sealing the tube, the mixture was stirred at room temperature for 1 hrs, then heated to 80 degrees and stirred for 10 hours, and then cooled to room temperature naturally. The reaction mixture was washed 3 times with ethyl acetate (80 mL x 3). There was insoluble floccules, and the organic phase was discarded; dichloromethane (80 mL x 1) was added to the aqueous phase, and the insoluble matter was removed by suction filtration after stirring. After separation, the aqueous phase was washed with dichloromethane (80 mL x 2); the aqueous phase was taken, concentrated hydrochloric acid was added under stirring to pH ~ 4, cooled to room temperature and suction filtered, and suction filtered overnight to obtain a filter cake of light gray solid compound 5 (11.9 g, yield 85.8%), MS = 259.90 (M + H) + .

[1052] Synthesis of compound 6:

[1053]

[1054] Benzyl chloride (6.1 g, 48 mmol) was added dropwise to compound 5 (5 g, 19 mmol) and potassium carbonate (6.66 g, 48 mmol) in N, N-dimethylformamide (80 mL). The reaction mixture was reacted at 80°C overnight. The reaction solution was cooled to room temperature, water was added, and ethyl acetate was extracted twice, dried over anhydrous sodium sulfate, and the organic phase was spin-dried and purified by normal phase silica gel column to obtain compound 6 (6 g, yield 97%) as a white solid. LCMS: [M+H] + =440.01.

[1055] Synthesis of compound 7:

[1056]

[1057] Sodium hydroxide aqueous solution (20 mL, 1 mol / L) was added dropwise to tetrahydrofuran (100 mL) of compound 6 (6 g, 13.6 mmol). The reaction mixture was reacted at room temperature for 2 hours. Water (200 mL) was added to the reaction solution, and the pH was adjusted to 2-3 with 1N hydrochloric acid. Solids precipitated, filtered, and the filter cake was rinsed with water (3 x 25 mL) and dried to obtain white solid compound 7 (5 g, yield 100%), LCMS: [M+H] + =350.16.

[1058] Synthesis of compound 8:

[1059]

[1060] Compound 7 ( 2.5g , 7.1mmol ), SM2( 1.7g , 7.1mmol ), HATU (3.5 g, 9.23 mmol) and DIEA (2.8 g, 22 mmol). The reaction mixture was reacted at room temperature for 2 hours, water (200 mL) was added to the system, a large amount of viscous material precipitated, the supernatant was poured out, and the viscous material was drained to obtain crude compound 8 (5 g, purity 92%, yield 100%). LCMS: [M+H] + =528.07.

[1061] Synthesis of compound 9:

[1062]

[1063] Under ice bath conditions, m-CPBA (7 g, 33 mmol) was dissolved in dichloromethane (60 mL) and added dropwise to compound 8 ( 6g , 11mmol ) in a dichloromethane solution (60 mL), and the reaction mixture was reacted at room temperature for 2 hours. Dichloromethane (200 mL) and saturated sodium bicarbonate (200 mL) were added to the reaction solution, and the organic phase was washed with sodium chloride (20 mL), and the organic phase was spin-dried and purified by normal phase column chromatography (DCM: MeOH = 10: 1) to obtain a white solid compound 9 (4 g, purity 95%, yield 85.7%) LCMS: [M+H] + = 544.12.

[1064] Synthesis of compound 10:

[1065]

[1066] Compound 9 (4 g, 7.3 mmol) was dissolved in methanol (40 mL) solution, 2M lithium hydroxide solution (20 mL) was added at room temperature, and stirred at room temperature for 1 h. The reaction was completed. The reaction solution was concentrated under reduced pressure to remove the organic solvent, 20 mL of water was added, and the pH was adjusted to 2 with 2M hydrochloric acid. A large amount of solid precipitated, which was filtered and dried to obtain crude compound 10 (3.6 g, purity 92%, yield 92%). LCMS: [M+H] + =530.05.

[1067] Synthesis of compound 11:

[1068]

[1069] Compound 10 (3.6 g, 6.8 mmol) and intermediate H (3.6 g, 6.8 mmol) were dissolved in a DMF / THF (20 mL / 20 mL) mixed solvent, and DMTMM (2.7 g, 8.8 mmol) was added. The mixture was stirred at room temperature for 2 hours under nitrogen protection. The reaction was completed at the intermediate control. Water (400 mL) was added to the system. A large amount of viscous material was precipitated. The supernatant was poured out, and the viscous material was dissolved in dichloromethane. The organic phase was spin-dried and purified by normal phase column chromatography (dichloromethane / methanol system) to obtain a light yellow solid compound 11 (5 g, purity 95%, yield 70%). LCMS: [M+H] + =1038.33.

[1070] Synthesis of compound 12:

[1071]

[1072] Compound 11 (2.5 g, 2.4 mmol) was dissolved in DMF (50 mL), and sulfur trioxide pyridine complex (5.7 g, 36 mmol) was added. After nitrogen protection, the temperature was raised to 45 ° C and stirred overnight. After the mid-control reaction was completed, water (200 mL) was added to the system, and a large amount of solid precipitated. It was filtered and dried to obtain a crude product, which was then purified by normal phase column chromatography (DCM / MeOH system) to obtain a light yellow solid compound 12 (2.3 g, purity 95%, yield 85%). LCMS: [M+H] + =1118.30.

[1073] Synthesis of compound I-43:

[1074]

[1075] Compound 12 (2.2 g, 1.9 mmol) was dissolved in dichloromethane (45 mL), and the reaction flask was replaced with nitrogen three times. The system was cooled to below -20°C, and BCl3.DCM solution (20 mL) was slowly added dropwise, with the internal temperature not higher than -20°C. After the addition was completed, stirring was continued at -20°C for 1 hour. After the mid-control reaction was completed, solid sodium bicarbonate (6.4 g) was added to the system in batches at -20°C, followed by water (2 g), and then methyl tert-butyl ether (120 mL) was slowly added to the system, and stirring was continued at no higher than -5°C for 30 min. The filter cake was rinsed with a small amount of methyl tert-butyl ether, and then dried with nitrogen. The solid was slurried with methyl tert-butyl ether (20 mL) / ethanol (20 mL) at room temperature for 1 h, filtered, and then dried with nitrogen to obtain 11 g of a crude solid. 3.5 g of the crude product was prepared under high pressure to obtain pure compound I-43 (270 mg, purity 98.1%, yield 50%), LCMS: [M+H]+=782.19. 1 H NMR (CD3OD-d4, 400MHz): δ (ppm) 1.43-1.45 (m, 6H), 2.08-2.13 (m, 1H), 2.34-2.37 (m, 1H), 2.42 (s, 3H), 3.40- 3.52(m, 3H), 3.54-3.70(m, 4H), 4.17-4.22(m, 1H), 5.22-5.24(m, 1H), 6.85(s, 1H), 6.99(s, 1H), 7.06(s, 1H).

[1076] Example 44 Synthesis of Compound I-44

[1077]

[1078] Synthesis of compound 1:

[1079]

[1080] Compound SM1 (10 g, 40.61 mmol) and 25% ammonia water (60 mL, 6 V) were added to a glass sealed tube, sealed, heated to 80 degrees in an oil bath and stirred for 12 hours, cooled to room temperature, and LC-MS showed that the reaction was complete. The reaction solution was transferred to a flask, concentrated and dehydrated under reduced pressure, and the remaining solid was stirred and slurried with acetonitrile (40 mL) for 30 minutes, filtered, and the filter cake was washed with acetonitrile (15 mL x 2). The filter cake was collected and dried to obtain a khaki solid compound 1 (7.6 g, yield 76%), MS = 246.1 (M+H) + .

[1081] Synthesis of compound 2:

[1082]

[1083] Compound 1 (7.1 g, 28.95 mmol) was suspended in acetonitrile (75 mL), NIS (7.16 g, 31.84 mmol) was added at room temperature, and stirred at room temperature overnight for 17 hours. The reaction mixture was filtered, and the filter cake was washed with acetonitrile (10 mL x 3). The filter cake was collected to obtain yellow solid compound 2 (9.6 g, yield 89%). MS = 371.8 (M+H) + .

[1084] Synthesis of compound 3:

[1085]

[1086] Compound 2 (6.6 g, 17.78 mmol), cesium carbonate (17.4 g, 53.34 mmol), Pd(dppf)Cl2-CH2Cl2 (1.3 g, 1.78 mmol), DMF (130 mL), trimethylcyclotriboroxane (3.5 M, 15 mL) were added to a reaction flask, nitrogen protection, and stirred overnight in an oil bath at 100 degrees for 16 hours. The DMF was removed by decompression and concentration with an oil pump, 40 g of silica gel was added and spin-dried, and column chromatography (220 g of silica gel, 0-25% (dichloromethane / methanol=2 / 1) / DCM) was performed to obtain a brown solid compound 3 (2.4 g, yield 52%), MS=260.14 (M+H) + .

[1087] Synthesis of compound 4:

[1088]

[1089] In reaction flask A, add chromium trioxide (1.94 g, 19.44 mmol), dissolve in water (2.7 mL), stir in a dry ice-ethanol bath (-30 degrees) at external temperature, slowly add concentrated sulfuric acid (1.7 mL, 31.92 mmol), precipitate insoluble matter, slowly add water (1.2 mL) to dilute and set aside.

[1090] In reaction flask B, compound 3 (2.8 g, 10.80 mmol) and acetone (150 mL) were added, and stirred at an external temperature of a dry ice-ethanol bath (-10 degrees). The oxidant in reaction flask A was slowly added to reaction flask B, and the mixture was naturally heated to room temperature and stirred for 1 hour after the addition. The solvent was removed by vacuum concentration, and the remaining small amount of water was removed by vacuum concentration with an oil pump to obtain a crude compound 4 (2.95 g), which was directly used in the next step reaction.

[1091] Synthesis of compound 5:

[1092]

[1093] Compound 4 (2.95 g, 10.80 mmol) was dissolved in N,N-dimethylformamide (50 mL), potassium carbonate (9.0 g, 64.80 mmol) and benzyl chloride (4.1 g, 32.40 mmol) were added at room temperature, and the reaction solution was stirred at 80°C overnight. Methyl tert-butyl ether (100 mL) was added to the reaction mixture at room temperature, stirred for 15 minutes, and the insoluble matter was removed by suction. Water (250 mL) was added to the filtrate, and the liquid was separated. The aqueous phase was extracted with methyl tert-butyl ether (100 mL x 2). There was still product in the aqueous phase. Saturated brine (100 mL) was added, and then extracted with methyl tert-butyl ether (100 mL x 2). The organic phases were combined and dried over anhydrous sodium sulfate. 9 g of silica gel was added to the filtrate, and the mixture was concentrated to dryness under reduced pressure. Column chromatography (40 g silica gel, 0-20% ethyl acetate / petroleum ether) was performed to obtain compound 5 (2.8 g, two-step reaction yield 57%) as a light yellow oil, MS = 454.3 (M+H) + .

[1094] Synthesis of compound 6:

[1095]

[1096] Compound 5 (2.8 g, 6.17 mmol) was dissolved in tetrahydrofuran (40 mL), and 1.0 M sodium hydroxide solution [(321 mg, 8.03 mmol) + water (8 mL)] was added at room temperature, and stirred at room temperature overnight. The reaction solution was adjusted to pH 5-6 with 1 M hydrochloric acid, and no solid was precipitated. Water (50 mL) was added, and the mixture was extracted with dichloromethane (50 mL x 4). The combined organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated to dryness under reduced pressure. Column chromatography (20 g silica gel, 0-25% (dichloromethane / methanol = 2 / 1) was performed to obtain a light yellow oil compound 6 (2.04 g, yield 91%), which was drained overnight to a waxy solid, MS = 364.2 (M+H) + .

[1097] Synthesis of compound 7:

[1098]

[1099] Compound 6 (1.136 g, 3.13 mmol), SM2 (700 mg, 3.01 mmol), N,N-dimethylformamide (20 mL), N,N-diisopropylethylamine (1.41 g, 10.91 mmol) were added successively to the reaction vessel, stirred under an ice-water bath, and then HATU (1.25 g, 3.29 mmol) was added. The reaction solution was naturally warmed to room temperature and stirred for 1.5 hours. LC-MS detection showed that the reaction was complete. Another attempted reaction (142 mg 1310A3) was combined with this reaction, water (200 mL) was added, and MTBE (50 mL x 2) was extracted. The combined organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. Column chromatography (20 g silica gel, 0-100% ethyl acetate / petroleum ether) was used to obtain a light brown oil compound 7 (1.4 g, yield 83%), MS = 542.2 (M+H) + .

[1100] Synthesis of compound 8:

[1101]

[1102] Compound 7 (1.4 g, 2.585 mmol) was added to a reaction flask, and dichloromethane (24 mL) was added. A solution of m-CPBA (900 mg, 4.433 mmol) in dichloromethane (24 mL) was added dropwise under stirring in an ice-water bath. The mixture was added dropwise within 5 minutes, and the mixture was naturally heated to room temperature and stirred for 1.5 hours. After the reaction was completed, the system was concentrated under reduced pressure and column chromatography (40 g silica gel, 0-25% (ethyl acetate / methanol=2 / 1) was performed to obtain a colorless oil compound 8 (1.2 g, yield 82%), MS=558.1 (M+H) + .

[1103] Synthesis of compound 9:

[1104]

[1105] Compound 8 (1.2 g, 2.15 mmol) was added to a reaction flask, methanol (30 mL) was added, 2 M sodium hydroxide (5 mL, 10 mmol) was added under stirring at room temperature, and the mixture was stirred at room temperature for 30 minutes. After the reaction was completed, the mixture was concentrated under reduced pressure to remove methanol, water (40 mL) was added, washed with methyl tert-butyl ether (50 mL), saturated brine (10 mL) was added, and the mixture was separated after standing for 30 minutes. The aqueous phase was taken, concentrated under reduced pressure to remove methyl tert-butyl ether, and the remaining aqueous phase was adjusted to pH ~ 4 with citric acid aqueous solution (3 g citric acid + 15 mL water), and insoluble matter was precipitated but aggregated. The mixture was stirred at room temperature for 45 minutes, dispersed, filtered, washed with water until nearly neutral, and then washed with petroleum ether (70 mL), dried, and the filter cake was collected and dried under reduced pressure with an oil pump to obtain a light yellow solid compound 9 (1.02 g, yield 87%), MS = 544.0 (M + H) + .

[1106] Synthesis of compound 10:

[1107]

[1108] Intermediate H (910 mg, 1.729 mmol) and compound 9 (920 mg, 1.692 mmol) were added to a reaction flask, and tetrahydrofuran / DMF (16 mL / 10 mL) was added under nitrogen protection. DMTMM (544 mg, 1.846 mmol) was added under stirring at room temperature and stirred overnight. After the reaction was completed, the mixture was concentrated under reduced pressure to remove THF and DMF, and dichloromethane / methanol = 10 / 1 was added to dissolve the mixture. Silica gel was added, and the mixture was spin-dried. Column chromatography (40 g silica gel, 0-27% (dichloromethane / methanol = 2 / 1) was performed to obtain yellow solid compound 10 (2.0 g), MS = 1052.3 (M+H) + .

[1109] Synthesis of compound 11:

[1110]

[1111] Compound 10 (1.19 g, 1.13 mmol) was added to the reaction bottle, and DMF (24 mL) was added. Under nitrogen protection, the mixture was stirred in an ice-water bath. Sulfur trioxide-pyridine complex (2.88 g, 18.10 mmol) was added at once, and the mixture was stirred in an ice-water bath for 10 minutes, and then stirred at 45 degrees overnight. After the reaction, water (250 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phase was washed with water (50 mL) and saturated brine (10 mL). The separation was slow. After separating part of the aqueous phase, the mixture was washed with water (50 mL) and saturated brine (30 mL). The separation was slow. After separating part of the aqueous phase, the mixture was washed with saturated brine (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate. The filtrate was concentrated to dryness under reduced pressure. Column chromatography (20 g silica gel, 0-27% (dichloromethane / methanol = 2 / 1) was performed to obtain yellow solid compound 10 (642 mg); column chromatography (40 g silica gel, 0-27% (dichloromethane / methanol = 2 / 1) was performed again to obtain yellow solid compound 11 (409 mg, yield 32%), MS = 1132.3 (M+H) + .

[1112] Synthesis of compound I-44:

[1113]

[1114] Compound 11 (409 mg, 1.236 mmol) was added to a 50 mL three-necked flask with a built-in thermometer. Under nitrogen protection, dichloromethane (9 mL) was added to dissolve the mixture. The mixture was cooled in a dry ice-ethanol bath with stirring. When the internal temperature was -30 °C, 1.0 M boron trichloride-dichloromethane solution (3.6 mL, 3.6 mmol) was added dropwise. The mixture was added dropwise within 10 minutes. The internal temperature was controlled not to be higher than -25 °C. A light brown insoluble substance was precipitated. The mixture was stirred at low temperature for 30 minutes. After the reaction, the internal temperature was maintained at -35 degrees, solid sodium bicarbonate (2.45 g) was added to the reaction bottle at one time, the internal temperature was raised to -30 degrees, water (400 mL) was added dropwise, the temperature was gradually raised to -5 degrees-0 degrees and stirred for 30 minutes; the temperature was lowered to -20 degrees, methyl tert-butyl ether (25 mL) was added dropwise, the internal temperature was controlled to be less than 0 degrees, stirred for 10 minutes, filtered under nitrogen protection, methyl tert-butyl ether (20 mL) was used to rinse the filter cake, and dried; the filter cake was collected, and slurried with methyl tert-butyl ether / ethanol = 1 / 1 (5 mL) for 30 minutes under nitrogen protection; filtered under nitrogen protection, methyl tert-butyl ether was used to rinse the filter cake, and dried; the filter cake was collected to obtain 2.55 g of a crude salt product, which was purified by high pressure preparation-HPLC, the preparation liquid was collected, and directly freeze-dried overnight to obtain an off-white solid compound I-44 (151 mg), MS = 796.10 (M+H) + , HPLC: 97.1%, 1HNMR (DMSO-d6, 400MHz): δ (ppm) 9.39 (dd, 1H), 8.72-8.64 (m, 1H), 7.17-7.03 (m, 1H), 6.80 (dd, 1H), 5.28-5 .23(m, 1H), 4.19-4.12(m, 1H), 4.02-3.20(m, 7H), 2.48-2.28(m, 4H), 2.24-2.00(m, 4H), 1.51-1.35(m, 6H).

[1115] Example 45 Synthesis of Compound I-45

[1116]

[1117] Synthesis of compound 1:

[1118]

[1119] Compound SM1 (2.2 g, 4.85 mmol) was added to a reaction flask, and dichloromethane (45 mL) was added. m-CPBA (1.97 g, 9.70 mmol) was added at room temperature and stirred overnight at room temperature. Insoluble matter precipitated. After the reaction was completed, 6 g of silica gel was added, and the mixture was concentrated to dryness under reduced pressure. Column chromatography (80 g of silica gel, dichloromethane / methanol = 10 / 1) was performed to obtain a light yellow oily compound 1 (2.29 g, yield 100%), MS = 470.2 (M+H) + .

[1120] Synthesis of compound 2:

[1121]

[1122] Compound 1 (2.29 g, 4.88 mmol) was dissolved in tetrahydrofuran (35 mL) and methanol (35 mL), and 2M sodium hydroxide solution (22 mL) was added at room temperature, and stirred at room temperature for 20 degrees for 2 days. After the reaction was completed, the reaction solution was concentrated under reduced pressure to remove tetrahydrofuran and methanol, and water (20 mL) was added to the residue, and stirred under a cold water bath. 1M hydrochloric acid was used to adjust the pH to 1-2, and insoluble matter was precipitated. After stirring for 1 hour, it was filtered and washed with water until it was nearly neutral. The filter cake was collected and dehydrated under reduced pressure with an oil pump to obtain an off-white solid compound 2 (1.7 g, yield 92%), MS = 380.2 (M+H) + .

[1123] Synthesis of compound 3:

[1124]

[1125] Compound 2 (1.7 g, 4.48 mmol) was added to a reaction flask, DMF (30 mL) was added to dissolve, and the mixture was stirred in an ice-water bath. N, N-diisopropylethylamine (1.5 g, 11.61 mmol) and HATU (2.05 g, 5.38 mmol) were added, and the mixture was stirred in an ice-water bath for 30 minutes. Under nitrogen protection at room temperature, a mixed solution of SM2 (1.36 g, 4.93 mmol), N, N-diisopropylethylamine (1.5 g, 11.61 mmol) and DMF (20 mL) was slowly added dropwise for 2.5 hours. After the addition was complete, the mixture was stirred at room temperature. After the reaction was completed, the reaction solution was concentrated under reduced pressure to remove DMF to obtain a brown oil, and water (100 mL) and saturated sodium bicarbonate aqueous solution (100 mL) were added, and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with saturated sodium chloride solution (100 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated to dryness under reduced pressure and purified by column chromatography (80 g silica gel, 0-50% (dichloromethane / methanol=10 / 1) to obtain a light brown oil compound 3 (1.76 g, yield 65%), MS=601.3 (M+H) + .

[1126] Synthesis of compound 4:

[1127]

[1128] Compound 3 (1.76 g, 2.93 mmol) was added to a reaction flask, tetrahydrofuran (30 mL) and methanol (30 mL) were added, and 2M sodium hydroxide solution (6 mL, 12 mmol) was added under stirring at room temperature, and stirred at room temperature for 45 minutes. The tetrahydrofuran and methanol were removed by concentration under reduced pressure, and water (100 mL) and saturated sodium chloride aqueous solution (50 mL) were added, and washed with methyl tert-butyl ether (100 mL), separated twice, and the aqueous phase was combined, and the pH was adjusted to 6.2-6.4 with 1M hydrochloric acid solution, and extracted with dichloromethane / methanol = 10 / 1 (200 mL), and separated after standing for a long time, and the aqueous phase was extracted with ethyl acetate (200 mLx3), and the combined organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain a light brown oil compound 4 (1.4 g, yield 81%), MS = 587.2 (M+H) + .

[1129] Synthesis of compound 5:

[1130]

[1131] Compound 4 (1.53 g, 2.61 mmol) was added to a reaction flask, tetrahydrofuran / DMF (24 mL / 15 mL) was added, and intermediate H (1.14 g, 2.169 mmol) and DMTMM (767 mg, 2.603 mmol) were added under stirring at room temperature, and the mixture was protected by nitrogen and stirred at room temperature for 1.5 hours. After the reaction was completed, tetrahydrofuran and DMF were removed by concentration under reduced pressure, and dichloromethane / methanol = 10 / 1 was added to dissolve, 6 g of silica gel was added, and the mixture was concentrated under reduced pressure to dryness, and column chromatography (80 g of silica gel, methanol / ethyl acetate column chromatography was used for purification to obtain a light brown foam compound 5 (1.15 g, yield 49%), MS = 1095.32 (M+H) + .

[1132] Synthesis of compound 6:

[1133]

[1134] Compound 5 (700 mg, 0.639 mmol) was added to the reaction bottle, DMF (14 mL) was added, nitrogen was protected, and the mixture was stirred in an ice-water bath. Sulfur trioxide-pyridine complex (1.63 g, 10.226 mmol) was added at one time, nitrogen was protected, and the mixture was stirred in an ice-water bath for 10 minutes, and the mixture was stirred at 45 degrees overnight. After the reaction was completed, ice water (50 mL) was added to the reaction solution, and insoluble matter was precipitated. The mixture was stirred for 5 minutes, filtered, and rinsed with ice water (10 mL x 5) until the pH of the filtrate was neutral. The filter cake was collected, and the crude product was concentrated and dehydrated under reduced pressure by an oil pump to obtain the crude product. The crude product was purified by column chromatography (20 g silica gel, dichloromethane / methanol = 2 / 1) to obtain a light brown foam compound 6 (370 mg, yield 49%), MS = 1175.6 (M+H) + .

[1135] Synthesis of compound I-45:

[1136]

[1137] Compound 6 (365 mg, 0.311 mmol) was added to a 50 mL three-necked flask with a built-in thermometer. Under nitrogen protection, dichloromethane (8 mL) was added to dissolve the mixture. The mixture was cooled and stirred in a dry ice-ethanol bath. When the internal temperature reached -30 °C, 1.0 M boron trichloride-dichloromethane solution (3.1 mL, 3.1 mmol) was added dropwise. The mixture was added dropwise within 10 minutes. The internal temperature was controlled not to be higher than -25 °C. A light brown insoluble substance was precipitated. The mixture was stirred at low temperature for 20 minutes. After the reaction, the internal temperature was maintained at -35 degrees, solid sodium bicarbonate (2.34 g) was added to the reaction bottle at one time, the internal temperature was raised to -30 degrees, water (365 mg) was added dropwise, the temperature was gradually raised to -5 degrees - 0 degrees and stirred for 30 minutes; the temperature was lowered to -30 degrees, methyl tert-butyl ether (22 mL) was added dropwise, the internal temperature was controlled to be less than 0 degrees, stirred for 10 minutes, and filtered under nitrogen protection, methyl tert-butyl ether (18 mL) was used to wash the filter cake, and it was dried; the filter cake was collected and purged under nitrogen Under nitrogen protection, methyl tert-butyl ether / ethanol = 1 / 1 (4.5 mL) was used for slurrying for 30 minutes, methyl tert-butyl ether (20 mL) was added, and suction was filtered under nitrogen protection, methyl tert-butyl ether (15 mL x 3) was used to rinse the filter cake, and the filter cake was dried; 2.4 g of a crude salt product was obtained, and the product was purified by high pressure preparation, and the preparation liquid was collected and directly freeze-dried for about 48 hours to obtain a white solid compound I-45 (128 mg), MS = 839.33 (M + H) + , HPLC: 96.7%, 1 H NMR (400MHz, CD3OD): δ (ppm) 7.08 (s, 1H), 6.96 (s, 1H), 5.38 (d, J = 5.6Hz, 1H), 4.45 (dt, J = 8.0, 5.5Hz, 1H), 4.03-3.53(m, 11H), 2.72-2.62(m, 1H), 2.47(s, 3H), 2.45-2.30(m, 1H), 2.21(s, 3H), 1.60(s, 6H).

[1138] Example 46 Synthesis of Compound I-46

[1139]

[1140] Synthesis of compound 1:

[1141]

[1142] SM1 (2.0 g, 6.7 mmol, 1.0 eq.), SM2 (1.6 g, 4.7 mmol, 0.7 eq.), HATU (2.8 g, 7.4 mmol, 1.1 eq.) were dissolved in DMF (20 mL), and N, N-diisopropylethylamine (2.6 g, 20.1 mmol, 3.0 eq.) was added. The reaction system was stirred at room temperature for 1 hour. After the reaction was completed, water and ethyl acetate were added to the system. After separation, the aqueous phase was back-extracted once. The organic phases were combined, backwashed with water, and the organic phase was concentrated under reduced pressure to obtain solid compound 1 (6.4 g, purity 90%).

[1143] Synthesis of compound 2:

[1144]

[1145] Compound 1 (5.9 g, 9.88 mmol, 1.0 eq.) was dissolved in dichloromethane (60 mL), and a solution of m-CPBA (6.8 g, 39.53 mmol, 4.0 eq.) in dichloromethane (60 mL) was added under ice bath; the reaction mixture was reacted at room temperature for 2 hours, and after the reaction was completed, a saturated sodium bicarbonate solution (60 mL) was added to the system, the liquids were separated, the organic phase was washed once with saturated brine, and then concentrated under reduced pressure, the crude product was purified by reverse phase column (acetonitrile / water system), and compound 2 (2.6 g, purity 95%, yield 42%) was obtained after freeze drying.

[1146] Synthesis of compound 3:

[1147]

[1148] Compound 2 (2.0 g, 3.26 mmol, 1.0 eq.) was dissolved in tetrahydrofuran / methanol solution (20 mL / 20 mL), 2 M lithium hydroxide solution (40 mL) was added at room temperature, and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure to remove the organic solvent, 6 M hydrochloric acid was added to adjust the pH to 3-4, extracted with ethyl acetate, separated, the organic phase was washed with water, and the organic phase was concentrated under reduced pressure to obtain a yellow solid compound 3 (1.0 g, purity 96%, yield 51%).

[1149] Synthesis of compound 4:

[1150]

[1151] Compound 3 (800 mg, 1.34 mmol, 1.0 eq.) and intermediate H (772 mg, 1.47 mmol, 1.1 eq.) were dissolved in a DMF / tetrahydrofuran mixed solution (32 mL / 48 mL), and DMTMM (434 mg, 1.47 mmol, 1.1 eq.) was added, and the reaction system was stirred at room temperature for 1 hour under nitrogen protection. After the reaction was completed, water and ethyl acetate were added to the system, and the liquid was separated. The aqueous phase was back-extracted once with ethyl acetate, and the combined organic phase was back-washed with water. The organic phase was concentrated under reduced pressure and purified by column chromatography (dichloromethane / methanol system) to obtain a white solid compound 4 (1.0 g, purity 96%, yield 66%).

[1152] Synthesis of compound 5:

[1153]

[1154] Compound 4 (1.2 g, 1.08 mmol, 1.0 eq.) was dissolved in DMF (12 mL), sulfur trioxide pyridine complex (2.8 g, 17.33 mmol, 16 eq.) was added, and the system was heated to 45°C under nitrogen protection and stirred overnight. After the reaction was completed, water and ethyl acetate were added to the system, and the liquids were separated. The aqueous phase was back-extracted once with ethyl acetate, and the combined organic phase was back-washed with water. The organic phase was concentrated under reduced pressure and purified by column chromatography (dichloromethane / methanol system) to obtain white solid compound 5 (1.1 g, purity 95%, yield 86%).

[1155] Synthesis of compound I-46:

[1156]

[1157] Compound 5 (1.1 g, 0.92 mmol, 1.0 eq) was dissolved in dichloromethane (26 mL), the reaction system was replaced with nitrogen 3 times and cooled to below -20 ° C, BCl3.DCM solution (1 M, 13.2 mL) was slowly added dropwise, the internal temperature was not higher than -20 ° C, and stirring was continued at -20 ° C for 1 hour after the addition was completed. After the reaction was completed, solid sodium bicarbonate (6.4 g) was added to the system in batches at -20 ° C, and then water (1 g) was added, and methyl tert-butyl ether (60 mL) was slowly added to the system, and stirring was continued at -5 ° C for 30 minutes, and filtered under nitrogen protection, the filter cake was rinsed with a small amount of methyl tert-butyl ether, dried with nitrogen, and the solid was slurried with methyl tert-butyl ether (8 mL) / ethanol (4 mL) at room temperature for 1 hour, filtered, and the filter cake was dried with nitrogen. The crude product was prepared by high pressure to obtain compound I-46 (347 mg, purity 95.7%, yield 41%). (ES+), [M+H] + =852; 1H NMR (400MHz, DMSO-d6): δ (ppm) 11.39 (t, J=5.8Hz, 1H), 9.44 (d, J=8.5Hz, 1H), 8.61-8 .29 (m, 2H), 8.10 (s, 1H), 7.98 (s, 1H), 7.51 (s, 1H), 6.92 (s, 1H), 5.25 (dd, J=8.5, 5.6H z, 1H), 4.20 (dt, J=24.1, 6.1Hz, 3H), 3.88-3.61 (m, 1H), 3.49 (ddd, J=14.0, 8.5, 3.3H z, 1H), 3.33 (q, J=6.5Hz, 2H), 2.35 (s, 3H), 2.23-1.90 (m, 2H), 1.49 (d, J=10.4Hz, 6H).

[1158] Biological evaluation

[1159] 1. Materials

[1160] Table 1. Screening combinations

[1161]

[1162]

[1163] Note: The above strains are from Huiyuan Biotechnology (Shanghai) Co., Ltd.

[1164] 2. Culture medium

[1165] Trypticase soy agar (TSA) (BD BBL 236950)

[1166] Cation-adjusted Mueller Hinton broth (CAMHB) (BD BBL 212322)

[1167] Maconkey agar (MA)(Hibio Biotech HB6238)

[1168] 3. Reagents and consumables

[1169] Aztreonam(MCE HY-B0129)

[1170] Disposable shake bottle, 250ml (Corning 430183)

[1171] Disposable dish, 90 mm (Nest 752001)

[1172] 96-well microtiter plate (Greiner 650162)

[1173] 4. Methods

[1174] Bacterial strain recovery

[1175] The 103 bacterial strains used for the minimum inhibitory concentration test were frozen in a -80℃ freezer and needed to be revived 2 days in advance. Use a sterile inoculation loop to scrape a small amount of frozen microorganisms and streak inoculate on a suitable solid culture medium plate, then place it in a normal incubator at 35±2℃ for about 20 hours.

[1176] ● Proteus mirabilis HDBPM 40: MA, normal atmosphere

[1177] ●The remaining 102 strains of bacteria: TSA, normal atmospheric environment

[1178] Use a sterile inoculation loop to pick 5-10 colonies with similar morphology from the above culture dish, streak and inoculate them again on the corresponding solid culture medium plate, and then place it in a common incubator at 35±2℃ for about 20 hours.

[1179] Inoculum preparation

[1180] Take 1.02x CAMHB out of the 4°C refrigerator and warm it at room temperature.

[1181] Pick 5-10 single microbial colonies from the solid culture dish and resuspend them in 500 μl of sterile saline (0.9% NaCl). Then adjust the OD value using a spectrophotometer. 600 To ~0.15.

[1182] The bacteria were then diluted 300-fold with 1.02x CAMHB to reach an inoculum concentration of ~2x 10 5 CFU / ml.

[1183] Notice:

[1184] ●The prepared microbial inoculum should be inoculated into the 96-well assay plate within 15 minutes.

[1185] ●The number of inoculated microorganisms can be obtained by plate colony counting.

[1186] Test board preparation

[1187] Test plate map

[1188] ●There are 3 test plate patterns in total, and each test uses one of the test plate patterns.

[1189] ● 8 rows (AH rows) of the test plate: 8 test compounds in sequence. The highest test concentration of the compound is 16, 32 or 64 μg / ml, and 2-fold serial dilutions are performed.

[1190] - Growth control (GC): medium containing microbial inoculum (1.02x CAMHB) and dimethyl sulfoxide (DMSO), without compound.

[1191] Compound Dilution:

[1192] The test and control compounds are dissolved in DMSO or H2O into a 6.4 mg / ml stock solution. The stock solution is diluted into a certain concentration of reserve solution, and the volume of the reserve solution is determined according to the experimental design. Transfer the corresponding volume of the reserve solution to the starting wells of the dilution plate (A1-H1), and then transfer half of the DMSO volume of the starting wells to the other wells. Dilute each compound 2-fold from column 1 to column 11 (for example, first transfer 30μl DMSO to columns 2-12, then pipette 30μl of compound from column 1 to column 2 and mix, then pipette 30μl of compound from column 2 to column 3 and mix, then pipette 30μl of compound from column 3 to column 4 and mix, and so on to column 11).

[1193] Transfer 1 or 2 μl of compound and DMSO from the compound plate to the corresponding wells of the assay plate.

[1194] Add 98 μl of the corresponding bacterial inoculum to the test plate.

[1195] After the system is added, cover the test plate with a sterile cover, centrifuge it at 800 rpm for 30 seconds, shake it on a shaker at 400 rpm for 1 minute to mix it, and then place it in a common incubator at 35±2°C for 20-24 hours.

[1196] Note: Carefully check the solubility of the compound in the original tube and in the test plate after adding the microbial inoculum. Precipitation may cause misjudgment. The ideal state is that the compound can be completely dissolved in the solvent at all concentrations.

[1197] Colony count

[1198] Inoculate bacteria (select 4-6 strains) with liquid culture medium from 10 -1 Dilute to 10 -3 (e.g. 100 μl of bacterial inoculum + 900 μl of 1.02x CAMHB).

[1199] Evenly spread 100 μl of the above bacterial dilution on the TSA plate, with 2 replicates for each dilution. After the culture medium is absorbed by TSA for 10 minutes, invert the plate and culture it in an incubator at 35±2°C for 24 hours.

[1200] Minimum inhibitory concentration record and colony count

[1201] Open the compound management system to check that the barcodes and compound assignments for each assay plate are correct.

[1202] Place the test plate on the plate reader, adjust the reflector to observe and record the bacterial growth in each well, and use the QCount system to take photos of each test plate.

[1203] The minimum inhibitory concentration of each compound was recorded according to the Clinical and Laboratory Standards Institute guidelines.

[1204] The colony numbers of bacterial inocula of different dilutions on TSA plates were counted and the bacterial inoculum volume was calculated.

[1205] result

[1206] This study detected the minimum inhibitory concentration of compounds against experimental strains using the micro-medium dilution method according to the Clinical and Laboratory Standards Institute guidelines. Compounds were diluted two-fold in 96-well plates from the highest test concentration of 16, 32 or 64 μg / ml. The bacterial inoculum in the test plate was revived from the corresponding culture plate and diluted in 1.02x CAMHB, and a growth control (GC well) was set up in the test plate. After the test plate was cultured at 35±2℃ in a normal incubator for about 20 hours, the minimum inhibitory concentration of each compound against different bacteria was observed and recorded. The following table lists the minimum inhibitory concentration values ​​of different compounds.

[1207] Table 2. MIC values ​​of the compounds of the present invention against bacterial strains (μg / ml)

[1208]

[1209]

[1210] Table 3. MIC values ​​(μg / ml) of the compounds of the present invention against Acinetobacter baumannii strains expressing metalloenzymes

[1211]

[1212] In Table 2 and Table 3: A: MIC≤4 B: 4<MIC≤8 C: 8<MIC≤16 D: MIC>16 NA=No data

[1213] Pharmacokinetic evaluation of compounds in mice

[1214] Drug administration and sampling

[1215] After the male CD-1 (ICR) mice were purchased, they were adaptively raised in this laboratory for at least 3 days. Three mice were used for tail vein injection (not fasting, free drinking water), with a dose of 10 mg / kg. Blood samples were collected by saphenous vein blood collection at 0.0833 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours after intravenous injection. The blood volume at each blood collection time point was about 30 μl, and it was placed in a centrifuge tube containing the anticoagulant EDTA-K2, centrifuged at 3,200g for 10 minutes at 4°C, and then the upper plasma sample was taken and stored in a -70±10°C refrigerator for testing. The experimental design is summarized in the table below:

[1216] Table 4. Pharmacokinetics of compounds in CD-1 (ICR)

[1217]

[1218] Biological sample processing methods

[1219] 1. Protein precipitation:

[1220] 1). Add 6 μL aliquots of unknown samples, standard curve, quality control, diluted quality control, single blank and double blank samples into a 1.5 mL centrifuge tube;

[1221] 2) Each sample (except the double blank sample) was precipitated with 120 μL of IS1-containing precipitant (the double blank sample was precipitated with 120 μL of pure MeOH), and then the mixture was vortexed (at least 15 seconds) and centrifuged at 12000g, 4°C for 15 minutes;

[1222] 3) 60 μL of supernatant was transferred to a 96-well plate, centrifuged at 4°C, 3220 g for 5 min, and 6 μL was injected for LC-MS / MS quantitative analysis.

[1223] 2. Dilution process:

[1224] 1) The dilution factor of 1 h plasma samples from 3 mice was 10: 2 μL of sample was added to 18 μL of blank matrix;

[1225] 2) The plasma samples of 3 mice at 0.0833h-0.5h were diluted 100 times: (18 μL of blank matrix was added to 2 μL of sample to obtain a sample diluted 10 times. 2 μL of the sample diluted 10 times was added to 18 μL of blank matrix to obtain an analytical sample diluted 100 times.

[1226] LC-MS / MS analysis conditions: chromatographic column: ACQUITY UPLC HSS T3 (2.1×50 mm, 1.8 μm), column temperature: 50°C; mobile phase A: 0.1% formic acid in water, mobile phase B: 0.1% formic acid in acetonitrile; flow rate: 0.65 ml / min. Internal standard: Verapamil (100 ng / mL)

[1227] 3. Data Analysis:

[1228] The concentration of the compound in plasma was detected by LC-MS / MS (LC-MS / MS-AK_Q-Trap 6500). The pharmacokinetic software WinNonlin [version: Phoenix TM 6.3, Manufacturer: Pharsight Corporation] Calculate pharmacokinetic parameters (V-Noncompartmental model 201).

[1229] The experimental results are as follows:

[1230] Compound I-7 I-35 I-43 I-44 Dosage mg / kg mouse 5 10 10 10 Cl ml / min / kg 19.6 19.5 17.3 9.61 Vss L / kg 0.48 0.57 0.24 0.19 T1 / 2 h 0.27 1.43 0.59 0.63 AUC μg*h / ml 4.24 8.53 9.66 17.3

Claims

1. Compound represented by formula (I): in, R1 and R2 are each independently selected from H, C1-C6 alkyl, C1-C6 haloalkyl; or R1 and R2 together with the carbon atom to which they are connected form a C3-C6 cycloalkyl, or R1 and R2 together with the carbon atom to which they are connected form a C3-C6 heterocycloalkyl; wherein the C3-C6 cycloalkyl, C3-C6 heterocycloalkyl is optionally substituted by C1-C6 alkyl, C1-C6 haloalkyl, halogen, hydroxyl; R3 is selected from H, C1-C6 alkyl, halogen, wherein the C1-C6 alkyl is optionally substituted with halogen or hydroxyl; L1 is selected from -NH-C(=O)-T-, wherein said T is absent; X is selected from 5-6 membered heteroaryl or phenyl; wherein the 5-6 membered heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O, S as ring atoms, and wherein the 5-6 membered heteroaryl is optionally substituted by P, P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substitution; Y is selected from 5-6 membered heteroaryl or 4-6 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl or 4-6 membered heterocycloalkyl contains 1, 2 or 3 heteroatoms selected from N as ring atoms, and the 5-6 membered heteroaryl or 4-6 membered heterocycloalkyl is optionally substituted by Q, Q is selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, wherein the C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substitution; R4 and R4' are each independently selected from H or C 1-4 alkyl; L2 is absent or selected from -(NR4) m -C 1-4 Alkylene-(NR4) n -、-(NR4) m -C 1-4 Alkylene-NR4-C(=NR4)-NR4-, -C 1-4 Alkylene-NR4-C 1-4 Alkylene-; wherein m is 0 or 1, n is 1 or 2; C 1-4 The alkylene group is optionally replaced by C 1-4 Alkyl, NH2, -C 1-4 Alkylene-NH2 substitution; A is selected from M or -(CO)-M, wherein M is selected from Wherein R8 is selected from H, C1-C6 alkyl, hydroxyl, C 1-4 Alkoxy; R9, R 10 , or R 11 are each independently selected from H, halogen, CN or OR 12 , R 12 is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylcarbonyl or -C(O)-NH2; R 14 and R 15 Each independently selected from: H, C 1-6 Alkyl, halogen, cyano, OR 16 ; where R 16 Selected from H, C1-C6 alkyl; L3 does not exist or is -O-; Z is selected from N, CR 13 , where R 13 Selected from H, or halogen; or its stereoisomers and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1, selected from: or its stereoisomers and pharmaceutically acceptable salts thereof.

3. The compound according to claim 1 or 2, or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, wherein: R3 is selected from H, C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by halogen; X is selected from 5-6 membered heteroaryl or phenyl; wherein at least one of the heteroatoms of the 5-6 membered heteroaryl is an N atom, and wherein the 5-6 membered heteroaryl is optionally substituted by P, P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4'substituted; R4 and R4' are each independently selected from H or C 1-4 alkyl.

4. The compound according to claim 3, or its stereoisomers and pharmaceutically acceptable salts thereof, wherein: R3 is selected from H, C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by halogen; X is selected from a 5-membered heteroaryl or a phenyl group; wherein at least one of the heteroatoms of the 5-membered heteroaryl group is an N atom, and wherein the 5-membered heteroaryl or the phenyl group is optionally substituted by P, and P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4'substituted; R4 and R4' are each independently selected from H or C 1-4 alkyl.

5. The compound according to claim 4, or its stereoisomers and pharmaceutically acceptable salts thereof, wherein: R3 is selected from H, methyl, halomethyl; X is selected from oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, phenyl; these groups are optionally substituted by P, P is selected from C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, halogen, NR4R4', hydroxyl, wherein the C 1-4 The alkyl group is optionally further substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4'substituted; R4 and R4' are each independently selected from H or C 1-4 alkyl.

6. The compound according to claim 1 or 2, or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are each independently selected from H, methyl, halomethyl, or R1 and R2 together with the carbon atom to which they are attached form cyclopropane, cyclobutane or cyclopentane; wherein the cyclopropane, cyclobutane or cyclopentane is optionally substituted by C1-C6 alkyl, C1-C6 haloalkyl, halogen, hydroxyl.

7. The compound according to claim 6, or its stereoisomers and pharmaceutically acceptable salts thereof, wherein: R1 and R2 are methyl groups, or R1 and R2 together with the carbon atoms to which they are attached form cyclopropane, cyclobutane or cyclopentane; wherein the cyclopropane, cyclobutane or cyclopentane is optionally substituted by C1-C6 alkyl, C1-C6 haloalkyl, halogen or hydroxyl; R3 is selected from H, methyl, CH2F; X is selected from oxazolyl, isoxazolyl, thiazolyl, phenyl, which are optionally substituted by P, which is selected from C 1-4 alkyl or NR4R4'; R4 and R4' are each independently selected from H or C 1-4 alkyl; Y is selected from 5-6 membered heteroaryl or 4-6 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl or 4-6 membered heterocycloalkyl contains 1 or 2 N atoms as ring atoms, and the 5-6 membered heteroaryl or 4-6 membered heterocycloalkyl is optionally substituted by Q, Q is selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, wherein the C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substitution; R4 and R4' are each independently selected from H or C 1-4 alkyl.

8. The compound according to claim 7, or its stereoisomers and pharmaceutically acceptable salts thereof, wherein: X is selected from oxazolyl, isoxazolyl, thiazolyl, phenyl, and these groups are optionally substituted by P, and P is methyl; Y is selected from pyrazolyl, pyridinyl, pyrrolyl, azetidinyl, pyrimidinyl, said group is optionally substituted by Q, Q is selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, wherein the C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substitution; R4 and R4' are each independently selected from H or C 1-4 alkyl; A is selected from M or -(CO)-M, wherein M is selected from Wherein R8 is hydroxyl; R9, R 10 , or R 11 Each is independently selected from H, halogen; R 14 and R 15 Each independently selected from: H, C 1-3 Alkyl, halogen, cyano, OR 16 ; where R 16 Selected from H, C1-C3 alkyl.

9. The compound according to claim 7, or its stereoisomers and pharmaceutically acceptable salts thereof, wherein: R1 and R2 are methyl groups, or R1 and R2 together with the carbon atoms to which they are attached form cyclopropane, cyclobutane, or cyclopentane; R3 is selected from H, methyl, CH2F; L1 is -NH-C(O)-; Y is selected from L2 is absent or selected from -(NR4) m -C 1-4 Alkylene-(NR4) n -、-(NR4) m -C 1-4 Alkylene-NR4-C(=NR4)-NR4-, -C 1-4 Alkylene-NR4-C 1-4 Alkylene-; wherein m is 0 or 1, n is 1 or 2; C 1-4 The alkylene group is optionally replaced by C 1-4 Alkyl, NH2, -C 1-4 Alkylene-NH2 substitution; A is selected from M or -(CO)-M, wherein M is selected from Wherein R8 is hydroxyl; R9, R 10 , or R 11 Each is independently selected from H, halogen; R 14 and R 15 Each is independently selected from: H, methyl; L3 does not exist; Z is CH, N, or CCl.

10. The compound according to claim 1 or 2, or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are methyl groups, or R1 and R2 together with the carbon atoms to which they are attached form cyclopropane, cyclobutane, or cyclopentane; R3 is selected from H, methyl, CH2F; L1 is -NH-C(O)-; X is selected from Y is selected from pyrazolyl, pyridinyl, pyrrolyl, azetidinyl, pyrimidinyl, said group is optionally substituted by Q, Q is selected from halogen, C 1-4 Alkyl, NR4R4', hydroxyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, wherein the C 1-4 The alkyl group is optionally substituted with a hydroxyl group, a C 1-4 Alkoxy, NR4R4' substitution; R4 and R4' are each independently selected from H or C 1-4 alkyl; L2 is absent or selected from -(NH) m -C 1-4 Alkylene-(NH) n -、-(NH) m -C 1-4 Alkylene-NH-C(=NH)-NH-, -C 1-4 Alkylene-NH-C 1-4 Alkylene-; wherein m is 0 or 1, n is 1 or 2; C 1-4 The alkylene group is optionally replaced by C 1-4 Alkyl, NH2, -C 1-4 Alkylene-NH2 substitution; A is selected from M or -(CO)-M, wherein M is selected from L3 does not exist; Z is CH, N, or CCl.

11. The compound according to claim 1 or 2, or a stereoisomer thereof and a pharmaceutically acceptable salt thereof; in: R1 and R2 are methyl groups, or R1 and R2 together with the carbon atoms to which they are attached form cyclopropane, cyclobutane, or cyclopentane; R3 is selected from H, methyl, CH2F; L1 is -NH-C(O)-; X is selected from Y is selected from the following groups: L2 is absent or selected from -C 1-4 Alkylene-NH-, -C 1-4 Alkylene -(NH)2-, -NH-C 1-4 Alkylene-NH-, -C 1-4 Alkylene-NH-C(=NH)-NH-, -C 1-4 Alkylene-NH-C 1-4 Alkylene-; wherein C 1-4 The alkylene group is optionally substituted with NH2, -CH2-NH2; A is selected from M or -(CO)-M, wherein M is selected from L3 does not exist; Z is CH, N, or CCl.

12. A compound selected from: or its stereoisomers and pharmaceutically acceptable salts thereof.

13. A pharmaceutical composition comprising the compound according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier.

14. Use of the compound according to any one of claims 1 to 12 in the preparation of a medicament for treating and preventing diseases caused by Gram-negative bacterial infection.

15. The method according to claim 14, wherein the Gram-negative bacteria is selected from the group consisting of Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae, Citrobacter acidophilus, Citrobacter freundii, Proteus, Shigella shigella, Serratia marcescens, Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis, Campylobacter, Helicobacter pylori, Vibrio cholerae, Haemophilus influenzae, Mycobacterium, Bacteroides fragilis, Bacillus cereus and Stenotrophomonas maltophilia.

16. The use according to claim 14, wherein the disease is selected from respiratory tract infection, urinary tract infection, central nervous system infection, ear infection, abdominal infection, cardiovascular infection, skin or soft tissue infection, bone and joint infection, genital infection, eye infection, oral infection.

17. The use according to claim 16, wherein the respiratory tract infection disease comprises an upper respiratory tract infection disease and a lower respiratory tract infection disease.

18. The use according to claim 17, wherein the upper respiratory tract infection disease comprises pharyngitis, and the lower respiratory tract infection disease comprises tracheitis, bronchitis, pneumonia caused by Enterobacter and Serratia marcescens.

19. The use according to claim 16, wherein the urinary tract infection diseases include simple and complicated pyelonephritis, recurrent cystitis, complicated urinary tract infection, simple urinary tract infection.

20. The use according to claim 16, wherein the central nervous system infection disease comprises encephalitis, meningitis, and brain abscess.

21. The use according to claim 16, wherein the ear infection disease comprises otitis externa and otitis media.

22. The use according to claim 16, wherein the abdominal infection disease comprises peritonitis.

23. The use according to claim 16, wherein the cardiovascular infectious disease comprises blood infection, endocarditis, myocarditis, pericarditis.

24. The use according to claim 23, wherein the blood infection comprises sepsis or bacteremia.

25. The use according to claim 16, wherein the bone and joint infection diseases include arthritis and osteomyelitis.

26. The use according to claim 16, wherein the genital infection disease comprises genital ulcer, vaginitis, cervicitis.

27. The use according to claim 16, wherein the eye infection disease comprises conjunctivitis, keratitis, endophthalmitis.

28. The use according to claim 16, wherein the oral infection disease comprises gingivitis, periodontitis, pulpitis.

29. The use according to claim 14, wherein the disease is selected from pulmonary tuberculosis and pulmonary infection complicated by pulmonary fibrosis.